

**Saturday, 19. March 2022***Psy Day*

09:50 - 11:15

Congress Hall / Virtual Hall 1

**Psy1 - Psychological issues in hematopoietic stem cell transplantation***Chair:* Anna Barata, US

Psy1-01	<b>Psy Day Welcome note</b> <i>Speaker:</i> Martin Loučka, CZ	09:50 - 10:00
Psy1-02	<b>How do we evaluate psychological burden in HSCT patients and their families?</b> <i>Speaker:</i> Anna Barata, US	10:00 - 10:20
Psy1-03	<b>Trained to live again: An elite sport-inspired coaching for HSCT patients</b> <i>Speaker:</i> Sarah Calvin, FR	10:20 - 10:40
Psy1-04	<b>Positive psychology intervention to support Allogeneic Hematopoietic Cell Transplantation Recipients</b> <i>Speaker:</i> Hermioni Lokko, US	10:40 - 11:00
Psy1-05	<b>Discussion</b>	11:00 - 11:15

*Transplant and Search Coordinators Day*

09:50 - 11:15

Forum Hall / Virtual Hall 2

**TSCD1 - EBMT-WMDA Transplant and Search Coordinators Day - Emerging challenges in donor identification and selection***Chair:* Anne-Marie van Walraven, NL*Chair:* John Fitzgerald, IE

TSCD1-01	<b>Welcome</b> <i>Speaker:</i> Bronwen Shaw, US	09:50 - 10:00
TSCD1-02	<b>Is EU legislation taking care of donor safety?</b> <i>Speaker:</i> Sinéad Masterson, IE	10:00 - 10:20
TSCD1-03	<b>What does informed consent for treat and donation mean across borders?</b> <i>Speaker:</i> Lela Saou, NL	10:20 - 10:40
TSCD1-04	<b>How professional societies can help to comply with regulatory requirements</b> <i>Speaker:</i> Nicoletta Sacchi, IT	10:40 - 11:00
TSCD1-05	<b>QA</b>	11:00 - 11:15

*Pharmacists Day*

09:50 - 11:15

Panorama / Virtual Hall 3

**Pharm1 - Pharmacotherapy***Chair:* Tiene Bauters, BE*Chair:* Claudia Langebrake, DE

Pharm1-01	<b>Welcome</b> <i>Speaker:</i> Tiene Bauters, BE	09:50 - 10:00
Pharm1-02	<b>Role of the Pharmacist with CAR T Cells</b>	10:00 - 10:20

	<i>Speaker:</i> Estela Moreno, ES	
Pharm1-03	<b>Prevention and management of mucositis</b> <i>Speaker:</i> Nadjoua Maouche, GB	10:20 - 10:40
Pharm1-04	<b>Pharmacological treatment of GVHD</b> <i>Speaker:</i> Joerg Halter, CH	10:40 - 11:00
Pharm1-05	<b>QA</b>	11:00 - 11:15

*Data Management*

09:50 - 11:15

South Hall 1A+B / Virtual Hall 4

**DM1 - Data Management Session 1***Chair:* Bas Middelkoop, NL

DM1-01	<b>Welcome by the Registry Director</b> <i>Speaker:</i> Bas Middelkoop, NL	09:50 - 10:00
DM1-02	<b>Covid-19 and the EBMT Registry - an update</b> <i>Speaker:</i> Per Ljungman, SE	10:00 - 10:15
DM1-03	<b>New data collection forms</b> <i>Speaker:</i> Carina Gross, NL	10:15 - 10:30
DM1-04	<b>Q&amp;A - part I</b>	10:30 - 10:40
DM1-05	<b>Presentation of Vendor for new Registry Database</b> <i>Speaker:</i> Freija Descamps, BE	10:40 - 11:10
DM1-06	<b>Q&amp;A - part II</b>	11:10 - 11:15

*Patient, Family, and Donor Day*

09:50 - 11:15

North Hall / Virtual Hall 6

**PFD1 - Patient, Family and Donor Day: Being the perfect match***Chair:* Klara Kabatová-Maxová, CZ*Chair:* Gillian Adams, GB

PFD1-01	<b>Welcome</b> <i>Speaker:</i> Bregje Verhoeven, NL <i>Speaker:</i> Pavel Jindra, CZ	09:50 - 10:00
PFD1-02	<b>Introduction by the session Chairs</b>	10:00 - 10:05
PFD1-03	<b>From donor to patient: Exploring the stem cell journeys</b> <i>Speaker:</i> Christian Chabannon, FR	10:05 - 10:20
PFD1-04	<b>Motivations, experiences and perspectives of bone marrow donation</b> <i>Speaker:</i> Jan Zeman, CZ	10:20 - 10:35
PFD1-05	<b>Donating to a Family Member: More than Just a Medical Procedure</b> <i>Speaker:</i> Galen Switzer, US	10:35 - 10:50
PFD1-06	<b>QA</b>	10:50 - 11:15

## Poster Sessions

09:50 - 18:00

ePoster Area

**Inborn Errors, Granulocyte and Osteoclast Disorders**

- P583 **NEUROLOGICAL OUTCOME AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MALIGNANT INFANTILE OSTEOPETROSIS** 09:50 - 09:50  
*Poster Presenter:* Simin Amin-Salehi, DE
- P585 **EARLY ALLOGENEIC HSCT FOR MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY** 09:50 - 09:50  
*Poster Presenter:* Anders Eivind Myhre, NO

## Poster Sessions

09:50 - 18:00

ePoster Area

**Solid Tumours**

- P649 **AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION USING 18 MCI/KG <sup>131</sup>I-MIBG AND HIGH-DOSE CHEMOTHERAPY IN HIGH-RISK NEUROBLASTOMA: A SINGLE-CENTER EXPERIENCE** 09:50 - 09:50  
*Poster Presenter:* Amir Ali Hamidieh, IR

## Poster Sessions

09:50 - 18:00

ePoster Area

**New Drugs- and Cell-based Immune Therapies**

- P153 **A TRI-SPECIFIC KILLER ENGAGER (TRIKE®) AGAINST B7-H3 (GTB-5550) ENHANCES NK CELL MEDIATED KILLING OF MULTIPLE MYELOMA** 09:50 - 09:50  
*Poster Presenter:* Aimee Merino, US
- P154 **PRE-CLINICAL DEVELOPMENT AND CHARACTERISATION OF A DECITABINE-INDUCED REGULATORY HLAG<sup>+</sup>CD4<sup>+</sup>-T CELL-ENRICHED CELL PRODUCT AGAINST GVHD** 09:50 - 09:50  
*Poster Presenter:* Memnon Lysandrou, GR
- P155 **PEMBROLIZUMAB FOR THE TREATMENT OF RELAPSED AND REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT AND IN TRANSPLANT-NAÏVE PATIENTS** 09:50 - 09:50  
*Poster Presenter:* Khalid Halahleh, JO
- P156 **HLA-MISMATCHED STEM CELL MICROTRANSPLANTATION AS A TREATMENT OPTION FOR DE NOVO AND RELAPSED/REFRACTORY AML/MDS IN ELDERLY PATIENTS.** 09:50 - 09:50  
*Poster Presenter:* Rosalía Alonso Trillo, ES
- P157 **USE OF VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Cemaleddin Ozturk, TR
- P158 **RETROSPECTIVE COMPARISON OF THE AMICUS BLUE™ ONLINE ECP SYSTEM TO CURRENT OFFLINE AND ONLINE ECP METHODS, FOCUS ON AGVHD** 09:50 - 09:50

	<i>Poster Presenter:</i> Tarik Kanouni, FR	
P159	<b>EFFECTIVE LYSIS OF MOLM-13 AND AML BLASTS BY TRIPLEBODY SPM-2 (CD123-16-33) IN COMBINATION WITH SUBSETS OF NK CELLS</b> <i>Poster Presenter:</i> Claus-Philipp Maier, DE	09:50 - 09:50
P160	<b>DARATUMUMAB-CONTAINING REGIMEN IN THE TREATMENT OF RELAPSED HEMATOLOGICAL MALIGNANCIES IN CHILDREN AFTER ALLOGENEIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Zhihui Li, CN	09:50 - 09:50
P161	<b>DRIVING CELL THERAPY IN TREATMENT OF MRD-POSITIVE ACUTE PEDIATRIC LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC-SCT: BLINATUMOMAB + DLI</b> <i>Poster Presenter:</i> Francesco Paolo Tambaro, IT	09:50 - 09:50
<i>Poster Sessions</i> 09:50 - 18:00		ePoster Area
<b>Haemoglobinopathy</b>		
P575	<b>SICKLE CELL DISEASE AND THALASSEMIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: EVALUATION OF PULMONARY RISK FACTORS AND MANIFESTATIONS</b> <i>Poster Presenter:</i> A.J. Tulling, NL	09:50 - 09:50
P576	<b>THIOTEPA AND SUPPRESSION OF ENDOGENOUS HAEMOPOIESIS WITH HYDROXYCARBAMIDE AND HYPERTRANSFUSIONS ABROGATES RISK OF GRAFT FAILURE IN HAPLOIDENTICAL RIC HCT FOR PAEDIATRIC PATIENTS WITH SCD</b> <i>Poster Presenter:</i> Daniel Dexter, GB	09:50 - 09:50
P577	<b>48 HLA-IDENTICAL RELATED HEMATOPOIETIC STEM CELL TRANSPLANTS IN SICKLE CELL DISEASE: IMPROVING RESULTS DURING THE LAST DECADE</b> <i>Poster Presenter:</i> Marina García Morin, ES	09:50 - 09:50
P578	<b>HEMOGLOBIN, LACTATE DEHYDROGENASE, AND FACIT-FATIGUE NORMALIZATION RATES IN PATIENTS TREATED WITH PEGCETACOPLAN: RESULTS FROM THE PEGASUS AND PRINCE PHASE 3 CLINICAL TRIALS</b> <i>Poster Presenter:</i> Brian Mulherin, US	09:50 - 09:50
P579	<b>PEGCETACOPLAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND BASELINE HEMOGLOBIN LEVELS AT OR ABOVE 10 GRAMS PER DECILITER: A POST HOC ANALYSIS</b> <i>Poster Presenter:</i> Jens Panse, DE	09:50 - 09:50
P580	<b>MATCHED-RELATED BONE MARROW TRANSPLANTATION FOR LOW-RISK CHILDREN WITH SICKLE CELL DISEASE IS AN APPROPRIATE STARTING POINT FOR ALLOGENEIC BMT PROGRAMS.</b> <i>Poster Presenter:</i> Mane S. Gizhlaryan, AM	09:50 - 09:50
P581	<b>T-HAPLO FOR SCD: A PHASE II TRIAL TO ASSESS HAPLOIDENTICAL AB T-DEPLETED STEM CELL</b>	09:50 - 09:50

**TRANSPLANTATION IN PATIENTS WITH SCD WITH NO AVAILABLE MSD, UN UPDATE**

*Poster Presenter:* Jürgen Föll, DE

- |      |  |               |
|------|--|---------------|
| P582 | <p><b>PRE-TRANSPLANT IMMUNOSUPPRESSION AND RELATED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES: SUCCESSFUL ENGRAFTMENT AND NO SEVERE GVHD.</b></p> <p><i>Poster Presenter:</i> Brandon Brown, US</p> | 09:50 - 09:50 |
|------|--|---------------|

*Poster Sessions*

09:50 - 18:00

**ePoster Viewing**

ePoster Area

*Poster Sessions*

09:50 - 18:00

**Immunodeficiency Diseases and Macrophages**

ePoster Area

- |      |   |               |
|------|---|---------------|
| P588 | <p><b>CLINICAL AND IMMUNOLOGICAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY: 20 YEARS' EXPERIENCE FROM A MONOCENTRIC COHORT OF 220 PATIENTS</b></p>  | 09:50 - 09:50 |
| P589 | <p><b>MACHINE LEARNING-BASED APPROACH TO PREDICT PROGNOSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY IMMUNODEFICIENCY DISORDERS</b></p> <p><i>Poster Presenter:</i> Xiaowen Zhai, CN</p>                     | 09:50 - 09:50 |
| P590 | <p><b>AN INTERNATIONAL MULTI-CENTRE REVIEW OF HAEMATOPOIETIC CELL TRANSPLANTATION FOR RIPK1 DEFICIENCY</b></p> <p><i>Poster Presenter:</i> Rebecca B Walsh, GB</p>  | 09:50 - 09:50 |
| P591 | <p><b>TARGETED BUSULFAN-BASED REDUCED-INTENSITY REGIMEN IN MHC CLASS II DEFICIENCY AND CHRONIC GRANULOMATOUS DISEASE: SINGLE CENTER STUDY</b></p> <p><i>Poster Presenter:</i> Mohammed Essa, SA</p>                                 | 09:50 - 09:50 |
| P592 | <p><b>AUTOINFLAMMATORY PERIODIC FEVER, IMMUNODEFICIENCY AND THROMBOCYTOPENIA (PFTI) WDR1-LINKED. CASE REPORT OF A SUCCESSFUL SECOND HAEMATOPOIETIC STEM CELL TRANSPLANTION</b></p> <p><i>Poster Presenter:</i> Sara Redondo, ES</p> | 09:50 - 09:50 |
| P593 | <p><b>ALLOGENEIC HSCT IN CHILDREN WITH SEVERE TREATMENT-REFRACTORY INFLAMMATORY BOWEL DISEASE (IBD)</b></p> <p><i>Poster Presenter:</i> Tanja Vallée, DE</p>  | 09:50 - 09:50 |
| P594 | <p><b>WISKOTT ALDRICH SYNDROME CAUSED BY NOVEL WASP INTERACTING PROTEIN(WIP) MUTATION IS ASSOCIATED WITH JUVENILE MYELOMONOCYTIC LEUKEMIA - A CASE REPORT.</b></p> <p><i>Poster Presenter:</i> Srividhya Senthil, GB</p>            | 09:50 - 09:50 |

## Poster Sessions

09:50 - 18:00

ePoster Area

**Non-haematopoietic Stem Cells and Regenerative Medicine**

- P162 **CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON'S JELLY IN PATIENTS WITH CEREBRAL PALSY** 09:50 - 09:50  
*Poster Presenter:* Dariusz Boruczowski, PL
- P164 **CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON'S JELLY IN PATIENTS WITH NEUROLOGICAL/GENETIC DISEASES** 09:50 - 09:50  
*Poster Presenter:* Michał Piątek, PL

## Poster Sessions

09:50 - 18:00

ePoster Area

**Non-infectious Early Complications**

- P349 **THE DEFIFRANCE REGISTRY STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE IN PATIENTS WITH VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) FOLLOWING CHEMOTHERAPY** 09:50 - 09:50  
*Poster Presenter:* Ibrahim Yakoub-Agha, FR
- P350 **THE ROLE OF CONJUGATED MONOCLONAL ANTIBODIES IN DEVELOPMENT OF POST-TRANSPLANT VENO-OCCLUSIVE DISEASE: SINGLE CENTER STUDY** 09:50 - 09:50  
*Poster Presenter:* Mikhail M. Kanunnikov, RU
- P351 **EASIX PREDICTS VENO-OCCLUSIVE DISEASE AND SURVIVAL IN CHILDREN WHO UNDERWENT HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Koray Yalcin, TR
- P352 **SINUSOIDAL OBSTRUCTION SYNDROME/VENO-OCCLUSIVE DISEASE AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A STUDY ON BEHALF OF THE SPANISH HSCT AND CELLULAR THERAPY GROUP (GETH).** 09:50 - 09:50  
*Poster Presenter:* Ignacio Gómez-Centurión, ES
- P354 **RISK FACTORS FOR POOR GRAFT FUNCTION IN 231 PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Fabio Giglio, IT
- P356 **CD34-SELECTED STEM CELL BOOST IN PEDIATRIC PATIENTS WITH POOR GRAFT FUNCTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH DURABLE ENGRAFTMENT AND EXCELLENT OVERALL SURVIVAL** 09:50 - 09:50  
*Poster Presenter:* Ellen Fraint, US
- P357 **PROSPECTIVE EVALUATION OF UPPER AND LOWER GASTROINTESTINAL ENDOSCOPIES AND BIOPSIES IN THE DIAGNOSIS AND MANAGEMENT OF ALLOGENEIC HEMATOPOIETIC STELL CELL TRANSPLANT RECIPIENTS WITH PERSISTENT DIARRHEA.** 09:50 - 09:50  
*Poster Presenter:* Ana Belén Bocanegra, ES

P358	<b>CYTOKINE RELEASE SYNDROME DURING ATG/ATLG SEROTHERAPY FOR GVHD PROPHYLAXIS BEFORE ALLOGENEIC HSCT: INCIDENCE AND EARLY CLINICAL IMPACT ACCORDING TO ASTCT GRADING CRITERIA</b> <i>Poster Presenter: Philipp Wohlfarth, AT</i>	09:50 - 09:50
P359	<b>RELATIONSHIP OF PRE-TRANSPLANT BODY COMPOSITION AND BONE MINERAL DENSITY ASSESSED BY DUAL ENERGY X-RAY ABSORPTION WITH EARLY COMPLICATIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter: Anna Czyn, PL</i>	09:50 - 09:50
P360	<b>DEFIBROTIDE CAUSES DECREASED EXPRESSION OF INFLAMMATORY GENES AND PROTEINS BY ACTIVATED PRIMARY HUMAN PULMONARY MICROVASCULAR ENDOTHELIAL CELLS</b> <i>Poster Presenter: Alexandra Laberko, GB</i>	09:50 - 09:50
P361	<b>USE OF EMAPALUMAB IN THE PERI-TRANSPLANT PERIOD TO PREVENT GRAFT FAILURE IN PATIENTS AT RISK</b> <i>Poster Presenter: Pietro Merli, IT</i>	09:50 - 09:50
P363	<b>EFFICACY OF RECOMBINANT HUMAN THROMBOPOIETIN FOR THE TREATMENT OF SECONDARY FAILURE OF PLATELET RECOVERY AFTER ALLOGENEIC HSCT</b> <i>Poster Presenter: erlie jiang, AS</i>	09:50 - 09:50
P365	<b>NEUROLOGICAL COMPLICATIONS IN CHILDREN AFTER ALLOGENIC HSCT: A SINGLE CENTER EXPERIENCE</b> <i>Poster Presenter: Natalia Bronina, RU</i>	09:50 - 09:50
P366	<b>A NEW GENERATION LIGHTWALKER® LASER - EFFECTIVE PROPHYLAXIS OPTION IN PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION. PROSPECTIVE RANDOMIZED OPEN-LABEL STUDY.</b> <i>Poster Presenter: Anna Irga-Staniukiewicz, PL</i>	09:50 - 09:50
P367	<b>SAFETY PROOF OF ROMIPLOSTIM IMMEDIATELY AFTER CORD-BLOOD TRANSPLANTATION: RESULTS OF A PHASE 1 TRIAL</b> <i>Poster Presenter: Naoki Kurita, JP</i>	09:50 - 09:50
P368	<b>PURE RED CELL APLASIA AMONG ABO MISMATCHED HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A 10 YEARS RETROSPECTIVE STUDY.</b> <i>Poster Presenter: Elisabetta Metafuni, IT</i>	09:50 - 09:50
P369	<b>PREVENTION OF HEPATIC SINUSOIDAL OBSTRUCTIVE SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION BY PROSTAGLANDIN E1</b> <i>Poster Presenter: Sungnam Lim, KR</i>	09:50 - 09:50
P370	<b>HSCT-ASSOCIATED ENDOTHELIAL DAMAGE IN REAL LIFE: RETROSPECTIVE ANALYSIS IN 155 CONSECUTIVE PATIENTS</b> <i>Poster Presenter: Giorgia Mancini, IT</i>	09:50 - 09:50
P371	<b>COMPLETE LIVER-DONOR CHIMERISM AFTER LIVER</b>	09:50 - 09:50

	<b>TRANSPLANTATION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION.</b>	
	<i>Poster Presenter:</i> Marek Ussowicz, PL	
P372	<b>SEVERE GI REGIMEN RELATED TOXICITIES INCREASE WITH AGE IN PATIENTS RECEIVING AUTOLOGOUS TRANSPLANT FOR LYMPHOMA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Geoffrey Shouse, US	
P373	<b>LECTIN PATHWAY INHIBITOR FOR TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Parth J Ganatra, IN	
P374	<b>EXTRACELLULAR DNA IN CHILDREN WITH VENOOCCLUSIVE DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION TREATED WITH DEFIBROTIDE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Peter Svec, SK	
P375	<b>WEIGHT LOSS POST ALLOGENEIC STEM CELL TRANSPLANT IS ASSOCIATED WITH INCREASED TRANSPLANT RELATED MORTALITY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Kayla Madsen, CA	
P377	<b>COMPASSIONATE USE NARSOPLIMAB TO TREAT TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY IN A PEDIATRIC PATIENT WITH MULTI-ORGAN FAILURE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Michelle Schoettler, US	
P378	<b>INCIDENCE AND IMPACT ON SURVIVAL OF SINUSOIDAL OBSTRUCTION SYNDROME/VENO-OCCLUSIVE DISEASE IN ADULT PATIENTS AFTER ALLOHCT - RETROSPECTIVE PALG ANALYSIS. VALIDATION OF EBMT SEVERITY SCORING SYSTEM</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Patrycja Mensah-Glanowska, PL	
P379	<b>EASIX AND ENDOTHELIAL CELL DYSFUNCTION IN ALLOGENEIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Laura Pardo Gambarte, ES	
P380	<b>VENO-OCCLUSIVE DISEASE AFTER HIGH-DOSE BUSULFAN-MELPHALAN IN NEUROBLASTOMA - A 10 YEAR SINGLE CENTRE EXPERIENCE (2011-2021)</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Yashashree Gupta, GB	
P381	<b>A REAL-WORLD EVIDENCE SYSTEMATIC LITERATURE REVIEW (SLR) OF THE METRICS USED TO DETECT VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)</b>	09:50 - 09:50
	<i>Poster Presenter:</i> James Angus, GB	
P382	<b>LOW RATES OF TESTING AND HIGH PREVALENCE OF VITAMIN D DEFICIENCY BEFORE AND AFTER TRANSPLANTATION AT AN AUSTRALIAN TRANSPLANT CENTRE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Jacinta Perram, AU	
P383	<b>SYSTEMATIC LITERATURE REVIEW OF THE NATURAL HISTORY OF HEMATOPOIETIC STEM CELL TRANSPLANT-</b>	09:50 - 09:50



	<b>ASSOCIATED THROMBOTIC MICROANGIOPATHY IN ADULTS</b>	
	<i>Poster Presenter:</i> Steve Whitaker, US	
P384	<b>A CASE SERIES OF POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES SYNDROME) IN PEDIATRIC TRANSPLANTATION RECIPIENTS AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION: SINGLE CENTER EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Hatice Ilgen Sasmaz, TR	
P385	<b>EFFICACY OF ORAL CRYOTHERAPY IN PREVENTING MUCOSITIS AND REDUCING MORBIDITY WHEN ADMINISTERED DURING CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Munira Moosajee, PK	
P386	<b>OUTCOMES RELATED TO PEDIATRIC INTENSIVE CARE UNIT ADMISSION IN THE FIRST 100 DAYS POST HEMATOPOIETIC CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Hasan Hashem, JO	
P387	<b>THE RECIPIENT-SPECIFIC ANTIBODIES (RSA) IN MISMATCHED RELATED DONORS MAY AFFECT TRANSPLANT-RELATED COMPLICATIONS.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Alicja Sadowska-Klasa, PL	
P388	<b>CLINICAL FACTORS ASSOCIATED WITH RED BLOOD CELL AND PLATELET TRANSFUSION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Laura Pardo Gambarte, ES	
P389	<b>ROLE OF N. ACETYL CYSTEINE IN REDUCING THE MUCOSITIS IN BONE MARROW TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Chatada Srivaishnava Ranjit Kumar, IN	
P390	<b>HEPATIC VENOOCCLUSIVE DISEASE AS MAIN COMPLICATION OF AUTOLOGOUS STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> MARÍA AMPARO PIMENTEL VILLAR, ES	
<i>Poster Sessions</i>		
09:50 - 18:00		ePoster Area
<b>Haematopoietic Stem Cells</b>		
P001	<b>A COMPREHENSIVE MODEL TO PREDICT SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Meng zhu Shen, CN	
P002	<b>ANTIBODY RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Alice Huang, CH	
P003	<b>POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ACUTE LEUKEMIA PATIENTS RECEIVING MORE THAN 5/10 HLA-MISMATCHED ALLOGENEIC STEM CELL TRANSPLANTATION: A STUDY ON BEHALF OF THE ALWP</b>	09:50 - 09:50

**OF THE EBMT***Poster Presenter:* Michele Wieczorek, FR

- |      |   |               |
|------|---|---------------|
| P004 | <b>INFLUENCE OF C-KIT MUTATIONS ON PROGNOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH CORE BINDING FACTOR AML WITH RUNX1-RUNX1T1 FUSION GENE</b> | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Hai He, CN   |               |
| P005 | <b>A PREDICTED MODEL FOR REFRACTORY/RECURRENT CYTOMEGALOVIRUS INFECTION AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION.</b>   | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Shuang Fan, CN   |               |
| P006 | <b>VALIDATION OF THE REVISED PRETRANSPLANT ASSESSMENT OF MORTALITY SCORE AFTER ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE</b>                              | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Annalisa Ruggeri, IT   |               |
| P007 | <b>EXCELLENT RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY PH-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA</b>  | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Yanzhi Song, CN  |               |
| P009 | <b>A COMPARISON BETWEEN ATG AND PT-CY GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS IN PATIENTS WITH LYMPHOMA UNDERGOING REDUCED INTENSITY CONDITIONING REGIMEN HSCT FROM 1 ANTIGEN MMUD</b>            | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Annalisa Paviglianiti, ES  |               |
| P010 | <b>PRECEDING PROTEINURIA AS A RISK AND PROGNOSTIC FACTOR FOR TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IN ADULT ACUTE MYELOID LEUKEMIA COHORTS</b>                                       | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Gi June Min, KR  |               |
| P011 | <b>COVID19 VACCINE RESPONSES IN PATIENTS POST STEM CELL TRANSPLANT</b>  | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Fayhan Alroqi, SA  |               |
| P012 | <b>MULTIPLE MYELOMA: HOME TREATMENT IS POSSIBLE IN A TERTIARY HOSPITAL. FROM AUTOLOGOUS STEM CELL TRANSPLANTATION TO ORAL THERAPY.</b>  | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Laura Solán, ES  |               |
| P014 | <b>HAPLOIDENTICAL TRANSPLANT FROM PBSC WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AND CONTROLLED NUMBER OF T LYMPHOCYTES</b>  | 09:50 - 09:50 |
|      | <i>Speaker:</i> Fulvio Porta, IT  |               |
| P015 | <b>PREDICTORS OF OUTCOMES IN HEMATOPOIETIC CELL TRANSPLANTATION FOR FANCONI ANEMIA: A MULTICENTER ANALYSIS</b>  | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Maria Cancio, US   |               |
| P016 | <b>ADVERSE EVENTS OF MRNA-1273 SARS-COV-2 VACCINE IN RECENT ALLOGENEIC HEMATOPOIETIC STEM CELL</b>  | 09:50 - 09:50 |

**TRANSPLANT RECIPIENTS***Poster Presenter:* Nil Albiol, ES

P017	<b>QUALITY OF LIFE RELATED-FACTORS IN LONG-TERM SURVIVORS FOLLOWING ALLOGENIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Juan José Domínguez-García, ES	
P018	<b>HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) INTERNATIONAL COOPERATIVE PROJECT IN IRAQI KURDISTAN: A 3 YEAR FOLLOW UP ON THALASSEMIA PATIENTS AND IMPACT OF SARSCOV2 INFECTION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Marta Verna, IT	
P019	<b>USE OF ABATACEPT AS GVHD PROPHYLAXIS IN PEDIATRIC PATIENTS UNDERGOING HSCT FROM MATCHED OR MISMATCHED UNRELATED DONOR</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Pietro Merli, IT	
P020	<b>EARLY ABSOLUTE LYMPHOCYTE RECOVERY PREDICTS BETTER SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA AND NON-HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER STUDY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Carles Tolosa, ES	
P021	<b>EFFICACY AND SAFETY OF VENETOCLAX IN THE TREATMENT OF RECRUDESCENCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> erlie jiang, AS	
P022	<b>EFFICACY OF HEMATOPOIETIC STEM CELL BOOST FOR PATIENTS PRESENTING POOR GRAFT FUNCTION (PGF) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) : A MULTICENTER RETROSPECTIVE STUDY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Maude Gaffet, FR	
P023	<b>ADVERSE REACTIONS DURING INFUSION OF ALLOGENEIC HAEMATOPOIETIC STEM CELLS GRAFTS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Nikolina Friščić, HR	
P024	<b>TOTAL BODY IRRADIATION BASED CONDITIONING REGIMEN IMPROVE THE SURVIVAL OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA AFTER ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Jiahua Niu, CN	
P025	<b>SURVIVAL EFFICACY OF MDS/AML PATIENTS WITH TP53 GENE ALTERATION RECEIVED ALLO-GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> erlie jiang, AS	
P026	<b>OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Fabrizio Pane, IT	
P027	<b>OUTCOMES OF ALLO-HSCT FOR ADULTS WITH PRIMARY</b>	09:50 - 09:50

	<b>MEDIASTINAL B CELLS LYMPHOMA: A RETROSPECTIVE STUDY ON BEHALF OF THE SFGM-TC AND THE LYSA GROUP.</b>	
	<i>Poster Presenter:</i> Baptiste Le Calvez, FR	
P029	<b>DEGREE OF CELL PACKING OF CRYOPRESERVED AT -80°C HEMATOPOIETIC STEM CELLS DOES NOT AFFECT THEIR VIABILITY AND HEMATOLOGIC RECOVERY OF TRANSPLANTED MYELOMA PATIENTS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ivan Tonev, BG	
P030	<b>LYMPHOCYTE DOSE IN GRAFT, CLONOGENIC EFFICIENCY AND MALE SEX AS PREDICTIVE FACTORS OF EARLY LYMPHOCYTE RECOVERY FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Jesus Fernandez-Sojo, ES	
P032	<b>IMPROVEMENT IN ACUTE NEUROLOGICAL COMPLICATIONS RELATED TO STEM CELL TRANSPLANT IN SICKLE CELL DISEASE: LESSONS FROM OUR EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> José Manuel Marco Sánchez, ES	
P033	<b>THIOTEPA-TREOSULFAN-FLUDARABINE (TTF) AS CONDITIONING REGIMEN IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) FOR MYELOFIBROSIS OR MYELOYDYSPLASTIC SYNDROME: A SINGLE CENTER EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Filippo Antonio Canale, IT	
P034	<b>NON-CRYOPRESERVED PERIPHERAL BLOOD STEM CELL GRAFT FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA AND LYMPHOMA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Panarat Noiperm, TH	
P036	<b>FEASIBILITY OF DARATUMUMAB FOR ADULT PATIENTS WITH CD38 POSITIVE ACUTE MYELOID LEUKEMIA RELAPSED AFTER ALLOGENIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> erlie jiang, AS	
P037	<b>THE EFFECT OF DELAYED CORD CLAMPING ON THE QUALITY OF COLLECTED CORD BLOOD UNITS FOR BANKING</b>	09:50 - 09:50
	<i>Poster Presenter:</i> AHMAD DARWISH, EG	
P038	<b>COVID-19 RISK PERCEPTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECEPTORS FOLLOWING MRNA-1273 SARS-COV-2 VACCINATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Nil Albiol, ES	
P039	<b>ACUTE GRAFT VERSUS HOST DISEASE IS COMMON IN PATIENTS WHO DEVELOP ENGRAFTMENT SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Mariah Wright, US	
P040	<b>REVIEW OF OCCURRENCES AT A HAEMATOPOETIC STEM</b>	09:50 - 09:50

<b>CELL TRANSPLANT COLLECTION AND PROCESSING FACILITY IN SOUTH AFRICA</b>		
	<i>Poster Presenter:</i> Laurel Anderson, ZA	
P041	<b>CARDIOTOXICITY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: ARE THERE DIFFERENCES BETWEEN AUTOLOGOUS AND ALLOGENEIC?</b> <i>Poster Presenter:</i> Asuncion Borrero Borrego, ES	09:50 - 09:50
P042	<b>ALLOGENEIC TRANSPLANTATION (ALLOHCT) IN ACUTE MYELOID LEUKEMIA (AML) WITH FLT3 MUTATIONS: STUDY OF OUTCOME AT THE ERA OF TARGETED THERAPY</b> <i>Poster Presenter:</i> Natassa - Eleni Loutsidi, GR	09:50 - 09:50
P043	<b>UNRELATED DONOR TRANSPLANTATION IN APLASTIC ANEMIA WITH A QUADRUPLE GVHD PROPHYLAXIS</b> <i>Poster Presenter:</i> Sabrina Giammarco, IT	09:50 - 09:50
P044	<b>EVALUATION OF DISEASE PROGRESSION/RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA WAITING FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT IN BRAZIL</b> <i>Poster Presenter:</i> GIANCARLO FATOBENE, BR	09:50 - 09:50
P045	<b>GASTROINTESTINAL MICROBIOME CHANGES DURING AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA</b> <i>Poster Presenter:</i> Vitalii Chebotkevich, RU	09:50 - 09:50
P046	<b>FEASIBILITY OF TRANSPLANTATION FOR MYELOMA IN RESOURCE CONSTRAINED SETTING; REAL-WORLD DATA ON SURVIVAL AND COST OF TREATMENT FROM THE FIRST HAEMATO-ONCOLOGY CENTRE IN SRI LANKA.</b> <i>Poster Presenter:</i> Saman Hewamana, LK	09:50 - 09:50
P047	<b>RESULTS OF ALLOGENEIC STEM CELL TRANSPLANTATION IN BONE MARROW FAILURES: A SINGLE-CENTER EXPERIENCE</b> <i>Poster Presenter:</i> Vildan Özkocaman, TR	09:50 - 09:50
P048	<b>STRATEGIC COST ANALYSIS OF HEMATOPOIETIC STEM CELL BANKING FROM CORD BLOOD: AN EGYPTIAN MODEL</b> <i>Poster Presenter:</i> AHMAD DARWISH, EG	09:50 - 09:50
P049	<b>CLADRIBINE ADDED TO MODIFIED BUSULFAN/CYCLOPHOSPHAMIDE CONDITIONING FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA</b> <i>Poster Presenter:</i> erlie jiang, AS	09:50 - 09:50
P050	<b>TRYPAN BLUE AND FLOW CYTOMETRY CELL VIABILITY TESTING OF PACKED OR DILUTED CRYOPRESERVED AT -80°C HEMATOPOIETIC STEM CELLS SHOW SIMILAR RESULTS</b> <i>Poster Presenter:</i> Ivan Tonev, BG	09:50 - 09:50
P051	<b>ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN IRANIAN PATIENTS WITH</b>	09:50 - 09:50

**CONGENITAL SIDEROBLASTIC ANEMIA: A SINGLE-CENTER EXPERIENCE**

*Poster Presenter:* Bibi Shahin Shamsian, IR

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Stem Cell Mobilization, Collection and Engineering**

- |      |  |               |
|------|--|---------------|
| P052 | <p><b>NO ADDED BENEFIT FROM HIGH-DOSE CYCLOPHOSPHAMIDE STEM CELL MOBILIZATION IN MULTIPLE MYELOMA IN FIRST COMPLETE REMISSION AFTER BORTEZOMIB-BASED INDUCTION THERAPY</b></p> <p><i>Poster Presenter:</i> Pedro Baptista, PT</p>                | 09:50 - 09:50 |
| P053 | <p><b>EFFECT OF CD34+ CELL DOSE ON CLINICAL OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE</b></p> <p><i>Poster Presenter:</i> Alexandra Pedraza, ES</p>                                | 09:50 - 09:50 |
| P055 | <p><b>PROLONGED INFUSION TIME OF CYCLOPHOSPHAMIDE IS MORE EFFECTIVE AS A STEM CELL MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS□A RETROSPECTIVE MONOCENTRIC REPORT</b></p> <p><i>Poster Presenter:</i> Yanjuan Li, CN</p>   | 09:50 - 09:50 |
| P056 | <p><b>UPREGULATED EXPRESSION OF SIRT5, SIRT6 AND SIRT7 IS ASSOCIATED WITH HIGHER NUMBER OF CD34+ CELLS COLLECTED AT FIRST APHERESIS.</b></p> <p><i>Poster Presenter:</i> Anna Szmigielska-Kaplon, PL</p>   | 09:50 - 09:50 |
| P057 | <p><b>STEM CELL APHERESIS: ACCURACY OF THE PREDICTION OF THE STEM CELL YIELD USING PRE-APHERESIS CD34+ CELL COUNT</b></p> <p><i>Poster Presenter:</i> Maximilian Hornung, DE</p>   | 09:50 - 09:50 |
| P058 | <p><b>HANDLING OF ALLOGENEIC RELATED AND UNRELATED HPC GRAFTS DURING THE COVID-19 PANDEMIC - A SURVEY FROM THE INFECTIOUS DISEASES AND CELLULAR THERAPY &amp; IMMUNOBIOLOGY WORKING PARTY</b></p> <p><i>Poster Presenter:</i> Nina Worel, AT</p> | 09:50 - 09:50 |
| P059 | <p><b>CRYOPRESERVATION OF ALLOGENEIC STEM CELLS MAY BE ASSOCIATED WITH INCREASED EARLY RELAPSE COMPARED WITH FRESH PRODUCT: A COHORT STUDY OF IRISH PATIENTS</b></p> <p><i>Poster Presenter:</i> Chris Armstrong, IE</p>                         | 09:50 - 09:50 |
| P061 | <p><b>EXTRACORPOREAL PHOTOPHERESIS - COMPARISON OF THE IN-LINE AND OFF-LINE SYSTEM</b></p> <p><i>Poster Presenter:</i> Miriam Lanska, CZ</p>   | 09:50 - 09:50 |
| P062 | <p><b>PREDICTION OF COST-EFFECTIVE CALCULATION OF APHERESIS BLOOD VOLUME ACHIEVING TARGET CD3+ CELL NUMBER FOR THE MANUFACTURING OF CAR-T CELLS - A SINGLE CENTER COHORT STUDY</b></p> <p><i>Poster Presenter:</i> Efrat Rosenbaum, IL</p>       | 09:50 - 09:50 |

P063	<b>MODIFICATIONS OF A STANDARD ARA-C MOBILIZATION PROTOCOL FOR AMBULATORY CONDITIONS</b> <i>Poster Presenter:</i> Magdalena Dutka, PL	09:50 - 09:50
P064	<b>PLERIXAFOR. A FIXED DOSE OF 12 MG FOR RESCUING POOR MOBILIZER PATIENTS WITH MYELOMA OR LYMPHOMA.</b> <i>Poster Presenter:</i> Amado Karduss-Urueta, CO	09:50 - 09:50
P065	<b>ADOPTING PLERIXAFOR IN A LIMITED RESOURCE SCENARIO: CLINICAL AND PHARMACOECONOMIC COMPARISON OF HEMATOPOIETIC STEM CELL MOBILIZATION STRATEGIES.</b> <i>Poster Presenter:</i> Livia Mariano, BR	09:50 - 09:50
P066	<b>THE IMPACT OF CRYOPRESERVATION OF PERIPHERAL BLOOD STEM CELLS (PBSC) ON EARLY CLINICAL OUTCOME AFTER ALLO-HSCT</b> <i>Poster Presenter:</i> Iwona Mitrus, PL	09:50 - 09:50
P067	<b>HEMATOPOIETIC RECOVERY WITH MANAGEABLE COMPLICATIONS AFTER STEM CELL BOOST WITH IMMUNOMAGNETIC SELECTION IN THE THERAPY OF ALLOGENEIC POOR GRAFT FUNCTION</b> <i>Poster Presenter:</i> Jowita Frackiewicz, PL	09:50 - 09:50
P068	<b>A COMPARISON OF MOBILIZATION REGIMENS IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA</b> <i>Poster Presenter:</i> Thea Chandler, GB	09:50 - 09:50
P069	<b>CLINICO-LABORATORISTIC ASPECTS OF CRYOPRESERVATION OF PERIPHERAL BLOOD STEM CELLS (PBSC) IN MATCH UNRELATED TRANSPLANT</b> <i>Poster Presenter:</i> Gabriele Facchin, IT	09:50 - 09:50
P070	<b>AUTOLOGOUS STEM CELL TRANSPLANTATION IN A PATIENT WITH RED CELLS AGGLUTINATION IN LOW TEMPERATURE</b> <i>Poster Presenter:</i> Iwona Mitrus, PL	09:50 - 09:50
P071	<b>FACTORS LIMITING THE ACCESS TO PERFORMING AN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN CANDIDATES. A SINGLE CENTER EXPERIENCE IN MEXICO.</b> <i>Poster Presenter:</i> Mario Alberto Tapia Bravo, MX	09:50 - 09:50
P072	<b>MOBILIZATION OF HEMATOPOIETIC STEM CELLS WITH LENOGRASTIM IN MULTIPLE MYELOMA PATIENTS WITH MINIMAL RESIDUAL DISEASE</b> <i>Poster Presenter:</i> Ja Min Byun, KR	09:50 - 09:50
P073	<b>SAFETY OF BONE MARROW HEMATOPOIETIC STEM CELL COLLECTION FROM A SARS-COV-2 POSITIVE DONOR: A SINGLE EXPERIENCE DURING THE ITALIAN PANDEMIC</b> <i>Poster Presenter:</i> Gabriele Magliano, IT	09:50 - 09:50
P074	<b>THE IMPACT OF DARA-VRD ON STEM CELL MOBILISATION AND SUCCESSFUL ENGRAFTMENT; A REAL WORLD CASE SERIES</b>	09:50 - 09:50

	<i>Poster Presenter:</i> Janki Patel, GB	
P075	<b>EFFICACY OF PLERIXAFOR PLUS G-CSF IN PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA WHO HAVE HAD MOBILIZATION FAILURE WITH AT LEAST TWO REGIMENS. A RETROSPECTIVE STUDY</b> <i>Speaker:</i> Vildan Özkocaman, TR	09:50 - 09:50
P076	<b>HAEMATOPOETIC STEM CELL TRANSPLANT COLLECTIONS DURING THE COVID-19 PANDEMIC IN SOUTH AFRICA</b> <i>Poster Presenter:</i> Tanya Nadia Glatt, ZA	09:50 - 09:50
P077	<b>PREDICTIVE FACTORS OF POOR MOBILIZATION IN MULTIPLE MYELOMA PATIENTS</b> <i>Poster Presenter:</i> Nur Soyer, TR	09:50 - 09:50
P078	<b>PREDICTING THE SUCCESS OF PERIPHERAL BLOOD PROGENITOR CELLS COLLECTION WITH CVC</b> <i>Speaker:</i> Ana Salselas, PT	09:50 - 09:50
<i>Poster Sessions</i> 09:50 - 18:00		ePoster Area
<b>Stem Cell Donor</b>		
P169	<b>DONOR KLRC2 DELETION GENOTYPE IS ASSOCIATED WITH UPREGULATION OF ALLOREACTIVITY PATHWAYS WITH INCREASED GVHD AND NRM FOLLOWING T-REPLETE HAPLOIDENTICAL HCT</b> <i>Poster Presenter:</i> Sarita Rani Jaiswal, IN	09:50 - 09:50
P170	<b>HLA-MISMATCHED UNRELATED DONOR TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS HLA-HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH ACTIVE ACUTE MYELOID LEUKEMIA</b> <i>Poster Presenter:</i> Frédéric Baron, BE	09:50 - 09:50
P171	<b>EXCELLENT 3-YEAR SURVIVAL IN RECIPIENTS OF MISMATCHED UNRELATED DONOR TRANSPLANTS USING POST-TRANSPLANT CYCLOPHOSPHAMIDE: LONGER TERM OUTCOMES OF A NATIONAL MARROW DONOR PROGRAM-SPONSORED PROSPECTIVE CLINICAL TRIAL.</b> <i>Poster Presenter:</i> Bronwen Shaw, US	09:50 - 09:50
P172	<b>ANALYSIS OF UNRELATED ALLOGENEIC HSC DONORS WHO TESTED POSITIVE FOR SARS-COV-2 AT DIFFERENT DONATION STAGES, AND THE EFFECT ON DONATION OUTCOMES: A DONOR REGISTRY EXPERIENCE</b> <i>Poster Presenter:</i> Ruta Maniusste, GB	09:50 - 09:50
P173	<b>MYELOABLATIVE CONDITIONING AND PERIPHERAL BLOOD STEM CELLS FROM HAPLOIDENTICAL DONORS OFFERS COMPARABLE OUTCOMES TO MATCHED DONORS IN ALLOGENEIC TRANSPLANTATION FOR HAEMATOLOGICAL MALIGNANCIES</b> <i>Poster Presenter:</i> Kristjan Paulson, CA	09:50 - 09:50
P174	<b>PERSONALIZED STRATEGY FOR ALLOGENEIC STEM CELL TRANSPLANTATION GUIDED BY MACHINE LEARNING: A</b>	09:50 - 09:50



	<b>REAL-WORLD DATA ANALYSIS OF THE JAPANESE TRANSPLANT REGISTRY UNIFIED MANAGEMENT PROGRAM</b>	
	<i>Poster Presenter:</i> Hiroshi Okamura, JP	
P175	<b>DONOR SPECIFIC ANTI-HLA (DSA) ANTIBODIES IN HSCT AND DESENSITIZATION STRATEGIES</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ursula La Rocca, IT	
P176	<b>RETROSPECTIVE ANALYSIS OF THE IMPACT OF RECIPIENT-DONOR HLA-DISPARITY ON VIRAL REACTIVATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Anke Habermehl, AT	
P177	<b>THE CLINICAL OUTCOMES OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH HAPLOIDENTICAL STEM CELLS COMBINED WITH UMBILICAL CORD BLOOD TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Biqi Zhou, CN	
P178	<b>CHRONIC GVHD AFTER MISMATCH UNRELATED DONOR STEM CELL TRANSPLANTATION (9/10) MAY BE ASSOCIATED WITH PIRCHE (PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES) CALCULATED FROM SIX LOCI HLA.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Marcelina Grabowska, PL	
P179	<b>HIGHER DONOR AGE WITH A CUT-OFF OF 50 YEARS IS ASSOCIATED WITH INCREASED NON-RELAPSE MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Yasmine Kadri, CA	
P180	<b>RESEARCH ON THE EFFECTS OF TRANSPLANTATION OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL ON RECIPIENTS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> erlie jiang, AS	
P181	<b>ALLOGENEIC STEM CELLS AND LYMPHOCYTE DONATIONS: RESPONDING TO THE SARS-COV-2 CHALLENGE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Cristina Tassi, IT	
P182	<b>IMPACT OF GRAFT CD3 LYMPHOCYTE CELL DOSE ON CLINICAL OUTCOMES IN PEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Upasana Karthik, IN	
P183	<b>UNRELATED HEMATOPOIETIC PERIPHERAL BLOOD STEM CELL DONORS' EXPERIENCE; RESULTS ON 880 DONORS OF THE EZER MIZION ISRAELI NATIONAL BONE MARROW DONOR REGISTRY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Roni Zisser (Diamant), IL	
P184	<b>TRANSPLANT ACTIVITY IN MEXICO DURING THE COVID19 PANDEMIC: ON THE WAY TO RECOVERY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Andres Gomez-De Leon, MX	

P185	<b>NO IMPACT OF DONOR TYPE ON ALLOGENEIC TRANSPLANTATION (ALOHCT) OUTCOMES IN PATIENTS WITH MYELOID MALIGNITY ≥60 YEARS OLD</b> <i>Poster Presenter: Veronika Schneiderová, CZ</i>	09:50 - 09:50
P186	<b>A REPORT ON UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AT THE LARGEST CHILDREN'S MEDICAL HOSPITAL IN IRAN</b>	09:50 - 09:50
P187	<b>COMPARISON OF THE LONG-TERM OUTCOMES OF HLA-MISMATCHED UNRELATED DONOR TRANSPLANTATION AND SINGLE UNRELATED CORD BLOOD TRANSPLANTATION AFTER REDUCED INTENSITY/TOXICITY CONDITIONING</b> <i>Poster Presenter: Masatomo Kuno, JP</i>	09:50 - 09:50
P188	<b>IMPACT OF ABO INCOMPATIBILITY ON HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT. A SINGLE CENTER RETROSPECTIVE STUDY.</b> <i>Poster Presenter: Beatriz Astibia Mahillo, ES</i>	09:50 - 09:50
P189	<b>IMPACT OF ABO MISMATCH ON SURVIVAL AND ENGRAFTMENT IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter: Benjamin J. McCormick, US</i>	09:50 - 09:50
P191	<b>HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE</b> <i>Poster Presenter: Isabel Iturrate, ES</i>	09:50 - 09:50
P192	<b>PROPOSAL OF THE DIAGNOSTIC WORKUP OF <i>PLASMODIUM</i> SPP. SEROPOSITIVE ALLOGENEIC STEM CELL DONORS</b> <i>Poster Presenter: Rafal Machowicz, PL</i>	09:50 - 09:50
P193	<b>A SINGLE CENTER EXPERIENCE OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH UNMANIPULATED GRAFT - CASE SERIES OF ELEVEN PATIENTS</b> <i>Poster Presenter: Ilina Micheva, BG</i>	09:50 - 09:50
<i>Poster Sessions</i> 09:50 - 18:00		ePoster Area
<b>Graft-versus-host Disease - Clinical</b>		
P202	<b>REAL-WORLD DATA ON RUXOLITINIB IN STEROID-REFRACTORY ACUTE INTESTINAL GRAFT-VERSUS-HOST-DISEASE</b> <i>Poster Presenter: Francesca Biavasco, DE</i>	09:50 - 09:50
P203	<b>BORTEZOMIB MAINTENANCE AFTER UPFRONT ALLOGENEIC TRANSPLANTATION IN MYELOMA PATIENTS: LESS CHRONIC GVHD AND IMMUNOSUPPRESSION BUT STILL NO IMPACT ON SURVIVAL</b> <i>Poster Presenter: Jean-Sebastien Claveau, US</i>	09:50 - 09:50
P204	<b>BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER 2 OR MORE PRIOR LINES OF SYSTEMIC</b>	09:50 - 09:50

	<b>THERAPY: LONG-TERM SAFETY FOLLOW-UP OF THE PIVOTAL PHASE 2 ROCKSTAR STUDY (KD025-213)</b>	
	<i>Poster Presenter:</i> Corey Cutler, US	
P205	<b>INTERLEUKIN-1 GENE SINGLE NUCLEOTIDE POLYMORPHISMS: IMPACT ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Bernd Gruhn, DE	
P206	<b>FECAL MICROBIOTA TRANSPLANTATION IN THE TREATMENT OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE SURVEY OF THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Grzegorz Basak, PL	
P207	<b>PROSPECTIVE MULTICENTER NON INTERVENTIONAL OBSERVATIONAL STUDY ON THE USE OF ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN (ATLG) IN UNRELATED DONOR TRANSPLANTATION IN ADULTS WITH HAEMATOLOGICAL MALIGNANCIES (ATOS STUDY)</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Jürgen Finke, DE	
P208	<b>GRAFT VERSUS HOST DISEASE RELATED EOSINOPHILIC FASCIITIS</b>	09:50 - 09:50
	<i>Speaker:</i> Lucía López-Corral, ES	
P209	<b>METHOTREXATE OR MYCOPHENOLATE MOFETIL WITH CYCLOSPORINE AND ANTITHYMOCYTE GLOBULIN IN MATCHED UNRELATED DONOR TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH BUSULFAN-FLUDARABINE REDUCED-INTENSITY CONDITIONING: AN ALWP STUDY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Jacques-Emmanuel Galimard, FR	
P210	<b>TRIPLE AGENTS GVHD PROPHYLAXIS FOR HLA MATCHED DONOR: POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS THYMOGLOBULINES AND METHOTREXATE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Elisabetta Metafuni, IT	
P211	<b>TEN YEARS OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: WHAT HAVE WE LEARNED?</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Anne B Verbeek, NL	
P212	<b>RUXOLITINIB AS AN EFFECTIVE AND STEROID-SPARING FIRST-LINE TREATMENT IN NEWLY-DIAGNOSED BOS PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Xiaoyu Zhang, CN	
P213	<b>IMPACT OF TIMING OF CYCLOSPORINE-A ADMINISTRATION IN GRAFT-VERSUS-HOST-DISEASE AND PATIENT OUTCOMES IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Anne Banet, FR	
P214	<b>EARLY RESULTS OF PHASE I STUDY OF SHR0302, A</b>	09:50 - 09:50

	<b>SELECTIVE JAK1 INHIBITOR, COMBINED WITH PREDNISONE IN FIRST-LINE TREATMENT OF CGVHD AFTER ALLO-HSCT</b> <i>Poster Presenter:</i> Xianmin Song, CN	
P215	<b>ANTIBIOTIC USE AND ILEOCOLONIC IMMUNE CELLS COMPOSITION IN PATIENTS RECEIVING FECAL MICROBIOTA TRANSPLANTATION FOR REFRACTORY ACUTE INTESTINAL GVHD</b> <i>Poster Presenter:</i> Peter Neumeister, AT	09:50 - 09:50
P216	<b>CLINICAL AND ECONOMIC BURDEN ASSOCIATED WITH GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HSCT) IN FRANCE</b> <i>Poster Presenter:</i> David Michonneau, FR	09:50 - 09:50
P217	<b>POST-TRANSPLANT-CYCLOPHOSPHAMIDE AND SHORT-TERM EVEROLIMUS AS GRAFT-VERSUS-HOST-PROPHYLAXIS IN PATIENTS WITH HIGH-RISK LYMPHOMA AND MYELOMA - FINAL RESULTS OF THE PHASE II OCTET-EVER TRIAL.</b> <i>Poster Presenter:</i> Udo Holtick, DE	09:50 - 09:50
P218	<b>INCIDENCE AND RISK FACTORS FOR HYPONATREMIA INDUCED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Marta Gómez Hernando, ES	09:50 - 09:50
P219	<b>HOST VERSUS GRAFT HLA-DPB1 MISMATCHES PROMOTE CLINICAL GRAFT VERSUS HOST DISEASE</b> <i>Poster Presenter:</i> Callum Wright, GB	09:50 - 09:50
P220	<b>VARIABLE IMPACT OF GRAFT CD3<sup>+</sup> CELLS ON GRAFT VERSUS HOST DISEASE IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: IS THE ROLE OF DONOR CD3<sup>+</sup> CELLS OVERESTIMATED?</b> <i>Poster Presenter:</i> Zeynep Arzu Yegin, TR	09:50 - 09:50
P221	<b>THE USE OF VEDOLIZUMAB AS SECOND-LINE THERAPY FOR STEROID-REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS HOST DISEASE IN CHILDREN</b> <i>Poster Presenter:</i> Gleb Bronin, RU	09:50 - 09:50
P222	<b>PREDICTIVE VALUE OF ST2, REG3A AND MAGIC ALGORITHM IN SURVIVAL AND COMPLICATIONS RELATED TO HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRASPLANT CYCLOPHOSPHAMIDE: SINGLE CENTER EXPERIENCE</b> <i>Poster Presenter:</i> Marta Fonseca Santos, ES	09:50 - 09:50
P223	<b>PANCREATIC ATROPHY AND RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: PREDICTIVE FACTORS AND PROGNOSIS</b> <i>Poster Presenter:</i> Yosuke Okada, JP	09:50 - 09:50
P224	<b>SAFETY OF HOME CARE IN PATIENTS WITH PREVIOUS AUTOLOGOUS STEM CELL TRANSPLANT PURSUING ALLOGENEIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50

*Poster Presenter: Marta Garcia-Recio, ES*

P225	<b>MODULAATE, A 2-PART, DOSE-FINDING, EFFICACY AND SAFETY TRIAL WITH ALPHA-1 ANTITRYPSIN FOR PREVENTION OF ACUTE GRAFT VS. HOST DISEASE: PART 1 SAFETY AND PHARMACOKINETIC RESULTS</b>	09:50 - 09:50
	<i>Poster Presenter: John Mallee, US</i>	
P226	<b>THE ATG DOSE AND TLC DON'T IMPACT ON THE DEVELOPMENT OF GVHD AND VIRAL REACTIVATIONS IN PATIENTS UNDERGOING CD34+ SELECTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION.</b>	09:50 - 09:50
	<i>Poster Presenter: Ángela Sánchez Cayuela, ES</i>	
P228	<b>HLA MOLECULAR MISMATCH AND ITS IMPLICATION IN THE ALLORESPONSE AND OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter: Marta Gómez Hernando, ES</i>	
P229	<b>POST-TRANSPLANT CYCLOPHOSPHAMIDE, ABATACEPT, AND SHORT COURSE OF TACROLIMUS (CAST) FOR GRAFT-VERSUS-HOST DISEASE PREVENTION FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter: A Samer Al-Homsi, US</i>	
P230	<b>POST TRANSPLANTATION CYCLOPHOSPHAMIDE BASED GVHD PROPHYLAXIS ACROSS DONOR TYPES - A SINGLE CENTER EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter: Jan Vydra, CZ</i>	
P231	<b>HIGH EXPRESSION OF CD62L AS A SIGNATURE OF STEROID-REFRACTORY/RESISTANT GVHD REVEALED BY IMMUNE PROFILING AND MACHINE LEARNING</b>	09:50 - 09:50
	<i>Poster Presenter: Yuntian Ding, DE</i>	
P232	<b>CYTOKINE TRAJECTORIES AND RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter: Lars Klingen Gjørde, DK</i>	
P233	<b>SIMILAR OUTCOMES OF PTCY AND ATG BASED GVHD PROPHYLAXIS IN HEMATOPOIETIC CELL TRANSPLANTATION FROM MATCHED UNRELATED DONORS</b>	09:50 - 09:50
	<i>Poster Presenter: Jan Vydra, CZ</i>	
P234	<b>ANTI-THYMOCYTE GLOBULIN (ATG) EQUALIZE THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE (GVHD) AMONG UNRELATED AND IDENTICAL SIBLING DONOR TRANSPLANTATION.</b>	09:50 - 09:50
	<i>Poster Presenter: Agustina Cia, AR</i>	
P235	<b>FIRST-LINE STEROID-FREE SYSTEMIC TREATMENT OF ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER NOVEL PROPHYLAXIS REGIMENS IN ADULTS</b>	09:50 - 09:50
	<i>Poster Presenter: Ivan Moiseev, RU</i>	
P236	<b>PEMBROLIZUMAB AND ALLOTRANSPLANTS FOR RELAPSED REFRACTORY CLASSICAL HODGKIN LYMPHOMA</b>	09:50 - 09:50

- Poster Presenter:* Khalid Halahleh, JO
- P237 **CLINICAL ANALYSIS OF AIR-LEAK SYNDROME FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS** 09:50 - 09:50  
*Poster Presenter:* Wei Zhao, CN
- P238 **COMPARISON OF REGULATORY T CELL SUBPOPULATION BETWEEN ANTITHYMOCYTIC GLOBULIN AND POST-TRANSPLANTCYCLOPHOSPHAMIDE FOR PREVENTION OF THE GVHD IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Ik-Chan Holtick, KR
- P239 **CLINICAL AND ECONOMIC BURDEN ASSOCIATED WITH ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HSCT) IN GERMANY** 09:50 - 09:50  
*Poster Presenter:* Udo Holtick, DE
- P240 **TREATMENT PATTERN CHARACTERIZATION AND OUTCOMES IN CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS TREATED WITH EXTRACORPOREAL PHOTOPHERESIS IN CLINICAL PRACTISE IN SWEDEN** 09:50 - 09:50  
*Poster Presenter:* Gösta Berlin, SE
- P241 **LONG-TERM FOLLOW-UP OF RUXOLITINIB FOR THERAPY IN CORTICOSTEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: A SINGLE CENTER-EXPERIENCE** 09:50 - 09:50  
*Poster Presenter:* Ali Ünal, TR
- P242 **PHARMACOKINETICS OF DIFFERENT TACROLIMUS FORMULATIONS FOR GVHD PREVENTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.** 09:50 - 09:50  
*Poster Presenter:* Carmen Martínez, ES
- P243 **PROPHYLACTIC DEFIBROTIDE IS EFFECTIVE FOR ACUTE GRAFT VERSUS HOST DISEASE AS WELL AS SINUSOIDAL OBSTRUCTIVE SYNDROME** 09:50 - 09:50  
*Poster Presenter:* Selami Kocak Toprak, TR
- P244 **PROSPECTIVE ANALYSIS OF THE INCIDENCE AND OUTCOME OF LATE ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE FROM MULTIPLE TRANSPLANT CENTERS** 09:50 - 09:50  
*Poster Presenter:* Ronja Langer, DE
- P245 **MYELOID-DERIVED SUPPRESSOR CELLS PREDICT RESPONSE TO RUXOLITINIB-CORTICOSTEROIDS THERAPY FOR ACUTE GRAFT VERSUS HOST DISEASE** 09:50 - 09:50  
*Poster Presenter:* Bo Peng, CN
- P247 **RELATIONSHIP WITHIN ANAEROBICIDAL ANTIBIOTICS, CLOSTRIDIUM DIFFICILE INFECTION AND THE DEVELOPMENT AND DEGREE OF DIGESTIVE GRAFT VERSUS HOST DISEASE.** 09:50 - 09:50  
*Poster Presenter:* Asuncion Borrero Borrego, ES
- P248 **LOW-DOSE ANTITHYMOCYTE GLOBULIN PLUS LOW-DOSE POSTTRANSPLANT CYCLOPHOSPHAMIDE COULD MITIGATE THE RISK OF GRAFT VERSUS HOST DISEASE** 09:50 - 09:50

	<b>AFTER HAPLOIDENTICAL TRANSPLANTATION FROM MATERNAL/COLLATERAL DONORS</b> <i>Poster Presenter:</i> Xianmin Song, CN	
P249	<b>GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS BASED ON EVEROLIMUS AND TACROLIMUS IN CHILDREN WITH ACUTE LEUKEMIA AND JMML AFTER HAPLO-HSCT</b> <i>Poster Presenter:</i> Ludmila Zubarovskaya, RU	09:50 - 09:50
P250	<b>EXOCRINE PANCREATIC INSUFFICIENCY AS AN ATYPICAL MANIFESTATION OF CHRONIC GRAFT VERSUS HOST DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Ana Puchol Crespo, ES	09:50 - 09:50
P251	<b>ASSESSMENT OF EFFICACY AND TOXICITY OF METHOTREXATE IN THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE</b> <i>Poster Presenter:</i> Isabella Gonçalves Ramos, BR	09:50 - 09:50
P252	<b>TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH EXTRACORPOREAL PHOTOPHERESIS. EXPERIENCE IN A CENTER</b> <i>Poster Presenter:</i> Paula López de Ugarriza, ES	09:50 - 09:50
P253	<b>APOPTOSIS AND CYTOKINE SECRETION OF T CELLS DURING ECP TREATMENT FOR CGVHD USING THE AMICUS™ BLUE™ ONLINE ECP SYSTEM</b> <i>Poster Presenter:</i> Yendry Ventura-Carmenate, AE	09:50 - 09:50
P254	<b>ROUTINE USE OF ANTI-THYMOCYTE GLOBULIN (ATG) RESULTS IN LOW INCIDENCE OF SEVERE GRAFT-VERSUS-HOST DISEASE: A SINGLE CENTER EXPERIENCE</b> <i>Poster Presenter:</i> Flóra Kovácsová, CZ	09:50 - 09:50
P255	<b>JAK 1/2 INHIBITOR (RUXOLITINIB) MIGHT HAVE A POSITIVE EFFECT ON MDSCS</b> <i>Poster Presenter:</i> Jingjing Yang, CN	09:50 - 09:50
P256	<b>LONG-TERM OUTCOME IN PATIENTS RECEIVING IMATINIB FOR STEROID-REFRACTORY CHRONIC GVHD/ FOR REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE WITH FIBROTIC FEATURES: A SINGLE-CENTER EXPERIENCE</b> <i>Poster Presenter:</i> Ali Ünal, TR	09:50 - 09:50
P258	<b>ESCALATING COMBINATORY FIRST-LINE TREATMENT FOR SEVERE ACUTE GVHD AFTER HEMATOPOIETIC STEM CELL TRANSPLANT</b> <i>Poster Presenter:</i> Francesco Saraceni, IT	09:50 - 09:50
P259	<b>RETROSPECTIVE SINGLE CENTER ANALYSIS OF ALPHA 1 ANTITRYPSIN FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE GUT AFTER MULTIPLE LINES OF PRETREATMENT</b> <i>Poster Presenter:</i> Katharina Nickel, DE	09:50 - 09:50
P260	<b>MESENCHYMAL STROMAL CELLS IN PATIENTS WITH III-IV GRADE STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE: 8 YEARS OF EXPERIENCE</b>	09:50 - 09:50

	<i>Poster Presenter:</i> Adomas Bukauskas, LT	
P261	<b>A SINGLE CENTRE EXPERIENCE OF RUXOLITINIB FOR TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE</b> <i>Poster Presenter:</i> Zoe Kirkham, GB	09:50 - 09:50
P262	<b>A PROSPECTIVE ANALYSIS OF THE CHANGES IN THE IMMUNE PROFILE OF SR-CGVHD PATIENTS UNDERGOING ECP TREATMENT WITH THE AMICUS BLUE™ ONLINE ECP SYSTEM</b> <i>Poster Presenter:</i> Yendry Ventura-Carmenate, AE	09:50 - 09:50
P263	<b>ASSOCIATION BETWEEN VITAMIN D AND GVHD BIOMARKERS WITH RESPONSE TO IMMUNOSUPPRESSION AND SURVIVAL IN ACUTE GVHD: AN EXPLORATORY STUDY</b> <i>Poster Presenter:</i> Jose Ros-Soto, GB	09:50 - 09:50
P264	<b>ANTI-THYMOCYTE GLOBULIN TO PREVENT GRAFT VERSUS HOST DISEASE AFTER HLA MATCHED RELATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS</b> <i>Poster Presenter:</i> Nabil YAFOUR, DZ	09:50 - 09:50
P265	<b>SAFETY AND EFFECTIVENESS OF THE AMICUS BLUE™ ONLINE ECP SYSTEM IN SR-CGVHD PATIENTS DURING A 6-MONTH TREATMENT REGIMEN</b> <i>Poster Presenter:</i> Yendry Ventura-Carmenate, AE	09:50 - 09:50
P266	<b>A RANDOMIZED, OPEN LABEL, MULTICENTRE, PHASE 3 TRIAL OF FIRST LINE TREATMENT WITH MSC VERSUS BAT IN PATIENTS WITH STEROID REFRACTORY ACUTE GVHD (IDUNN TRIAL)</b> <i>Poster Presenter:</i> Robert Zeiser, DE	09:50 - 09:50
P267	<b>EXTRACORPOREAL PHOTOPHERESIS- A CASE BASED NEW EXPERIENCE IN TREATING CHRONIC GVHD</b> <i>Poster Presenter:</i> Lazar Chadievski, MK	09:50 - 09:50
<i>Poster Sessions</i> 09:50 - 18:00		ePoster Area
<b>Infectious Complications</b>		
P268	<b>RECONSTITUTION OF <i>BACTEROIDES FRAGILIS</i> AND <i>FAECALIBACTERIUM PRAUSNITZII</i> ASSOCIATED WITH CLINICAL RESPONSE IN ACUTE INTESTINAL GVHD</b> <i>Poster Presenter:</i> Ivan Moiseev, RU	09:50 - 09:50
P269	<b>THE MANAGEMENT OF CYTOMEGALOVIRUS INFECTION AMONG EBMT CENTERS: A SURVEY FROM INFECTIOUS DISEASES WORKING PARTY OF EBMT</b> <i>Poster Presenter:</i> Simone Cesaro, IT	09:50 - 09:50
P270	<b>ENDOTHELIAL COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH RESOLVED COVID 19 DISEASE</b> <i>Poster Presenter:</i> Christian Niederwieser, DE	09:50 - 09:50
P272	<b>SAFETY AND IMMUNOGENICITY OF A MENINGOCOCCAL</b>	09:50 - 09:50



	<b>RECOMBINANT VACCINE IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE STUDY WITH A 12 MONTHS FOLLOW-UP</b> <i>Poster Presenter:</i> Christine Robin, FR	
P273	<b>IMPACT OF FLUOROQUINOLONE PROPHYLAXIS ON BLOODSTREAM INFECTION INCIDENCE IN THE FIRST 30 DAYS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Chiara Maria Dellacasa, IT	09:50 - 09:50
P274	<b>BK POLYOMAVIRUS-LOADS REFLECT NAKED DNA FRAGMENTS AFFECTING QUANTIFICATION AND IDENTIFICATION OF VARIANT IMMUNODOMINANT LTAG AND VP1 EPITOPES IN HCT PATIENTS WITH BKPYV-ASSOCIATED HEMORRHAGIC CYSTITIS (BKPYV-HC)</b> <i>Poster Presenter:</i> Karoline Leuzinger, CH	09:50 - 09:50
P275	<b>ANTI-SARS-COV-2 MONOCLONAL ANTIBODY THERAPY IS EFFECTIVE AT PREVENTING SEVERE DISEASE IN STEM CELL TRANSPLANT AND CELLULAR IMMUNOTHERAPY RECIPIENTS DIAGNOSED WITH SARS-COV-2</b> <i>Poster Presenter:</i> Eloho Ajayi, US	09:50 - 09:50
P276	<b>ANTIBODY RESPONSE AFTER VACCINATION WITH BNT162B2 MRNA VACCINE AGAINST SARS-COV-2 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES POST HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A SINGLE-CENTER PROSPECTIVE STUDY</b> <i>Poster Presenter:</i> John V. Asimakopoulos, GR	09:50 - 09:50
P277	<b>INCIDENCES OF INFECTIONS AND VIRAL REACTIVATIONS MORE FREQUENT WITH ATG THAN WITH POST-TRANSPLANTION CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS IN MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATIONS</b> <i>Poster Presenter:</i> Mesire Aydin, NL	09:50 - 09:50
P278	<b>CLINICAL COURSE AND OUTCOMES OF COVID-19 IN PEDIATRIC PATIENTS AFTER CHEMOTHERAPY, IMMUNOSUPPRESSIVE THERAPY AND HEMATOPOIETIC CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Tatiana Bykova, RU	09:50 - 09:50
P279	<b>EFFICACY AND SAFETY OF MRNA SARS-COV-2 VACCINATION IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS: SINGLE CENTRE EXPERIENCE.</b> <i>Poster Presenter:</i> Maria Huguet, ES	09:50 - 09:50
P280	<b>THE EFFECT OF HLA MATCHING ON EARLY POST-TRANSPLANT INFECTIONS IN PATIENTS RECEIVING TRIPLE PTCY-BASED GVHD PROPHYLAXIS</b> <i>Poster Presenter:</i> John Marra, IT	09:50 - 09:50
P281	<b>IMPACT OF LEVOFLOXACIN PROPHYLAXIS WITHDRAWAL ON PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTER ALLOGENEIC STEM CELL TRANSPLANT</b> <i>Poster Presenter:</i> Daniela Clerici, IT	09:50 - 09:50

P282	<b>OUTCOME OF POST-VACCINATION COVID-19 IN HEMATOPOIETIC STEM CELL TRANSPLANT AND CAR T CELL TREATMENT RECIPIENTS; RESULTS FROM AN IDWP PROSPECTIVE SURVEY.</b> <i>Poster Presenter:</i> Per Ljungman, SE	09:50 - 09:50
P283	<b>INCREASED RISK OF BLOODSTREAM INFECTIONS IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION COMBINED WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE</b> <i>Poster Presenter:</i> Maria Queralt Salas, ES	09:50 - 09:50
P284	<b>THE TIMING OF CLINICALLY SIGNIFICANT CMV INFECTION FOLLOWING ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) IS ASSOCIATED WITH POOR SURVIVAL; A NATIONAL MULTI-CENTRE COHORT STUDY</b> <i>Poster Presenter:</i> Michelle Yong, AU	09:50 - 09:50
P285	<b>HUMORAL RESPONSE TO ANTI-SARS-COV2 VACCINES IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS INCLUDING CYTOMETRIC ANALYSIS OF PERIPHERAL BLOOD LYMPHOCYTES</b> <i>Poster Presenter:</i> Agnieszka Tomaszewska, PL	09:50 - 09:50
P286	<b>THE VALUE OF BASELINE CHEST CT SCAN FOR THE DIAGNOSIS OF IPA IN PATIENTS WITH AML TREATED WITH INTENSIVE CHEMOTHERAPY: A RETROSPECTIVE SINGLE-CENTRE COHORT STUDY</b> <i>Poster Presenter:</i> Alexander Schauwvlieghe, BE	09:50 - 09:50
P287	<b>EFFECTIVE RAPID DIAGNOSIS OF BACTERIAL BLOODSTREAM INFECTIONS BY T2 MAGNETIC RESONANCE TECHNOLOGY IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Federica Galaverna, IT	09:50 - 09:50
P288	<b>DEVELOPMENT OF A RISK PREDICTION MODEL OF SUBSEQUENT BLOODSTREAM INFECTION AFTER CARBAPENEM-RESISTANT ENTEROBACTERIACEAE ISOLATED FROM PERIANAL SWABS SAMPLES IN PATIENTS WITH HEMATOLOGICAL DISEASES</b> <i>Poster Presenter:</i> erlie jiang, AS	09:50 - 09:50
P289	<b>PHASE 3 TRIAL OF TRANSPLANT RECIPIENTS WITH REFRACTORY CYTOMEGALOVIRUS WITH/WITHOUT RESISTANCE RECEIVING MARIBAVIR OR INVESTIGATOR-ASSIGNED THERAPIES: SUBGROUP ANALYSES OF EFFICACY AND SAFETY BY RENAL IMPAIRMENT</b> <i>Poster Presenter:</i> Sanjeet Dadwall, US	09:50 - 09:50
P290	<b>PERSISTENCE OF THE IMMUNE RESPONSE AFTER VACCINATION AGAINST SARS-COV-2 IN PATIENTS WITH ONCOHEMATOLOGICAL DISEASES WHO UNDERWENT AUTOLOGOUS OR ALLOGENIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Lucía Pérez-Lamas, ES	09:50 - 09:50
P291	<b>ADENOVIRUS INFECTION IN GI BIOPSIES OF IMMUNOCOMPROMISED PATIENTS WHO UNDERWENT</b>	09:50 - 09:50

**ALLOGENEIC STEM CELL TRANSPLANTATION***Poster Presenter:* Batia Avni, IL

- P292 **THE IMPACT OF INTESTINAL MICROBIOTA IN ATG-BASED MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC-CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Zhenyang Gu, CN
- P293 **CLINICAL OUTCOMES OF PATIENTS WITH EPSTEIN-BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY** 09:50 - 09:50  
*Poster Presenter:* Jaime Sanz Caballer, ES
- P294 **IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA ON BLOODSTREAM INFECTIONS IN EARLY PHASE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Yuliya Rogacheva, RU
- P295 **REAL-WORLD EXPERIENCE WITH ISAVUCONAZOLE IN ALLOGENEIC STEM CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Gillen Oarbeascoa, ES
- P296 **IMPACT OF SOCIETAL AND HEALTHCARE INFECTION CONTROL MEASURES ON INCIDENCE OF NON-SARS-2-COV RESPIRATORY VIRAL INFECTIONS IN HSCT IN-PATIENT ADMISSIONS; A SINGLE UK CENTRE EXPERIENCE** 09:50 - 09:50  
*Poster Presenter:* Jack Murrell, GB
- P297 **INFECTIVE COMPLICATIONS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES: RESULTS OF AN INNOVATIVE PROGRAM FOR SURVEILLANCE, PROPHYLAXIS AND TREATMENT (BATMO PROTOCOL)** 09:50 - 09:50  
*Poster Presenter:* Michele Malagola, IT
- P298 **BEYOND THE RESPIRATORY TRACT - THE IMPACT OF A RESPIRATORY VIRAL OUTBREAK IN A HSCT UNIT IN INDIA** 09:50 - 09:50  
*Poster Presenter:* Revathi Raj, IN
- P299 **THE HUMORAL RESPONSE TO SARS-COV2 VACCINATION IS INFLUENCED BY VACCINATION SCHEME, IMMUNOSUPPRESSION, LYMPHOCYTE COUNTS AND TIME AFTER ALLOHCT** 09:50 - 09:50  
*Poster Presenter:* Claudia Wehr, DE
- P300 **LETERMOVIR PROPHYLAXIS REDUCES PEAK CMV TITRES AND NEED FOR ADDITIONAL ANTIVIRAL TREATMENT IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION.** 09:50 - 09:50  
*Poster Presenter:* Michael Buckton, GB
- P301 **INCIDENCE AND OUTCOME OF CMV REACTIVATION IN NON-MALIGNANT PEDIATRIC HSCT RECIPIENTS** 09:50 - 09:50  
*Poster Presenter:* Zofia Szmit, PL

P302	<b>LOW RATE OF DOCUMENTED INFECTIONS AS THE CAUSE OF ENTEROCOLITIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: PROSPECTIVE STUDY BY THE GETH.</b> <i>Poster Presenter:</i> Sara Redondo, ES	09:50 - 09:50
P303	<b>OPEN-LABEL RANDOMIZED CONTROLLED STUDY OF CIPROFLOXACIN VERSUS RIFAXIMIN AS NEUTROPENIA PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SURVIVAL BENEFIT FOR CIPROFLOXACIN</b> <i>Poster Presenter:</i> Eleni Gavriilaki, GR	09:50 - 09:50
P304	<b>CHANGES IN RESPIRATORY VIRAL INFECTIONS LANDSCAPE AMONG ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DURING SARS-COV 2 PANDEMIC: SINGLE CENTRE REAL LIFE EXPERIENCE</b> <i>Poster Presenter:</i> Elisabetta Metafuni, IT	09:50 - 09:50
P305	<b>FECAL COLONIZATION IN PATIENTS FOLLOWING HEMATOPOIETIC STEM-CELL TRANSPLANTATION BY MULTIDRUG-RESISTANT BACTERIA: A SINGLE CENTER STUDY ON MICROBIAL SPECTRUM AND RESISTANCE PROFILE</b> <i>Poster Presenter:</i> Denis Niyazi, BG	09:50 - 09:50
P306	<b>PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTER FIRST AND SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: INCIDENCE, ETIOLOGY, RISK FACTORS AND OUTCOMES</b> <i>Poster Presenter:</i> Mobil Akhmedov, RU	09:50 - 09:50
P307	<b>THE PATIENT'S CMV SEROLOGICAL STATUS IS AN INDEPENDENT FACTOR FOR CMV INFECTION (CMVI) IN THE POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS ERA</b> <i>Poster Presenter:</i> Beatriz Herruzo, ES	09:50 - 09:50
P308	<b>THIRD-DOSE BNT162B2 VACCINE IS HIGHLY EFFICIENT AT INCREASING ANTI-RBD SARS-COV-2 IGG TITERS IN ALLO-HCT RECIPIENTS</b> <i>Poster Presenter:</i> Frédéric Baron, BE	09:50 - 09:50
P309	<b>POSOLEUCEL FOR THE PREVENTION OF CLINICALLY SIGNIFICANT INFECTIONS IN HIGH-RISK ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: DESIGN OF A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL</b> <i>Poster Presenter:</i> Simona Sica, IT	09:50 - 09:50
P310	<b>BLOODSTREAM INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS COLONIZED BY MULTIDRUG-RESISTANT BACTERIA</b> <i>Poster Presenter:</i> Ana Pilar Gonzalez-Rodriguez, ES	09:50 - 09:50
P311	<b>COVID-19 IN ALLOGENEIC STEM CELL TRANSPLANT PATIENTS: A LONGITUDINAL STUDY TROUGH EIGHTEEN MONTHS OF PANDEMIC</b> <i>Poster Presenter:</i> Monica Cabrero, ES	09:50 - 09:50

P312	<b>ANALYSIS OF THE EXPRESSION OF CYTOMEGALOVIRUS DRUG RESISTANCE GENE MUTATIONS IN PATIENTS HAVING CYTOMEGALOVIRUS INFECTION WITH POOR EFFICACY AFTER TRANSPLANTATION</b> <i>Poster Presenter:</i> Donglin Yang, CN	09:50 - 09:50
P313	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH PRIOR INFECTION CAUSED BY THE SARS-COV-2 (COVID-19)</b> <i>Poster Presenter:</i> Aleksandr Siniaev, RU	09:50 - 09:50
P314	<b>RITUXIMAB THERAPY AFTER PEDIATRIC HEMATOPOETIC STEM CELL TRANSPLANTATION CAN CAUSE PROLONGED B CELL DAMAGE AND INCREASES THE RISK FOR INFECTIONS</b> <i>Poster Presenter:</i> Michael Launspach, DE	09:50 - 09:50
P315	<b>CIDOFOVIR TREATMENT FOR BK-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER ALLOGENIC STEAM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: A RETROSPECTIVE ANALYSIS AT A SINGLE INSTITUTION</b> <i>Poster Presenter:</i> Mario Andres Sanchez-Salinas, ES	09:50 - 09:50
P316	<b>BLOODSTREAM INFECTIONS DUE TO CARBAPENEM-RESISTANT ENTEROBACTERIACEAE IN HEMATOLOGICAL PATIENTS: A RETROSPECTIVE SINGLE-CENTER STUDY</b> <i>Poster Presenter:</i> Lining Zhang, CN	09:50 - 09:50
P317	<b>THE ANTIBODY RESPONSE TO BNT162B2 OR MRNA-1273 VACCINES IN ALLOTRANSPLANT RECIPIENTS DEPENDS ON THE EXISTING RESPONSE TO ENDEMIC HUMAN CORONAVIRUSES AND PREVIOUS ATG THERAPY</b> <i>Poster Presenter:</i> Tor Henrik Anderson Tvedt, NO	09:50 - 09:50
P318	<b>ANTIBODY RESPONSES TO SARS-COV-2 VACCINATION/INFECTION IN HEMATOLOGICAL MALIGNANCIES AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS - A SINGLE-CENTER EXPERIENCE</b> <i>Poster Presenter:</i> Jaroslaw Dybko, PL	09:50 - 09:50
P319	<b>EPIDEMIOLOGY OF INVASIVE ASPERGILLOSIS CAUSED BY ASPERGILLUS NON-FUMIGATUS VS ASPERGILLUS FUMIGATUS IN ADULTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Yuliya Rogacheva, RU	09:50 - 09:50
P320	<b>PREVENTION OF CPE BLOODSTREAM INFECTION AND DEATH IN A PAEDIATRIC ALLOGENIC HSCT POPULATION : THE MANCHESTER STORY</b> <i>Poster Presenter:</i> Annalie Shears, GB	09:50 - 09:50
P321	<b>PROSPECTIVE TRIAL ON UROLOGICAL COMPLICATIONS IN LONG-TERM SURVIVORS OF ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) - ANALYSIS FOCUSED ON VIRAL UROLOGICAL INFECTIONS</b> <i>Poster Presenter:</i> Thomas Neumann, DE	09:50 - 09:50
P322	<b>CYTOMEGALOVIRUS REACTIVATION UNDER PRE-</b>	09:50 - 09:50

- EMPTIVE THERAPY DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT: THE PATTERN, SURVIVAL, AND RISK FACTORS IN SOUTH KOREA**  
*Poster Presenter:* Ka-Won Kang, KR
- P323 **CMV REACTIVATION AFTER ALLOHCT IN TWO GROUPS OF RECIPIENTS: FROM HAPLOIDENTICAL AND MISMATCHED UNRELATED DONOR - A PRELIMINARY ANALYSIS ON BEHALF OF POLISH ADULT LEUKEMIA GROUP** 09:50 - 09:50  
*Poster Presenter:* Jaroslaw Dybko, PL
- P324 **ANTIBODY RESPONSES AND SAFETY OF THE COMMERCIALY AVAILABLE VACCINES AGAINST SARS-COV-2 VIRUS IN ALLOGRAFTED PATIENTS: REAL WORLD DATA FROM A SINGLE CENTER** 09:50 - 09:50  
*Poster Presenter:* Panayotis Kaloyannidis, SA
- P325 **LETERMOVIR IS EFFECTIVE AS PRIMARY PROPHYLAXIS AGAINST CYTOMEGALOVIRUS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS, BUT LATE INFECTIONS OCCUR FOLLOWING DISCONTINUATION WHEN CELLULAR IMMUNITY IS IMPAIRED** 09:50 - 09:50  
*Poster Presenter:* Ifigeneia Tzannou, GR
- P326 **SARS COV-2 INFECTION AND COVID-19 IN HEALTH CARE WORKERS FROM A HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) UNIT BEFORE AND AFTER VACCINATION: A PROSPECTIVE COHORT STUDY** 09:50 - 09:50  
*Poster Presenter:* Clarisse Machado, BR
- P328 **OFF-LABEL USE OF LETERMIVIR IN A PEDIATRIC COHORT OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Pietro Merli, IT
- P329 **MONITORING AND MANAGEMENT OF CYTOMEGALOVIRUS REACTIVATION IN AUTOLOGOUS STEM CELL TRANSPLANT RECIPIENTS: RESULTS OF MORE THAN A DECADE OF EXPERIENCE** 09:50 - 09:50  
*Poster Presenter:* Vildan Özkocaman, TR
- P330 **COVID-19 IN HEMATOPOIETIC STEM-CELL TRANSPLANTATION RECIPIENTS: SINGLE CENTER EXPERIENCE** 09:50 - 09:50  
*Poster Presenter:* Zeynep Tugba Guven, TR
- P331 **INFECTIOUS COMPLICATIONS AFTER HEMATOPOIETIC ALLOGENEIC TRANSPLANTATION IN THE ERA OF FLT3 INHIBITORS** 09:50 - 09:50  
*Poster Presenter:* Ilaria Cutini, IT
- P332 **QTC PROLONGATION DURING LEVOFLOXACIN AND TRIAZOLE COMBINATION CHEMOPROPHYLAXIS: PREVALENCE AND PREDISPOSING RISK FACTORS IN A COHORT OF HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS** 09:50 - 09:50  
*Poster Presenter:* Ahmad Ibrahim, LB
- P333 **ANTIBODY RESPONSES TO SARS-COV-2 VACCINATION IN** 09:50 - 09:50

	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS</b>	
	<i>Poster Presenter:</i> Maria Liga, GR	
P335	<b>A STUDY FOR THE RELATIONSHIP BETWEEN FEVER IN NEUTROPENIC PATIENTS AND BACTERIA-DERIVED MICROVESICLES.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Sungnam Lim, KR	
P336	<b>SAFETY AND IMMUNOGENICITY OF BNT162B2 MRNA COVID-19 VACCINE IN JAPANESE PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Marika Watanabe, JP	
P337	<b>EFFICACY OF CYTOMEGALOVIRUS SPECIFIC IMMUNOGLOBULINS (CMV-IG) IN REDUCING CMV REACTIVATION IN PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Claire Geurten, BE	
P338	<b>OUTCOMES OF COVID-19 IN PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CELLULAR THERAPY: A SINGLE CENTER EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Flóra Kovácsová, CZ	
P339	<b>POSOLEUCEL FOR ADENOVIRUS INFECTION IN PEDIATRIC AND ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: DESIGN OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Kanchan Rao, GB	
P340	<b>OVERVIEW OF CYTOMEGALOVIRUS VIREMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: EXPERIENCE OF A POPULATION WITH HIGH SEROPREVALENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ana Karen Toledo Riquelme, MX	
P342	<b>CYTOMEGALOVIRUS VIREMIA RATE AND HEALTHCARE BURDEN OF DISEASE IN ADULT ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Riku Korhonen, FI	
P343	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HUMAN T-LYMPHOTROPIC VIRUS TYPE 1 (HTLV-1) LEUKEMIA-LYMPHOMA: TWO CASES REPORT.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Sofia Diaz-Lopez, ES	
P344	<b>HIGH DOSE CIDOFOVIR, CIPRO, AND IVIG COMBINATION TREATMENT FOR BK VIRUS HEMORRHAGIC CYSTITIS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Sami Brake, US	
P345	<b>ACTIVE SARS-COV-2 INFECTION ON THE DAY BEFORE AUTOLOGOUS STEM CELL TRANSPLANT IN A PATIENT WITH MULTIPLE MYELOMA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Marta Henriques, PT	
P346	<b>COVID-19 IN PATIENTS WITH HEMATOLOGICAL</b>	09:50 - 09:50

**DISEASES AFTER SCT : SINGLE CENTER OBSERVATION FROM BULGARIA , SOFIA, 859 BMT UNIT**

*Poster Presenter:* Penka Ganeva, BG

- |      |  |               |
|------|--|---------------|
| P347 | <b>MYCOBACTERIUM ABSCESSUS CATHETER RELATED INFECTION BLOODSTREAM IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>                      | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Miriam López, ES  |               |
| P348 | <b>HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: EASY DIAGNOSIS AND MANAGEMENT? A CASE REPORT</b> | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Ahmad Ibrahim, LB   |               |

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Conditioning Regimens**

- |      |   |               |
|------|---|---------------|
| P409 | <b>AUTOLOGOUS STEM CELL TRANSPLANTATION IN AL-AMYLOIDOSIS FOLLOWING YTTRIUM-90 LABELLED ANTI-CD66 (BESILESOMAB) MONOCLONAL ANTIBODY AS SOLE CONDITIONING IS ASSOCIATED WITH LOW TOXICITY AND DEMONSTRABLE DISEASE RESPONSES</b>     | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Kim Orchard, GB  |               |
| P410 | <b>IS 8- INSTEAD OF 12-GRAY TOTAL BODY IRRADIATION SUFFICIENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TRANSPLANTED IN FIRST COMPLETE REMISSION?</b>   | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Alexandros Spyridonidis, GR  |               |
| P412 | <b>THIOTEPA-BASED REDUCED-INTENSITY CONDITIONING ARE A VALID ALTERNATIVE TO TOTAL-BODY IRRADIATION-BASED REGIMENS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF THE ALWP OF THE EBMT</b>                                | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Annalisa Ruggeri, IT   |               |
| P413 | <b>EXCELLENT OUTCOME WITH FB4 REGIMEN IN PATIENTS WITH MYELOID MALIGNANCIES OLDER THAN 55 AND WITH HCT-CI SCORE</b>   | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Daniele Avenoso, GB  |               |
| P414 | <b>SHOULD ATG BE ADDED IN PTCY-BASED HLA-MATCHED UNRELATED PERIPHERAL-BLOOD STEM CELL TRANSPLANTATION? A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT</b>  | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Alexandros Spyridonidis, GR  |               |
| P415 | <b>COMPARISON OF FLUDARABINE/MELPHALAN(FLUMEL) WITH FLUDARABINE/MELPHALAN/BCNU OR THIOTEPA(FBM/FTM) IN PATIENTS WITH AML UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - A REGISTRY STUDY ON BEHALF OF THE EBMT ALWP</b> | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Jesus Duque-Afonso, DE   |               |
| P416 | <b>FLUDARABINE AND MELPHALAN CONDITIONING WITH</b>  | 09:50 - 09:50 |



	<b>THIOTEPA VERSUS TOTAL BODY IRRADIATION FOR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HAPLO-SCT)</b>	
	<i>Poster Presenter:</i> Supawee Saengboon, US	
P417	<b>EFFICACY OF TREOSULFAN IN COMBINATION WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC TRANSPLANTATION AS COMPARED WITH A MYELOABLATIVE CONDITIONING USING BUSULFAN AND FLUDARABINE.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> José Álvaro Calvo Sánchez, ES	
P418	<b>HIGH DOSE INTRAVENOUS BUSULFAN INCREASES RISK FOR HEMORRHAGIC CYSTITIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Abel Santos Carreira, CA	
P420	<b>AUC TARGETED BUSULFAN ADMINISTRATION CAN OVERCOME THE NEGATIVE IMPACT OF PRE-TRANSPLANT MRD POSITIVITY IN INTERMEDIATE RISK AML PATIENTS.</b>	09:50 - 09:50
P421	<b>OPTIMISING IN VIVO ALEMTUZUMAB LEVELS IN MATCHED UNRELATED HAEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Maymoon Madkhali, GB	
P423	<b>TOTAL BODY IRRADIATION-BASED CONDITIONING VERSUS CHEMOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Nour Ben Abdeljelil, TN	
P424	<b>COMPARISON OF PORCINE ALG AND RABBIT ATG ON OUTCOMES OF HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACQUIRED APLASTIC ANEMIA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Juan Chen, CN	
P425	<b>LOW DOSE ANTI T-LYMPHOCYTE GLOBULIN IN HIGH T-CELL CONTENT PBSC GRAFT: IMPROVING TRANSPLANT OUTCOMES IN POST-TRANSPLANT CYCLOPHOSPHAMIDE PLATFORM</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Raffaella Greco, IT	
P426	<b>FULL DONOR CHIMERISM IN PATIENTS UNDERGOING HSCT WITH A REDUCED CONDITIONING REGIMEN AFTER ONE OR TWO ALKYLATING AGENTS: A SINGLE CENTER EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Carolina Arevalo, ES	
P427	<b>OVERALL SURVIVAL IN ADVANCED STAGE MANTLE CELL LYMPHOMA AFTER EARLY AUTOLOGOUS STEM CELL TRANSPLANTATION WITH CISPLATIN, ETOPOSIDE, CYTARABINE AND MELPHALAN (PEAM) AS A CONDITIONING REGIMEN.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Daniel Franco-Saenz, MX	
P428	<b>HIGH-INTENSITY TREOSULFAN-ETOPOSIDE-FLUDARABINE CONDITIONING CAN BE SAFELY USED IN COMBINATION WITH MAJOR GVHD PREVENTION</b>	09:50 - 09:50

**PLATFORMS IN CHILDREN WITH LEUKEMIA***Poster Presenter:* Evgeniy Zhuravel, RU

- |  |  |               |
|--|--|---------------|
| P430   | <b>CHEMOKINE RECEPTOR 4 DIRECTED<br/>ENDORADIO THERAPY WITH [<sup>177</sup>LU]-PENTIXATHER IN<br/>ADDITION TO TOTAL BODY IRRADIATION AS<br/>CONDITIONING REGIMEN FOR RELAPSED/REFRACTORY<br/>ACUTE MYELOID LEUKEMIA - A RETROSPECTIVE<br/>ANALYSIS</b> | 09:50 - 09:50 |
| <i>Poster Presenter:</i> Krischan Braitsch, DE     |  |               |
| P431   | <b>POTENTIAL PHARMACOKINETICS INTERACTIONS<br/>BETWEEN BUSULFAN AND IRON CHELATION IN<br/>CHILDREN GIVEN HSCT FOR NON-MALIGNANT DISEASES</b>   | 09:50 - 09:50 |
| <i>Poster Presenter:</i> Francesca Compagno, IT    |  |               |
| P432   | <b>GVHD PROPHYLAXIS WITH POST TRANSPLANT<br/>CYCLOPHOSPHAMIDE AFTER ALLO-HSCT WITH<br/>MISMATCHED UNRELATED AND HAPLOIDENTICAL<br/>DONORS: RISK OF CMV REACTIVATION AT LETERMOVIR<br/>DISCONTINUATION</b>  | 09:50 - 09:50 |
| <i>Poster Presenter:</i> Maria Caterina Mico', IT  |  |               |
| P434   | <b>DECREASED GLOMERULAR FILTRATION RATE IS<br/>RELATED TO INCREASED MUCOSITIS IN AUTOLOGOUS<br/>STEM CELL TRANSPLANTATION CONDITIONED WITH<br/>HIGH DOSE MELPHALAN</b>   | 09:50 - 09:50 |
| <i>Poster Presenter:</i> Javier Arzuaga-Méndez, ES |  |               |
| P435   | <b>AUTOLOGOUS STEM CELL TRANSPLANTATION USING<br/>CYCLOPHOSPHAMIDE AND TOTAL BODY IRRADIATION<br/>FOR T- CELL LYMPHOMAS</b>  | 09:50 - 09:50 |
| <i>Poster Presenter:</i> Uğur Şahin, TR            |  |               |
| P436   | <b>COMPARISON OF GIT TOXICITY OF THE BEAM VS TEAM<br/>CONDITIONING BEFORE AUTOLOGOUS<br/>TRANSPLANTATION IN PATIENTS WITH LYMPHOMAS</b>  | 09:50 - 09:50 |
| <i>Poster Presenter:</i> Barbara Břízová, CZ       |  |               |
| P437   | <b>CLINICAL OUTCOMES OF REDUCED INTENSITY TBF<br/>CONDITIONING REGIMEN IN ADULT PATIENTS<br/>UNDERGOING ALLOGENEIC STEM CELL<br/>TRANSPLANTATION FOR LYMPHOID MALIGNANCIES</b>   | 09:50 - 09:50 |
| <i>Poster Presenter:</i> Marta Peña Domingo, ES    |  |               |
| P438   | <b>UPDATE ON A PILOT STUDY: FLUMELTBI PERIPHERAL<br/>BLOOD HLA-HAPLOIDENTICAL STEM CELL<br/>TRANSPLANTATION WITH POST-TRANSPLANT<br/>CYCLOPHOSPHAMIDE AND BORTEZOMIB (CY2BOR3)</b>   | 09:50 - 09:50 |
| <i>Poster Presenter:</i> Sowjanya Vuyyala, US      |  |               |
| P439   | <b>ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION<br/>FOR HODGKIN LYMPHOMA POST ANTI-PD1 INHIBITORS:<br/>INCORPORATION OF POST-TRANSPLANT<br/>CYCLOPHOSPHAMIDE IN THE CONDITIONING REGIMEN</b>  | 09:50 - 09:50 |
| <i>Poster Presenter:</i> Eleni Gavriilaki, GR      |  |               |
| P440   | <b>TREOSULFAN-BASED CONDITIONING FOR ALLOGENEIC<br/>HSCT IN CHILDREN: A CASE SERIES OF SINGLE CENTER<br/>EXPERIENCE</b>  | 09:50 - 09:50 |

- Poster Presenter:* Ali Bülent Antmen, TR
- P441 **CLOFARABINE FOLLOWED BY REDUCED INTENSITY CONDITIONING AS A SEQUENTIAL CONCEPT PRIOR TO ALLOGENEIC HSCT IN THREE PATIENTS WITH ADVANCED STAGED CUTANEOUS T CELL LYMPHOMA** 09:50 - 09:50  
*Poster Presenter:* Elena Stauffer, DE
- P442 **TEAM VERSUS BEAM CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MALIGNANT LYMPHOMAS. RETROSPECTIVE COMPARISON OF TOXICITY** 09:50 - 09:50  
*Poster Presenter:* Jana Stevkova, CZ
- P443 **HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION USING A COMBINATION OF G-CSF MOBILIZED BONE MARROW AND PERIPHERAL BLOOD CELLS IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES** 09:50 - 09:50  
*Poster Presenter:* Malek Benakli, DZ
- P444 **SINGLE CENTRE EXPERIENCE OF EFFICACY AND TOXICITY OF REDUCED-DOSE MELPHALAN CONDITIONING (140 MG/M<sup>2</sup> OR 110 MG/M<sup>2</sup>) IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA.** 09:50 - 09:50  
*Poster Presenter:* Dario Melotti, GB
- P445 **LONG-TERM FOLLOW-UP OF AUTO-HCT WITH TBI-BASED CONDITIONING REGIMEN IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS: A SINGLE-CENTER ANALYSIS** 09:50 - 09:50  
*Poster Presenter:* Tomasz Czerw, PL
- P446 **REDUCED INTENSITY CONDITIONING REGIMEN WITH TREOSULFAN FOR SECOND ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR MYELOYDYSPLASTIC SYNDROME. A SINGLE-CENTRE EXPERIENCE.** 09:50 - 09:50  
*Poster Presenter:* Jana Stevkova, CZ
- P447 **LOW DOSE ANTI-THYMOCYTE GLOBULIN WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR HIGH RISK HEMATOLOGIC MALIGNANCIES - UMC LJUBLJANA, SLOVENIA EXPERIENCE** 09:50 - 09:50  
*Poster Presenter:* Polona Novak, SI
- P448 **DETERMINATION OF TRANSPLANT CONDITIONING INTENSITY: A REAL-LIFE DATA** 09:50 - 09:50  
*Poster Presenter:* İrfan Yavaşoğlu, TR

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Non-infectious Late Effects, Quality of Life and Fertility**

- P391 **SECONDARY NEOPLASMS AFTER UMBILICAL CORD BLOOD TRANSPLANTATION. ON BEHALF OF EUROCORD AND THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION** 09:50 - 09:50

- Poster Presenter:* Fernanda Volt, FR
- P392      **HOW TO IMPROVE QUALITY OF LIFE IN ALLOGENEIC TRANSPLANT PATIENTS WITH A TELEMEDICINE-BASED PROTOCOL: MANDATORY DURING COVID-19 CRISIS, AN OPPORTUNITY FOR THE FUTURE.**      09:50 - 09:50  
*Poster Presenter:* Monica Cabrero, ES
- P393      **LATE EFFECTS: PATIENT-REPORTED AND PROXY-REPORTED OUTCOMES AMONG PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISEASES - WHAT DOESN'T KILL YOU, MAKES YOU STRONGER**      09:50 - 09:50  
*Poster Presenter:* Joëll Esmée Bense, NL
- P394      **A MOBILE PHONE APPLICATION AND PHYSICIAN DASHBOARD FOR REAL TIME REMOTE MONITORING OF SYMPTOMS, VITAL SIGN AND ACTIVITY IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.**      09:50 - 09:50  
*Poster Presenter:* Eshrak Al-Shaibani, CA
- P395      **ARE CARDIO-METABOLIC LATE-EFFECTS MODIFIABLE THROUGH A LOW-FAT DIET IN LONG-TERM SURVIVORS OF PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANTATION?**      09:50 - 09:50  
*Poster Presenter:* Louise Pedersen, DK
- P396      **SECONDARY NON-HEMATOLOGIC MALIGNANCIES INCREASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A NATIONWIDE CASE-CONTROL COHORT STUDY**      09:50 - 09:50  
*Poster Presenter:* Ka Young Kim, KR
- P397      **PULMONARY FUNCTION IS A STRONG PREDICTOR OF 2-YEAR OVERALL SURVIVAL AND NON-RELAPSE MORTALITY AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION**      09:50 - 09:50  
*Poster Presenter:* Frederikke Schierbeck, DK
- P398      **RELAPSE AND SEVERE GRAFT-VERSUS-HOST-DISEASE HAVE A NEGATIVE IMPACT ON LONG-TERM SYMPTOMS AND QUALITY OF LIFE OF PATIENTS THREE YEARS AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**      09:50 - 09:50  
*Poster Presenter:* Simone Oerlemans, NL
- P399      **THE TIMING OF RATG MATTERS: MSD-PBSCT PATIENTS RECEIVING 2D-ATG REGIMEN HAVE LOWER CUMULATIVE INCIDENCE OF RELAPSE AND BETTER DFS THAN THOSE RECEIVING 4D-ATG REGIMEN.**      09:50 - 09:50  
*Poster Presenter:* Nan Wang, CN
- P400      **EMERGENCY DEPARTMENT CONSULTATION IN ALLOGENEIC HSCT RECIPIENTS - DATA FROM THE VIENNA HSCT PROGRAM**      09:50 - 09:50  
*Poster Presenter:* Clara Katharina Baumann, AT
- P401      **LONG-TERM PSYCHOSOCIAL IMPACT OF PEDIATRIC HEMATOLOGICAL STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISEASES: A QUALITATIVE STUDY**      09:50 - 09:50

	<i>Poster Presenter:</i> Joëll Esmée Bense, NL	
P402	<b>ENDOCRINOPATHIES IN LONG-TERM FOLLOW-UP AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Mario Alberto Tapia Bravo, MX	
P403	<b>MEN´S HEALTH AND UROLOGICAL OUTCOMES IN LONG-TERM SURVIVORS OF ALLOGENEIC STEM CELL TRANSPLANTATION - RESULTS OF A PROSPECTIVE CLINICAL TRIAL</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Thomas Neumann, DE	
P404	<b>THE IMPACT OF THROMBOPOIETIN RECEPTOR AGONISTS ON BONE MARROW FIBROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Zeynep Arzu Yegin, TR	
P405	<b>ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS SURVIVING AT LEAST 2 YEARS WITHOUT RELAPSE. OUTCOME AND RISK-FACTORS.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Bjørn Linder Grønvold, NO	
P406	<b>CUMULATIVE INCIDENCE OF THYROID DISORDERS IN PATIENTS UNDERGOING HSCT AT THE FOSCAL CLINIC IN THE PERIOD 2009 - 2019</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Claudia Sossa-Melo, CO	
P407	<b>INCIDENCE OF MALE HYPOGONADISM AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE OF A REFERRAL CENTER</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Claudia Sossa-Melo, CO	
P408	<b>INCIDENCE OF PRIMARY OVARIAN INSUFFICIENCY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE OF A REFERENCE CENTER</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Claudia Sossa-Melo, CO	
<i>Poster Sessions</i>		
09:50 - 18:00		ePoster Area
<b>Paediatric Issues</b>		
P472	<b>HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INHERITED IMMUNE DISORDERS : 30-YEAR ITALIAN SINGLE- CENTER EXPERIENCE.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Gianluca Dell'Orso, IT	
P473	<b>HEMATOPOIETIC STEM CELL TRANSPLANTATION IS AN EFFECTIVE THERAPEUTIC MODALITY FOR THE INFANTS WITH HIGH-RISK ACUTE LEUKEMIA.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Michael Maschan, RU	
P474	<b>PLASMA LEVELS OF MRP-8/14 ASSOCIATE WITH NEUTROPHIL RECOVERY, ENGRAFTMENT SYNDROME AND BACTERIAL BLOOD STREAM INFECTIONS FOLLOWING PEDIATRIC ALLOGENEIC HSCT[</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Katrine Kielsen, DK	
P475	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND</b>	09:50 - 09:50

	<b>UNRELATED DONORS IN CHILDREN WITH HEMATOLOGIC MALIGNANCIES USING "NAÏVE" (CD45RA+) T-CELL-DEPLETED GRAFTS.</b>	
	<i>Poster Presenter:</i> Blanca Molina Angulo, ES	
P476	<b>MATCHED SIBLING DONOR TRANSPLANT WITH REDUCED INTENSITY CONDITIONING HAS EXCELLENT RESULTS IN PEDIATRIC BONE MARROW FAILURE SYNDROMES</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Joseph Oved, US	
P477	<b>UPFRONT STEM CELL TRANSPLANT FROM MATCHED UNRELATED DONORS IN NEWLY DIAGNOSED IDIOPATHIC SEVERE APLASTIC ANAEMIA AND REFRACTORY CYTOPENIA OF CHILDHOOD. THE SPANISH EXPERIENCE.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Victor Quintero, ES	
P478	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ludmila Zubarovskaya, RU	
P479	<b>INCIDENCE OF INVASIVE FUNGAL DISEASE AND RISK FACTORS IN 368 CHILDREN RECEIVING ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: A UK MULTI-CENTRE, PROSPECTIVE AUDIT ON NATIONAL ANTI-FUNGAL GUIDELINES</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Giorgio Ottaviano, GB	
P480	<b>LEVOFLOXACIN PROPHYLAXIS AND PARENTERAL NUTRITION HAVE A DETRIMENTAL EFFECT ON INTESTINAL MICROBIAL NETWORKS IN PEDIATRIC PATIENTS UNDERGOING ALLO-HSCT</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Daniele Zama, IT	
P481	<b>SPORTS MEDICINE PHYSICIANS AND EXERCISE SCIENTISTS IN A TRANSPLANT UNIT: PRECISION EXERCISE AND BEYOND</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Adriana Balduzzi, IT	
P482	<b>DEVELOPING A PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION-COMPOSITE RISK SCORE TO PREDICT OUTCOMES IN CHILDREN WITH ACUTE LEUKEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Madhavi Lakkaraja, US	
P483	<b>TREOSULFAN-BASED CONDITIONING REGIMEN IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS: AN ANALYSIS OF SPANISH GROUP OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (GETH)</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Antonio Perez-Martínez, ES	
P484	<b>PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) PERFORMED EARLY AFTER DIAGNOSIS OF PEDIATRIC CHRONIC MYELOID LEUKEMIA (CML)</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Meinolf Suttorp*, DE	

P485	<b>PLASMA ST2 LEVELS ARE ASSOCIATED WITH AGVHD SEVERITY AND TREATMENT RESPONSE IN PEDIATRIC HSCT</b> <i>Poster Presenter:</i> Nakisa Gadanehzadeh, DK	09:50 - 09:50
P486	<b>PRELIMINARY DATA FROM AN EARLY PHASE TRIAL IN CHILDREN USING POOLED GRANULOCYTES TO GENERATE TRANSIENT T-CELL EXPANSION AFTER CORD BLOOD TRANSPLANT IN HIGH-RISK LEUKAEMIA</b> <i>Poster Presenter:</i> Roisin Borrill, GB	09:50 - 09:50
P487	<b>UPFRONT ALTERNATIVE DONOR HSCT FOR PEDIATRIC PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA</b> <i>Poster Presenter:</i> Ho Joon Im, KR	09:50 - 09:50
P488	<b>RELAPSE AFTER TRANSPLANTATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN CELLULAR THERAPIES ERA. A RETROSPECTIVE ANALYSIS OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) PEDIATRIC COMMITTEE</b> <i>Poster Presenter:</i> MARTA GONZALEZ VICENT, ES	09:50 - 09:50
P489	<b>NON-OSTEOPENIC BONE PATHOLOGY POST-HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN PATIENTS WITH INBORN ERRORS OF IMMUNITY (IEI)</b> <i>Poster Presenter:</i> Zainab Golwala, GB	09:50 - 09:50
P490	<b>IMPACT OF LEVOFLOXACIN-BASED PROPHYLAXIS DURING THE PRE-ENGRAFTMENT PHASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PEDIATRIC RECIPIENTS: A SINGLE-CENTER RETROSPECTIVE MATCHED ANALYSIS.</b> <i>Poster Presenter:</i> Alessia G Servidio, IT	09:50 - 09:50
P491	<b>ENDOTHELIAL INJURY IMPACT ON THE RESULTS OF EX VIVO T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH MALIGNANT HEMOPATHIES</b> <i>Poster Presenter:</i> Iván López Torija, ES	09:50 - 09:50
P492	<b>HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN IN JORDAN 2003-2021: ACTIVITY AND TRENDS</b> <i>Poster Presenter:</i> Rawad Rihani, JO	09:50 - 09:50
P493	<b>RE-VISIT OF THE APPLICATIONS OF GRANULOCYTE COLONY-STIMULATING FACTOR IN PEDIATRIC PATIENTS UNDERGOING AUTOLOGOUS HIGH DOSE CHEMOTHERAPY WITH STEM CELL RESCUE - SINGLE CENTER EXPERIENCE</b> <i>Poster Presenter:</i> Parmeet Manku, CA	09:50 - 09:50
P494	<b>ANALYSIS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TYROSINE KINASE INHIBITOR ERA: A MULTICENTER, PROSPECTIVE STUDY ON PEDIATRIC CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (JPLSG CML-08)</b> <i>Poster Presenter:</i> CHIKAKO TONO, JP	09:50 - 09:50
P495	<b>REDUCED INTENSITY CONDITIONING REGIMEN IN CHILDREN WITH NON-MALIGNANT DISEASES: HIGH</b>	09:50 - 09:50

	<b>INCIDENCE OF MIXED CHIMERISM WITHOUT IMPACT ON OVERALL SURVIVAL AND DISEASE FREE SURVIVAL</b>	
	<i>Poster Presenter:</i> Maria Isabel Benitez Carabante, ES	
P496	<b>PRIMARY IMMUNODEFICIENCIES: HSCT EXPERIENCES OF A SINGLE PEDIATRIC CENTER IN ARGENTINA.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Maria Daniela Iglesias, AR	
P497	<b>SUCCESSFUL HAPLOIDENTICAL STEM CELL TRANSPLANT WITH POST TRANSPLANT DECITABINE FOR 3 PATIENTS WITH HIGH RISK JUVENILE MYELOMONOCYTIC LEUKAEMIA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Frances Yeap, SG	
P499	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH LYMPHOBLASTIC LYMPHOMA NOT ACHIEVING REMISSION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ludmila Zubarovskaya, RU	
P500	<b>HAPLOIDENTICAL T CELL DEPLETED HSCT REPRESENTS A SAFE THERAPEUTIC ALTERNATIVE TO MSD TRANSPLANTATION IN PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Katharina Kleinschmidt, DE	
P501	<b>IRON OVERLOAD AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: VARIES BY DISEASE TYPE, IMPROVES OVER TIME. A SINGLE CENTER EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Aharon Gefen, IL	
P502	<b>HAPLOIDENTICAL STEM CELL TRANSPLANT IN PAEDIATRIC PATIENTS WITH RECURRENT OR TREATMENT-REFRACTORY SEVERE APLASTIC ANAEMIA AND REFRACTORY CYTOPENIA OF CHILDHOOD.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Victor Quintero, ES	
P503	<b>VERY LOW DAY-100 AND 1-YEAR TRANSPLANT-RELATED MORTALITY (TRM) IN THE PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION PROGRAM AT KING HUSSEIN CANCER CENTER</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Hasan Hashem, JO	
P504	<b>FAVOURABLE EVOLUTION OF A HEMATOPOIETIC STEM CELL TRANSPLANT IN A CBL SYNDROME PATIENT AFTER SPLENECTOMY AND IMMUNOSUPPRESSION SUSPENSION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Sara Redondo, ES	
P505	<b>NONTUBERCULOUS MYCOBACTERIAL INFECTION AMONG PAEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Yasmina Mozo, ES	
P506	<b>DONOR LYMPHOCYTE INFUSION POST HAEMATOPOIETIC STEM CELL TRANSPLANTATION - FUNDENI CLINICAL INSTITUTE EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Cristina Jercan, RO	
P507	<b>MODIFIED JOHNS HOPKINS CONDITIONING PROTOCOL</b>	09:50 - 09:50



**FOR NON-MALIGNANT HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN**

*Poster Presenter:* Chatada Srivaishnava Ranjit Kumar, IN

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Acute Leukaemia**

- |      |   |               |
|------|---|---------------|
| P509 | <p><b>HLA-HAPLOIDENTICAL TRANSPLANTATION WITH PTCY IN AML PATIENTS WITH ACTIVE DISEASE AT TRANSPLANTATION: BETTER SURVIVAL WITH BM THAN WITH PBSC IN PATIENTS &amp;GT; 55 YEARS</b></p> <p><i>Poster Presenter:</i> Frédéric Baron, BE</p>                      | 09:50 - 09:50 |
| P510 | <p><b>TCRAB+/CD19+-DEPLETION IN SECOND ALLOGENIC HSCT IN CHILDREN ACUTE LEUKEMIA.</b></p> <p><i>Speaker:</i> Michael Maschan, RU</p>  | 09:50 - 09:50 |
| P511 | <p><b>POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED ANTI-GVHD PROPHYLAXIS IN PATIENTS WITH ALL TREATED IN CR WITH ALLO-HCT FROM HAPLOIDENTICAL VS HLA-MISMATCHED UNRELATED DONORS: AN ALWP EBMT ANALYSIS</b></p> <p><i>Poster Presenter:</i> Arnon Nagler, IL</p>      | 09:50 - 09:50 |
| P512 | <p><b>PROPHYLACTIC OR PRE-EMPTIVE USE OF TYROSINE KINASE INHIBITORS POST-ALLOGENEIC STEM CELL TRANSPLANTATION IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. A SUB-ANALYSIS OF GITMO ALL STUDY</b></p> <p><i>Poster Presenter:</i> Anna Candoni, IT</p>      | 09:50 - 09:50 |
| P513 | <p><b>AUTOLOGOUS VERSUS HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA IN FIRST COMPLETE REMISSION WITH UNDETECTABLE MINIMAL RESIDUAL DISEASE: CHINESE DATA</b></p> <p><i>Poster Presenter:</i> Yiyang Ding, CN</p> | 09:50 - 09:50 |
| P514 | <p><b>SEQUENTIAL CONDITIONING WITH HIGH DOSE MELPHALAN FOLLOWED BY BUSULFAN AND FLUDARABINE IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)</b></p> <p><i>Poster Presenter:</i> Matthias Stelljes, DE</p>                    | 09:50 - 09:50 |
| P515 | <p><b>IMPACT OF DONOR AND PATIENT <i>TGFB1</i> -1347C&amp;GT;T VARIANT IN ACUTE MYELOID LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION</b></p> <p><i>Poster Presenter:</i> IVAN MARTIN, ES</p>  | 09:50 - 09:50 |
| P516 | <p><b>POST-TRANSPLANT CYCLOPHOSPHAMIDE SEPARATES GRAFT-VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECTS AFTER HLA-MATCHED STEM-CELL TRANSPLANTATION (SCT) FOR AML.</b></p> <p><i>Poster Presenter:</i> Avichai Shimoni, IL</p>                | 09:50 - 09:50 |
| P517 | <p><b>COMPARISON OF HAPLOIDENTICAL AND MATCHED UNRELATED DONOR HSCT WITH UNIFORM</b></p>  | 09:50 - 09:50 |

	<b>POSTTRANSPLANTATION CYCLOPHOSPHAMIDE GVHD PROPHYLAXIS IN DE NOVO AML</b>	
	<i>Poster Presenter:</i> Dmitrii Zhogolev, RU	
P518	<b>ALLOGENEIC TRANSPLANTATION FOR ADULTS WITH ACUTE MEGAKARYOBLASTIC LEUKEMIA, A STUDY FROM ACUTE LEUKEMIA WORKING PARTY OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (EBMT).</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Enrico Maffini, IT	
P520	<b>AUTOLOGOUS VERSUS HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA IN FIRST REMISSION WITH UNDETECTABLE MINIMAL RESIDUAL DISEASE: A EUROPEAN PRELIMINARY ANALYSIS:</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Norbert-Claude Gorin, FR	
P521	<b>INFLUENCE OF THE EXPRESSION OF GENES CHARACTERISTIC OF LEUKEMIC STEM CELLS ON THE RESULTS OF ALLOGENEIC HSCT IN CHILDREN WITH ACUTE MYELOID LEUKEMIA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ludmila Zubarovskaya, RU	
P522	<b>THE CLINICAL CHARACTERISTICS AND PROGNOSIS OF AYA AND OLDER ADULT EARLY T-CELL PRECURSOR LEUKEMIA/LYMPHOMA: A REAL-WORLD MULTICENTER STUDY IN CHINA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Jinyan Xiao, CN	
P523	<b>OUTCOME PREDICTION BY THE KNOWLEDGE BANK APPROACH IN AML PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Lara Bischof, DE	
P524	<b>MIDOSTAURIN MAINTENANCE VS ALLO SCT VS W&amp;W IN FLT3 MUTATED AML. A "REAL LIFE" MULTICENTER STUDY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Adolfo de la Fuente, ES	
P525	<b>THE EBMT DISEASE RISK STRATIFICATION SYSTEM (DRSS) ALLOWS PREDICTION OF RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Yasmine Kadri, CA	
P526	<b>STRUCTURAL ANALYSIS OF LEUKEMIA-ASSOCIATED PROTEIN TYROSINE PHOSPHATASE PTPN21 AND PROTEIN INTERACTION NETWORK ANALYSIS OF ITS WILD TYPE AND MUTANTS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Zijun Qian, CN	
P527	<b>THIOTEPA, BUSULFAN AND FLUDARABINE: A CONDITIONING-REGIMEN FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Anne Banet, FR	
P528	<b>MOLECULAR GENETIC CHANGES AND MRD AFTER FIRST INDUCTION CHEMOTHERAPY WERE RELATED WITH PROGNOSIS IN ACUTE LYMPHOBLASTIC LKUKEMIA</b>	09:50 - 09:50

	<i>Poster Presenter:</i> Xue Sun, CN	
P529	<b>PATTERNS OF RELAPSE AND OUTCOMES IN PATIENTS WITH ACUTE LEUKEMIA POST ALLOGENIC TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Megha Saroha, IN	
P530	<b>PREEMPTIVE IMMUNOTHERAPY FOR MINIMAL RESIDUAL DISEASE IN PATIENTS WITH T(8;21) ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Shuang Fan, CN	
P531	<b>SIMILAR OS AND DFS AFTER ATG OR POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) AS GVHD PROPHYLAXIS IN PATIENTS WITH ALL IN CR 1 AFTER ALLOGENEIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Christian Niederwieser, DE	
P532	<b>INTEGRATED GENOMIC AND SINGLE-CELL MOLECULAR ANALYSES OF DONOR CELL LEUKEMIA AFTER HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Huiqiao Chen, CN	
P533	<b>CAN ALLOGENEIC STEM CELL HEMATOPOIETIC TRANSPLANT WITH ANY TYPE OF DONOR BE THE STANDARD POST-REMISSION TREATMENT IN INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION?</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Juan Manuel Cerezo Martín, ES	
P534	<b>RISK FACTORS FOR CENTRAL NERVOUS SYSTEM RELAPSE AFTER ALLOGENEIC H-SCT IN FLT3-MUTATED AML</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Khoulood Kouidri, DE	
P535	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER RETROSPECTIVE STUDY.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Daniel Alzetta, IT	
P536	<b>THE OUTCOME OF AML AND MDS PATIENTS RELAPSED AFTER ALLOGENEIC TRANSPLANTATION, SINGLE CENTRE EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Markéta Šťastná Marková, CZ	
P537	<b>CONTROL LEUKEMIA BY INDUCING ANTI-CANCER IMMUNE REACTIVITY <i>IN VIVO</i>? POTENTIAL OF A DC-TRIGGERED MECHANISM</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Helga Schmetzer, DE	
P538	<b>SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN RELAPSED ACUTE MYELOID LEUKEMIA - RETROSPECTIVE ANALYSIS OF THE OUTCOME</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Anna Lojko-Dankowska, PL	
P539	<b>PRE-CONDITIONING ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) PREDICTS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50

**OUTCOMES***Poster Presenter:* Ka Young Kim, KR

- |      |   |               |
|------|---|---------------|
| P542 | <b>ALLOGENIC STEM CELL TRANSPLANTATION AND PERI TRANSPLANT STRATEGIES IN PATIENTS WITH RELAPSED/REFRACTORY OR INTERMEDIATE/HIGH RISK NPM1 MUTATED ACUTE MYELOID LEUKEMIA - A SINGLE CENTER EXPERIENCE</b> | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Paul Jäger, DE   |               |
| P543 | <b>VIALE-T: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA</b>                  | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Charles Craddock, GB   |               |
| P544 | <b>OPTIMIZATION OF FLUDARABINE-PHARMACOKINETICS TO REDUCE THE RI IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION</b>   | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Tharshika Thavayogarajah, CH   |               |
| P545 | <b>RELEVANCE OF VITAMIN D IN PATIENTS UNDERGOING HLA MATCHED ALLOGENIC STEM CELL TRANSPLANT FOR ACUTE LEUKAEMIA</b>   | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Nishant Jindal, IN   |               |
| P546 | <b>EVALUATION OF DIFFERENT MAINTENANCE TREATMENT STRATEGIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN FLT3 POSITIVE AML PATIENTS</b>  | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Elena Stauffer, DE   |               |
| P547 | <b>OUTCOME OF ACUTE LEUKEMIA IN INFANTS: A REPORT FROM A SINGLE THIRD LEVEL CENTER IN MADRID, SPAIN.</b>  | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Bárbara Ochoa Fernández, ES  |               |
| P548 | <b>POST-TRANSPLANT TREATMENT IN HIGH-RISK ACUTE MYELOID LEUKAEMIA: A SINGLE CENTER REAL-LIFE EXPERIENCE</b>   | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Gianluca Cavallaro, IT   |               |
| P549 | <b>OFF-LABEL VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS FOR POST-ALLOGENEIC HSCT AML RELAPSE</b>   | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Fabio Serpenti, IT   |               |
| P550 | <b>ALLOGENEIC BONE MARROW TRANSPLANT IN INFANT WITH ACUTE LEUKEMIA</b>  | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Monia Ben Khaled, TN   |               |
| P551 | <b>PHILADELPHIA CHROMOSOME-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA: FIRST EXPERIENCE OF DIAGNOSTICS AND DESCRIPTION OF CLINICAL CASES</b>   | 09:50 - 09:50 |
|      | <i>Poster Presenter:</i> Kseniia Afanaseva, RU  |               |
| P552 | <b>REAL-LIFE VALIDATION OF PROGNOSTIC RISK STRATIFICATION ACCORDING TO ELN 2017 IN PATIENTS WITH AML AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.</b>  | 09:50 - 09:50 |

	<i>Poster Presenter:</i> Clara Aparicio Pérez, ES	
P553	<b>TREATMENT OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND HISTORY OF HIGH-RISK RELAPSE WITH BONE MARROW TRANSPLANTATION AT THE NATIONAL INSTITUTE OF PEDIATRICS, MEXICO.</b> <i>Poster Presenter:</i> Alberto Olaya-Vargas, MX	09:50 - 09:50
P554	<b>FEASIBILITY OF MYELOABLATIVE ALLO-SCT FROM HAPLOIDENTICAL DONOR IN AML PATIENTS OLDER THAN 70 YEARS: A SINGLE-CENTRE EXPERIENCE</b> <i>Poster Presenter:</i> Kordelia Barbullushi, IT	09:50 - 09:50
P555	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA: A SINGLE CENTER EXPERIENCE</b> <i>Poster Presenter:</i> Osman Ilhan, TR	09:50 - 09:50
P556	<b>LONG TERM FOLLOW-UP AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS</b> <i>Poster Presenter:</i> Malek Benakli, DZ	09:50 - 09:50
<i>Poster Sessions</i> 09:50 - 18:00		ePoster Area
<b>Aplastic Anaemia</b>		
P557	<b>COMPARISON OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED SIBLING DONOR, HAPLOIDENTICAL DONOR, AND IMMUNOSUPPRESSIVE THERAPY FOR PATIENTS WITH ACQUIRED APLASTIC ANEMIA</b> <i>Poster Presenter:</i> Yuanfeng Zhang, CN	09:50 - 09:50
P559	<b>COVID-19 IN ADULT PATIENTS WITH BONE MARROW FAILURE SYNDROMES</b> <i>Poster Presenter:</i> Darya A. Chebykina, RU	09:50 - 09:50
P560	<b>CORRELATION OF DONOR CHIMERISM AND OUTCOMES IN CHILDREN WITH SEVERE APLASTIC ANEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Rajinder Bajwa, US	09:50 - 09:50
P561	<b>LONG-TERM OUTCOME IN FANCONI ANEMIA PATIENTS FROM THE ITALIAN NATIONAL DATABASE</b> <i>Poster Presenter:</i> Maura Faraci, IT	09:50 - 09:50
P562	<b>HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH APLASTIC ANEMIA: A GATMO-TC EXPERIENCE</b> <i>Poster Presenter:</i> Ana Lisa Basquiera, AR	09:50 - 09:50
P564	<b>HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) TO TREAT PURE RED CELL APLASIA (PRCA)</b> <i>Poster Presenter:</i> shengnan zhou, CN	09:50 - 09:50

## Poster Sessions

09:50 - 18:00

ePoster Area

**Autoimmune Diseases**

- P566 **NT-PROBNP MEASUREMENTS DURING CYCLOPHOSPHAMIDE CONDITIONING IN PATIENTS UNDERGOING AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS SUGGEST INCREASED CARDIAC STRAIN** 09:50 - 09:50  
*Poster Presenter:* Ross Penglase, AU
- P567 **RESIDUAL RECIPIENT T-CELLS ARE RESPONSIBLE FOR SEVERE LUPUS NEPHRITIS IN RALS-ASSOCIATED LUPUS NEPHRITIS PERSISTENCE AFTER ALLOGENEIC, MATCHED SIBLING DONOR TRANSPLANT.** 09:50 - 09:50  
*Poster Presenter:* Srividhya Senthil, GB
- P568 **ENCEPHALITIS AND THROMBOTIC MICROANGIOPATHY AFTER MRNA SARS-COV2 VACCINE IN A PATIENT WITH CHRONIC GVHD: A CASE REPORT.** 09:50 - 09:50  
*Poster Presenter:* Carlota Mayor Bastida, ES

## Poster Sessions

09:50 - 18:00

ePoster Area

**Multiple Myeloma**

- P616 **BEST TREATMENT STRATEGY BEFORE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN POEMS PATIENTS** 09:50 - 09:50  
*Poster Presenter:* Simona Sica, IT
- P618 **TREATMENT COMPARISON OF CILTACABTAGENE AUTOLEUCEL VERSUS PHYSICIAN'S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS** 09:50 - 09:50  
*Poster Presenter:* Maria-Victoria Mateos, ES
- P619 **IMPACT OF DOUBLE-HIT GENETICS ON REAL-WORLD OUTCOMES OF MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) - A UK ASCT CENTRE EXPERIENCE** 09:50 - 09:50  
*Poster Presenter:* Aikaterini Panopoulou, GB
- P620 **LONG-TERM FOLLOW-UP OF TANDEM AUTOLOGOUS PLUS NON-MYELOABLATIVE ALLOGENEIC-SCT PROGRAM IN RELAPSED MYELOMA: AN AUSTRALIAN REPORT FROM THE ALFRED & THE MYELOMA AND RELATED DISEASES REGISTRY** 09:50 - 09:50  
*Poster Presenter:* Aditya Tedjaseputra, AU
- P621 **TANDEM AUTO-ALLO-HCT WITH USE OF HDM AND TOTAL MARROW IRRADIATION WITH BENDAMUSTINE AS REDUCED-TOXICITY MYELOABLATIVE CONDITIONING FOR YOUNGER PATIENTS WITH MULTIPLE MYELOMA** 09:50 - 09:50  
*Poster Presenter:* Sebastian Giebel, PL
- P622 **CUMULATIVE EFFECT OF CYTOGENETIC HITS ON MULTIPLE MYELOMA RELAPSE AFTER FRONT-LINE AUTOLOGOUS STEM CELL TRANSPLANT** 09:50 - 09:50

	<i>Poster Presenter:</i> Pedro Baptista, PT	
P623	<b>LOSS OF 13P AS AN INDEPENDENT PROGNOSTIC FACTOR FOR EARLY RELAPSE AFTER FIRST LINE AUTOLOGOUS STEM CELL TRANSPLANT IN MULTIPLE MYELOMA</b> <i>Poster Presenter:</i> Marta Henriques, PT	09:50 - 09:50
P624	<b>IMPACT OF TIMING OF STEM CELL RETURN FOLLOWING HIGH-DOSE MELPHALAN IN MYELOMA PATIENTS WITH RENAL IMPAIRMENT</b> <i>Poster Presenter:</i> George Nesr, GB	09:50 - 09:50
P625	<b>AUTOLOGOUS STEM CELL TRANSPLANTATION IN 540 MYELOMA PATIENTS: A RETROSPECTIVE SINGLE-CENTER, REAL- WORLD STUDY</b> <i>Poster Presenter:</i> Song-Yau Wang, DE	09:50 - 09:50
P626	<b>PROGNOSTIC FACTORS FOR OVERALL SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS</b> <i>Poster Presenter:</i> Lucia Rita Morais Bras, ES	09:50 - 09:50
P627	<b>TREATMENT LANDSCAPE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): REAL-WORLD OUTCOMES FOR STANDARD-OF-CARE</b> <i>Poster Presenter:</i> Michel Delforge, BE	09:50 - 09:50
P628	<b>NON-CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA: ABOUT 81 CASES.</b> <i>Poster Presenter:</i> Selim Jennane, MA	09:50 - 09:50
P629	<b>OUTCOME OF PATIENTS WITH MULTIPLE MYELOMA RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE PRE-CAR T CELL ERA</b> <i>Poster Presenter:</i> Carmen de Ramon Ortiz, CH	09:50 - 09:50
P630	<b>RESPONSE TO LENALIDOMIDE MAINTENANCE IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS TRANSPLANTATION. MODIFICATIONS DURING TREATMENT PLAN DUE TO ITS TOXICITY</b> <i>Poster Presenter:</i> Eduard Fort Casamartina, ES	09:50 - 09:50
P632	<b>TREATMENT OUTCOME AND PROGNOSTIC FACTORS OF NEWLY DIAGNOSED MULTIPLE MYELOMA RECEIVING BORTEZOMIB-BASED INDUCTION IN HONG KONG: AN ANALYSIS OF 448 PATIENTS</b> <i>Poster Presenter:</i> Hoi Ki Karen Tang, HK	09:50 - 09:50
P634	<b>EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH MULTIPLE MYELOMA WHO DEVELOPED PULMONARY COMPLICATIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Claudia Sossa-Melo, CO	09:50 - 09:50
P635	<b>MULTIPLE MYELOMA CHARACTERISTICS CORRELATED TO SERUM FREE LIGHT CHAIN RATIO AT DIAGNOSIS AND ASSOCIATION WITH EARLY RENAL DAMAGE</b> <i>Poster Presenter:</i> Danilo De Novellis, IT	09:50 - 09:50
P636	<b>TANDEM ASCT OR AMYELOABLATIVE ALLO-SCT IN</b>	09:50 - 09:50

	<b>PATIENTS HIGH RISK WITH MULTIPLE MYELOMA: A PHASE 3 BIOLOGICAL ASSIGNMENT TRIAL</b>	
	<i>Poster Presenter:</i> Beihui Huang, CN	
P637	<b>ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION IN PATIENTS WITH MYELOMA - UNICENTRIC STUDY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Tomas Kriz, CZ	
P638	<b>SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IS A COST-EFFECTIVE TREATMENT OPTION FOR MULTIPLE MYELOMA RELAPSING AFTER PRIOR ASCT: A SINGLE-CENTER EXPERIENCE IN CHINA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Lifan Kuang, CN	
P639	<b>AUTOLOGOUS STEM CELL TRANSPLANTATION IN AL AMYLOIDOSIS: A SINGLE CENTRE EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ines Santos Marques, PT	
<i>Poster Sessions</i>		
09:50 - 18:00		ePoster Area
<b>Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution</b>		
P449	<b>FOCUSING ATG TOWARDS HOST T-CELL DEPLETION ELIMINATES GRADE III-IV ACUTE GVHD AND IS ASSOCIATED WITH EARLY GRAFT VERSUS LEUKEMIA (GVL) IMMUNE RESPONSES</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Zaid Al-Kadhimi, US	
P450	<b>COMBINATION OF RUXOLITINIB AND INTERFERON A-2B IS EFFECTIVE FOR TREATMENT OF RELAPSE OR MINIMAL RESIDUAL DISEASE AFTER ALLO-SCT: PHASE I/II STUDY OF NCT02185261 AND NCT02568241</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Meng Lv, CN	
P451	<b>ASSESSMENT OF SARS-COV-2 SPECIFIC T-CELL RESPONSE IN IMMUNOCOMPROMISED PATIENTS FAILING TO SEROCONVERT IN RESPONSE TO SARS-COV-2 VACCINE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Gesine Bug, DE	
P452	<b>HIGHLY-SENSITIVE CHIMERISM ANALYSIS IN BLOOD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDHOOD LEUKEMIA: RESULTS FROM THE NORDIC MICROCHIMERISM STUDY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Anna Karen Haugaard, DK	
P453	<b>NGS-BASED VERIFICATION OF LOW MRD POSITIVITY IS HIGHLY SPECIFIC IN PREDICTION OF RELAPSE IN POST-TRANSPLANT ALL PATIENTS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Krystof Seferna, CZ	
P454	<b>IMMUNE RECONSTITUTION FOLLOWING BASILIXIMAB TREATMENT FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Dao-Xing Deng, CN	
P455	<b>POST-TRANSPLANT DAY +100 MRD DETECTION RATHER THAN MIXED CHIMERISM PREDICTS RELAPSES AFTER</b>	09:50 - 09:50



	<b>ALLO-SCT FOR INTERMEDIATE RISK AML PATIENTS TRANSPLANTED IN CR.</b>	
P456	<b>CLINICAL CHARACTERISTICS AND OUTCOME ANALYSIS FOR HLA LOSS PATIENTS BETWEEN MYELOID AND LYMPHOID MALIGNANCIES BY NEXT-GENERATION SEQUENCING</b> <i>Poster Presenter: Xianmin Song, CN</i>	09:50 - 09:50
P458	<b>SEQUENTIAL CONDITIONING IN NPM1 POSITIVE AML WITH MEASURABLE RESIDUAL DISEASE PRE-TRANSPLANT MIGHT OVERCOME NEGATIVE IMPACT OF RESIDUAL LEUKEMIA</b> <i>Poster Presenter: Alessia Fraccaroli, DE</i>	09:50 - 09:50
P459	<b>THE PATTERN OF IMMUNE RECONSTITUTION DETERMINES THE SURVIVAL AT THREE MONTHS AND THE DEVELOPMENT OF CHRONIC GRAFT-VERSUS HOST DISEASE IN ALLO-HSCT</b> <i>Poster Presenter: Valle Gómez García de Soria, ES</i>	09:50 - 09:50
P460	<b>GVHD IS ASSOCIATED WITH COMPROMISED RECONSTITUTION OF B-CELL PRECURSORS IN THE BONE MARROW FOLLOWING ALLOGENEIC HSCT</b> <i>Poster Presenter: Elisa Christine Peen, DK</i>	09:50 - 09:50
P461	<b>IDENTIFICATION OF RELATIONSHIP BETWEEN QUANTITATIVE CHIMERISM AND NPM1 POSITIVITY CUT OFF, AS PREDICTIVE FOR HAEMATOLOGICAL RELAPSE IN AML-NPM1+ ADULT PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANT</b> <i>Poster Presenter: Simona Maria Muggianu, IT</i>	09:50 - 09:50
P462	<b>IMMUNE-MONITORING FOR VIRUS-SPECIFIC T-CELL RESPONSES IN ALLOGENEIC HSCT RECIPIENTS: A SURVEY FROM THE EBMT CELLULAR THERAPY &amp; IMMUNOBIOLOGY WORKING PARTY</b> <i>Poster Presenter: Raffaella Greco, IT</i>	09:50 - 09:50
P463	<b>HIGH-SENSITIVE INDEL-QPCR CHIMERISM TO INDIVIDUALIZED POST-HSCT FOLLOW-UP IN MYELOID NEOPLASMS</b> <i>Poster Presenter: Candela Ceballos, ES</i>	09:50 - 09:50
P464	<b>OXIDATIVE BURST FLOW CYTOMETRY ASSAY FOR CHIMERISM IN PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter: Dmitry Pershin, RU</i>	09:50 - 09:50
P465	<b>THE APPLICATION OF DIGITAL POLYMERASE CHAIN REACTION FOR CHIMAERISM ENGRAFTMENT MONITORING IN SELECTED HAEMATOLOGICAL MALIGNANCIES: A SINGLE CENTRE EXPERIENCE</b> <i>Poster Presenter: Kimberley Robinson, GB</i>	09:50 - 09:50
P466	<b>CIRCULATING MICRO-RNA PROFILING IN PATIENTS RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION.</b> <i>Poster Presenter: Jesus Duque-Afonso, DE</i>	09:50 - 09:50

P467	<b>LATE RECOVERY OF DONOR STEM CELL CHIMERISM AFTER APPARENT GRAFT FAILURE WITH AUTOLOGOUS RECONSTITUTION: IMPLICATIONS FOR PLANNING SECOND TRANSPLANTS</b> <i>Poster Presenter:</i> Dafydd Stonehewer, GB	09:50 - 09:50
P468	<b>DAY +21 ABSOLUTE LYMPHOCYTE COUNT COULD BE AN INDEPENDENT PREDICTOR FOR THE OUTCOME OF ALOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH ACUTE LEUKAEMIA.</b> <i>Poster Presenter:</i> Kameliya Milcheva, BG	09:50 - 09:50
P469	<b>NEXT GENERATION SEQUENCING (NGS) FOR CHIMERISM MONITORING FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)- A SERVICE DEVELOPMENT PROPOSAL.</b> <i>Poster Presenter:</i> Laura Kusyk, GB	09:50 - 09:50
P470	<b>QUANTIFERON-MONITOR - A PREDICTIVE TOOL OF INFECTIOUS COMPLICATIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Kateřina Žibřidová, CZ	09:50 - 09:50
P471	<b>PERSISTENCE OF FIRST DONOR NATURAL KILLER CELLS AFTER A SECOND TRANSPLANT FOR INFANT ACUTE LYMPHOBLASTIC LEUKEMIA</b> <i>Speaker:</i> Francesco Paolo Tambaro, IT	09:50 - 09:50
<i>Poster Sessions</i> 09:50 - 18:00		ePoster Area
<b>Myelodysplastic Syndromes</b>		
P640	<b>IMPACT OF SPECIFIC ADVERSE CYTOGENETIC FEATURES ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOYDYSPLASTIC SYNDROME WITH VERY POOR RISK CYTOGENETICS.</b> <i>Poster Presenter:</i> Xavier Poiré, BE	09:50 - 09:50
P641	<b>INFLUENCE OF DONOR TYPE AND R-IPSS STRATIFICATION ON OUTCOMES FROM MYELOYDYSPLASTIC SYNDROME BONE MARROW TRANSPLANTATION LATIN AMERICAN REGISTRY</b> <i>Poster Presenter:</i> Fernando Barroso Duarte, BR	09:50 - 09:50
P642	<b>PRELIMINARY RESULTS OF BONE MARROW TRANSPLANTATION IN HYPOCELLULAR VARIANT MYELOYDYSPLASTIC SYNDROME FROM THE LATIN AMERICAN REGISTRY</b> <i>Poster Presenter:</i> Fernando Barroso Duarte, BR	09:50 - 09:50
P643	<b>BIOLOGICAL AND CLINICAL FACTORS OF PROGNOSIS IN PATIENTS WITH HIGH RISK MYELOYDYSPLASTIC SYNDROME</b> <i>Poster Presenter:</i> Nikolai Tsvetkov, RU	09:50 - 09:50
P644	<b>PROGNOSIS AND RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH PRIMARY AND THERAPY-RELATED</b>	09:50 - 09:50

**MYELODYSPLASTIC SYNDROME***Poster Presenter:* Elena Morozova, RU

- P645 **COMPARATIVE ANALYSIS OF DATA ON THE INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE MARROW TRANSPLANTATION AND PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY/2020 AND APRIL/2021** 09:50 - 09:50  
*Poster Presenter:* Fernando Barroso Duarte, BR

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Chronic Leukaemia and Other Myeloproliferative Disorders**

- P646 **THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH PRIMARY MYELOFIBROSIS** 09:50 - 09:50  
*Poster Presenter:* KuoJui Sun, TW
- P647 **RESULTS OF THERAPY FOR PATIENTS WITH ADVANCED PHASES OF CHRONIC MYELOID LEUKEMIA** 09:50 - 09:50  
*Poster Presenter:* Elena Morozova, RU
- P648 **WHAT CAN WE DO TO IMPROVE THE MANAGEMENT OF HSCT ELIGIBLE PATIENTS WITH CMML IN LATIN AMERICA?** 09:50 - 09:50  
*Poster Presenter:* Fernando Barroso Duarte, BR

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Data Management**

- P651 **OPTIMIZING TEAMWORK LEADS TO A HIGH QUALITY DATA COLLECTION** 09:50 - 09:50  
*Poster Presenter:* Meriem Kara, ES
- P652 **A PILOT PROJECT TO EVALUATE THE BENEFIT OF ADDITIONAL SUPPORT IN HCT RESEARCH DATA MANAGEMENT ON BEHALF OF ANTHONY NOLAN AND BSBMTCT** 09:50 - 09:50  
*Poster Presenter:* Shelley Hewerdine, GB
- P653 **ADAPTING INTERACTIVE PRE-STEM CELL TRANSPLANT SCREENING AND CLEARANCE DASHBOARD FOR PEDIATRIC NON-MALIGNANT BLOOD DISORDER PATIENTS: EXPERIENCE FROM A TERTIARY CARE CENTER DURING THE COVID-19 PANDEMIC** 09:50 - 09:50  
*Poster Presenter:* Mahasen AlSaleh, SA
- P654 **THE ROLE OF THE UK TRANSPLANT TRIALS NETWORK IMPACT IN DELIVERING THE AMADEUS STUDY DURING THE COVID-19 PANDEMIC** 09:50 - 09:50  
*Poster Presenter:* Wendy Ingram, GB
- P655 **A COST ANALYSIS FOR THE CELLULAR THERAPIES SUPPLY CHAIN: IDENTIFYING THE LOW HANGING FRUITS TO OPTIMIZE COST CONTROL** 09:50 - 09:50  
*Poster Presenter:* Elger Johannes Vink, US

P656 **OBSERVATIONAL TRENDS IN GVHD DATA SUBMISSIONS; DO CENTRES HAVE A DATA COLLECTION PROCESS AND IS THIS RESPONSIBLE FOR SUBMISSION IMPROVEMENTS?** 09:50 - 09:50

*Poster Presenter:* Clementina Abamba, GB

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Quality Management**

P659 **IMPACT ASSESSMENT OF SECOND AND THIRD WAVE OF SARS-COVID19 PANDEMIC ON ALLOGENEIC TRANSPLANT ACTIVITY THROUGH THE JACIE ANNUAL MANAGEMENT REVIEW OF A SINGLE TRANSPLANT PROGRAM.** 09:50 - 09:50

*Poster Presenter:* serena marotta, IT

P660 **THE IMPACT OF COVID 19 ON MULTIDRUG RESISTANT BACTERIAL INFECTION RATE IN A HSCT UNIT IN INDIA** 09:50 - 09:50

*Poster Presenter:* Revathi Raj, IN

P661 **HOW HEMATOPOIETIC STEM CELL TRANSPLANTATION ACTIVITY WAS AFFECTED DURING THE PANDEMIC? JACIE ACCREDITED CENTER REFLEX** 09:50 - 09:50

*Poster Presenter:* İlknur Kozanoglu, TR

P662 **A BIG FISH IN A BIG POND QUANTIFYING AND HIGHLIGHTING ALDER HEY'S CONTRIBUTION TO CLINICAL ACTIVITY AND PATIENT EXPERIENCE THROUGHOUT THEIR JOURNEY TO TRANSPLANT** 09:50 - 09:50

*Poster Presenter:* Helen Heartfield, GB

*Poster Sessions*

09:50 - 18:00

ePoster Area

**CAR-based Cellular Therapy - Clinical**

P088 **3RD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-TS) FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - RESULTS FROM AN ACADEMIC PHASE 1/2 TRIAL (HD-CAR-1)** 09:50 - 09:50

*Poster Presenter:* Patrick Derigs, DE

P089 **PRIMARY ANALYSIS OF ZUMA-12: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA (LBCL)** 09:50 - 09:50

*Oral Presenter:* Julio Chavez, US

P090 **COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR PATIENTS LARGE B-CELL LYMPHOMA (LBCL) IN THE UNITED STATES** 09:50 - 09:50

*Poster Presenter:* Patrick Johnston, US

P091 **PREDICTING GRADE 2-4 CRS WITH THE MODIFIED EASIX (MEASIX) SCORE IN PATIENTS WITH NHL TREATED WITH ANTI CD19 CAR-T CELLS.** 09:50 - 09:50

*Poster Presenter:* Eugenio Galli, IT

P093	<b>LONG-TERM (5 YEAR) OVERALL SURVIVAL IN ZUMA-1, THE PIVOTAL STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)</b> <i>Poster Presenter:</i> Caron A. Jacobson, US	09:50 - 09:50
P094	<b>OUTCOME AFTER RELAPSE POST CD19 CAR T-CELLS IN CHILDREN AND YOUNG ADULTS WITH RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)</b> <i>Poster Presenter:</i> Anna Alonso-Saladrigues, ES	09:50 - 09:50
P095	<b>A GLIMPSE OF CLINICAL &amp; LABORATORY FEATURES OF CARHLH SYNDROME IN PATIENTS RECEIVING BCMA CAR-T CELLS</b> <i>Poster Presenter:</i> Cheng Zu, CN	09:50 - 09:50
P096	<b>BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): SUBANALYSIS OF THE KARMMA TRIAL</b> <i>Poster Presenter:</i> Nina Shah, US	09:50 - 09:50
P097	<b>UPDATED RESULTS OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T) THERAPY IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (MM) AFTER 1-3 PRIOR LINES OF THERAPY</b> <i>Poster Presenter:</i> Katja Weisel, DE	09:50 - 09:50
P098	<b>CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T) THERAPY IN PATIENTS WITH EARLY RELAPSE AFTER INITIAL MULTIPLE MYELOMA (MM) THERAPY</b> <i>Poster Presenter:</i> Tessa Kerre, BE	09:50 - 09:50
P099	<b>CYTOKINE SCORING SYSTEM CAN EFFECTIVELY EVALUATE THE SEVERITY OF CRS AFTER CART</b> <i>Poster Presenter:</i> Hui Wang, CN	09:50 - 09:50
P100	<b>SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) FROM THE KARMMA STUDY</b> <i>Poster Presenter:</i> Paula Rodríguez Otero, ES	09:50 - 09:50
P101	<b>CYTOMEGALOVIRUS IMPACT IN B-CELL LYMPHOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY</b> <i>Poster Presenter:</i> Pere Barba, ES	09:50 - 09:50
P102	<b>AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES AN HIGHER PERCENTAGE OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELLS. DO WE NEED TIMELY LEUKAPHERESIS STRATEGIES?</b> <i>Poster Presenter:</i> Mirko Farina, IT	09:50 - 09:50

P104	<b>PATIENT-REPORTED OUTCOMES IN ZUMA-7, A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS STANDARD-OF-CARE THERAPY IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA</b> <i>Poster Presenter:</i> Mahmoud Elsayy, CA	09:50 - 09:50
P105	<b>CHARACTERIZATION OF CD19CAR-T CELLS PRODUCED WITH THE CLINIMACS PRODIGY® PLATFORM: EFFECTS OF PRODUCTION CYCLE LENGTH AND CLINICAL HISTORY OF THE DONOR WITH REGARD TO HSCT</b> <i>Poster Presenter:</i> Ekaterina Malakhova, RU	09:50 - 09:50
P106	<b>DYNAMICS OF CAR-T CELLS THERAPY ASSOCIATED CYTOPENIAS: A SINGLE-CENTER EXPERIENCE</b> <i>Poster Presenter:</i> Reyes Maria Martin-Rojas, ES	09:50 - 09:50
P107	<b>CD19-SPECIFIC CAR-T CELLS FOR THE TREATMENT OF CNS CHLOROMAS IN CHILDREN WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA</b> <i>Poster Presenter:</i> Sanam Shahid, US	09:50 - 09:50
P108	<b>EARLY LYMPHOCYTE COLLECTION FOR CART PRODUCTION IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA IMPROVES T CELL PARAMETERS.</b> <i>Poster Presenter:</i> Sigal Grisariu, IL	09:50 - 09:50
P109	<b>COST-EFFECTIVENESS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR TREATMENT OF RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)</b> <i>Poster Presenter:</i> Fei Fei Liu, GB	09:50 - 09:50
P110	<b>CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN THE CZECH REPUBLIC</b> <i>Poster Presenter:</i> Frantisek Folber, CZ	09:50 - 09:50
P111	<b>CD34 SELECTED STEM CELL BOOST CAN SAFELY IMPROVE CYTOPAENIAS FOLLOWING CAR-T THERAPY</b> <i>Poster Presenter:</i> Khushnuma Mullanfiroze, GB	09:50 - 09:50
P112	<b>BRIDGING CHEMOTHERAPY STRATEGIES IN CHILDREN UNDERGOING CART-CELLS FOR ALL</b> <i>Poster Presenter:</i> Macarena Oporto Espuelas, GB	09:50 - 09:50
P113	<b>HUMORAL AND T CELL IMMUNE RESPONSES TO ANTI-SARS-COV-2 VACCINES IN PEDIATRIC &amp; PATIENTS WITH ANTI-CD19 CAR-T-INDUCED B-CELL APLASIA</b> <i>Poster Presenter:</i> Andrea Jarisch, DE	09:50 - 09:50
P114	<b>VALIDATION OF COLLECTION AND CRYOPRESERVATION OF AUTOLOGOUS MONONUCLEAR CELLS INTENDED FOR CAR-T CELLS PRODUCTION</b> <i>Poster Presenter:</i> Ines Bojanic, HR	09:50 - 09:50
P115	<b>STUDY OF SPECIFIC LINEAGE CHIMERISM AS AN EARLY BIOMARKER OF RISK OF RELAPSE AFTER ANTI-CD19 CART THERAPY IN PATIENTS PREVIOUSLY TREATED</b>	09:50 - 09:50

**WITH AN ALLOGENEIC HSCT***Poster Presenter:* Antonio Perez-Martínez, ES

- |      |  |               |
|------|--|---------------|
| P116 | <b>AUTOLOGOUS STEM CELL BOOST FOR PROLONGED SEVERE CYTOPENIA AFTER TREATMENT WITH CD19-CAR-T-CELLS FOR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA -TWO CASE REPORTS</b><br><i>Poster Presenter:</i> Lukas Gaksch, AT                           | 09:50 - 09:50 |
| P117 | <b>CD72 IS A PROMISING SUBSTITUTE FOR CD19 AS A MALIGNANT B CELL TARGET IN IMMUNOTHERAPY AND A ROUGH B GATING MARKER FOR FLOW CYTOMETRY DETECTION</b><br><i>Poster Presenter:</i> Hui Wang, CN   | 09:50 - 09:50 |
| P118 | <b>DEVELOPING A DIETETIC SERVICE FOR PATIENTS UNDERGOING CAR-BASED CELLULAR THERAPY; EVALUATED WITH PATIENT REPORTED EXPERIENCE AND OUTCOME MEASURES.</b><br><i>Poster Presenter:</i> Juliet Morgan, GB                                      | 09:50 - 09:50 |
| P119 | <b>CAR-T AS A BRIDGE THERAPY IN A CASE OF ALL LATE RESISTANT RELAPSE</b><br><i>Poster Presenter:</i> Marta Comini, IT  | 09:50 - 09:50 |
| P120 | <b>FEASIBILITY OF AUTOLOGOUS STEM CELL TRANSPLANTATION AS BRIDGING THERAPY PRIOR TO CD19 CAR-T IN R/R LARGE B CELL LYMPHOMA</b><br><i>Poster Presenter:</i> Eugenio Galli, IT  | 09:50 - 09:50 |
| P121 | <b>COMMERCIAL MANUFACTURING EXPERIENCE OF TISAGENLECLEUCEL IN EUROPE: &amp;GT; 3 YEARS JOURNEY</b><br><i>Poster Presenter:</i> Bernd Eschgfaeller, CH  | 09:50 - 09:50 |
| P122 | <b>UNIVERSAL ANTI-CD123 CAR-<math>\Gamma</math>T CELLS COMBINED WITH DONOR LYMPHOCYTES INFUSION FOR RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b><br><i>Poster Presenter:</i> erlie jiang, AS | 09:50 - 09:50 |
| P123 | <b>SUCCESSFULL MANAGEMENT OF POST- CAR-T CELL COLD AGLUTININ MEDIATED REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA WITH DARATUMUMAB</b><br><i>Poster Presenter:</i> Siret Ratip, TR  | 09:50 - 09:50 |

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Lymphoma and Chronic Lymphocytic Leukemia**

- |      |  |               |
|------|--|---------------|
| P595 | <b>ALLOGENIC STEM CELL TRANSPLANTATION FOR SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)</b><br><i>Poster Presenter:</i> Kamal Alzahrani, US                                       | 09:50 - 09:50 |
| P596 | <b>HIGH RESPONSE RATE WITH LIMITED REMISSION DURATION AFTER ANTI-PD-1-BASED COMBINATIONS IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER NIVOLUMAB MONOTHERAPY FAILURE: THE ROLE AND</b> | 09:50 - 09:50 |

	<b>OPTIMAL TIMING OF ALLO-HSCT</b>	
	<i>Poster Presenter:</i> Liudmila Fedorova, RU	
P597	<b>ALLOGENEIC STEM CELL TRANSPLANTATION FOR CUTANEOUS T-CELL LYMPHOMA - A NATIONAL ANALYSIS</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Daniel Angelov, IE	
P599	<b>OUTCOME OF PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AFTER SEQUENTIAL HIGH-DOSE METHOTREXATE, CYTARABINE, THIOTEPA BASED CHEMOIMMUNOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ugne Ringeleviciute, LT	
P601	<b>HIGH-DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWING PLATINUM-FREE HIGH-DOSE CYTARABINE INDUCTION RESULTS IN EXCELLENT LONG TERM SURVIVAL IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ben-Niklas Baermann, DE	
P602	<b>TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA RECEIVING STEM CELL TRANSPLANTATION OUTSIDE EUROPE AND NORTH AMERICA: RESULTS FROM THE B-HOLISTIC STUDY</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Mubarak Al-mansour, SA	
P603	<b>PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF PERIPHERAL T-CELL LYMPHOMAS: A MULTICENTER EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Ivan Moiseev, RU	
P604	<b>ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION (ALLO-HSCT) FOR HODGKIN LYMPHOMA IN SWITZERLAND: 20 YEARS OF EXPERIENCE 2001-2020. FOR SBST WORKING GROUP.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Helena Simeunovic, CH	
P605	<b>HEMATOPOIETIC STEM CELL TRANSPLANT OUTCOMES IN NORTH AMERICAN ADULT T-CELL LEUKEMIA/LYMPHOMA</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Daniel Reef, US	
P607	<b>DOES HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AFFECT BONE MINERAL DENSITY IN PATIENTS WITH LYMPHOMA?</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Rebecca Fredriksson, SE	
P608	<b>HEMATOPOIETIC CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA: A LONG-TERM SINGLE CENTER EXPERIENCE</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Eleni Gavriilaki, GR	
P609	<b>AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS LYMPHOMA. A SINGLE INSTITUTION EXPERIENCE.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> BEATA OSTROWSKA, PL	



P610	<b>GEMCITABINE, CISPLATIN AND DEXAMETHASONE AS A SALVAGE AND MOBILIZATION CHEMOTHERAPY BEFORE AUTOLOGOUS STEM-CELL TRANSPLANTATION IS EFFECTIVE AND SAFE OUTPATIENT REGIMEN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS</b> <i>Poster Presenter: Ayla Gokmen, TR</i>	09:50 - 09:50
P611	<b>EFFICACY OF PD1-BLOCKADE IMMEDIATELY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA, BUT INVESTIGATIONS NEEDED TO ELUCIDATE THE IMPACT ON AUTOLOGOUS TRANSPLANTATION.</b> <i>Poster Presenter: Ahmad Ibrahim, LB</i>	09:50 - 09:50
P612	<b>ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION IN RELAPSED FOLLICULAR LYMPHOMA: UNICENTRIC ANALYSIS WITH 20 YEARS OF FOLLOW-UP</b> <i>Poster Presenter: Rita Pinho Peixeiro, PT</i>	09:50 - 09:50
P613	<b>SECONDARY HYPOGAMMAGLOBULINEMIA IN CLL</b> <i>Poster Presenter: Ali Ünal, TR</i>	09:50 - 09:50
P614	<b>POST-MARKET CLINICAL FOLLOW-UP OF THE AMICUS BLUE™ ONLINE ECP SYSTEM FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL)</b> <i>Poster Presenter: Tarik Kanouni, FR</i>	09:50 - 09:50
P615	<b>THE EXPRESSION OF CD268 HELPS TO DISTINGUISH CHRONIC LYMPHOCYTIC LEUKEMIA FROM OTHER MATURE B-CELL LYMPHOMAS</b> <i>Poster Presenter: Hui Wang, CN</i>	09:50 - 09:50

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Stem Cell Source**

P165	<b>COMPARISON OF THE CLINICAL OUTCOMES OF HAPLO VERSUS CORD BLOOD TRANSPLANTATION IN PEDIATRIC AML. A RETROSPECTIVE ANALYSIS ON BEHALF OF GETH</b> <i>Poster Presenter: Luisa Sisinni, ES</i>	09:50 - 09:50
P166	<b>OPTIMAL CORD BLOOD UNIT SELECTION RESULTS IN GOOD ENGRAFTMENT AND LOW TRM AND RELAPSE, BUT CONDITIONING INTENSITY MATTERS</b> <i>Poster Presenter: Chloe Anthias, GB</i>	09:50 - 09:50
P167	<b>IMPACT OF ALLO PBSC CRYOPRESERVATION ON GRAFT FUNCTION AND ACUTE GVHD</b> <i>Poster Presenter: Massimiliano Gambella, IT</i>	09:50 - 09:50
P168	<b>DOES HLA TISSUE GROUP CHANGE AFTER GRANULOCYTE TRANSFUSION?</b> <i>Poster Presenter: Ali Ünal, TR</i>	09:50 - 09:50

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Nurses Posters - Research**

NP047	<b>EVIDENCE-BASED TOPICAL APPROACH FOR SKIN GVHD: A LITERATURE REVIEW</b> <i>Oral Presenter:</i> Anna Campanati, IT	09:50 - 09:50
NP048	<b>THE EFFECT OF ORAL ICE APPLICATION ON PROTECTION FROM MUCOSITIS IN PATIENTS WITH AUTOLOGIC STEM CELL TRANSPLANTATION REQUESTING MELPHELAN TREATMENT: A RANDOMIZED CONTROLLED STUDY</b> <i>Oral Presenter:</i> Solmaz Zeybekci, TR	09:50 - 09:50
NP050	<b>HOW THE PHARMACIES SUPPORT STEM CELL TRANSPLANTATION PROGRAMS IN ITALY: A GITMO NG SURVEY</b> <i>Oral Presenter:</i> Maura Faraci, IT	09:50 - 09:50
NP051	<b>HAND HYGIENE TEACHING TECHNOLOGIES FOR THE HEALTHCARE TEAM AND CAREGIVERS: SYSTEMATIC REVIEW</b> <i>Oral Presenter:</i> Renata Cristina de Campos Pereira Silveira, BR	09:50 - 09:50
<i>Poster Sessions</i> 09:50 - 18:00		ePoster Area
<b>Nurses Posters - Paediatric</b>		
NP038	<b>EBMT MIDDLE-INCOME COUNTRIES PEDIATRIC ADVANCED CARE TRAINING PROJECT</b> <i>Oral Presenter:</i> Eugenia Trigo, ES	09:50 - 09:50
NP039	<b>GASTROSTOMY FEEDING IS SAFE AND EFFECTIVE IN IMPROVING THE NUTRITIONAL STATUS OF CHILDREN WITH CANCER AND THOSE UNDERGOING BONE MARROW TRANSPLANT: A SYSTEMATIC REVIEW</b> <i>Oral Presenter:</i> James Evans, GB	09:50 - 09:50
NP040	<b>THE DELIVERY OF EFFECTIVE PATIENT EDUCATION FOR PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) PATIENTS AND THEIR CAREGIVERS</b> <i>Oral Presenter:</i> Yan Yin Lim, SG	09:50 - 09:50
NP041	<b>THE TYRANNY OF DISTANCE IN PAEDIATRIC BMT WITHIN AUSTRALIA</b> <i>Oral Presenter:</i> Lucy Maurice, AU	09:50 - 09:50
NP042	<b>NURSE PRACTICE FOR USE OF INTRAVENOUS NEEDLE-LESS CONNECTORS IN CENTRAL VENOUS CATHETERS STUDY</b> <i>Oral Presenter:</i> Claudia Pina Pino, ES	09:50 - 09:50
NP044	<b>PAEDIATRIC UNRELATED UMBILICAL CORD BLOOD TRANSPLANT RECIPIENTS HAVE A SIGNIFICANTLY PROLONGED LENGTH OF STAY COMPARED WITH MATCHED SIBLING OR MATCHED UNRELATED DONOR RECIPIENTS</b> <i>Oral Presenter:</i> Aisha Hannan, GB	09:50 - 09:50
NP045	<b>ACCREDITATIONS AND INSPECTIONS: AN OPPORTUNITY TO IMPROVE. EXPERIENCE IN AN ITALIAN PEDIATRIC CENTER DURING THE LOCKDOWN PERIOD.</b> <i>Oral Presenter:</i> Giuseppe Marco Deiana, IT	09:50 - 09:50

NP046	<b>EDUCATIONAL PROGRAM FOR NURSES INVOLVED IN THE CARE OF PEDIATRIC STEM CELL TRANSPLANT (SCT) PATIENTS</b> <i>Oral Presenter:</i> Nathalie Herman, BE	09:50 - 09:50
<i>Poster Sessions</i> 09:50 - 18:00		ePoster Area
<b>Nurses Posters - Adult</b>		
NP001	<b>PEER AMBASSADOR SUPPORT - A NEW MODEL OF PSYCHOSOCIAL SUPPORTIVE CARE IN A HEMATOLOGICAL CLINICAL CARE SETTING</b> <i>Oral Presenter:</i> Kristina Nørskov, DK	09:50 - 09:50
NP002	<b>VULVO-VAGINAL CHRONIC GRAFT VERSUS HOST DISEASE: A MONOCENTRIC LONGITUDINAL STUDY.</b> <i>Oral Presenter:</i> Francesca Palmisano, IT	09:50 - 09:50
NP003	<b>A DIGITAL EDUCATION PATHWAY FOR ALLOGENEIC TRANSPLANT PATIENTS: IMPLEMENTATION TO MAINTENANCE, KEEPING THE MOMENTUM GOING</b> <i>Oral Presenter:</i> Zoe Evans, CA	09:50 - 09:50
NP004	<b>ANXIETY AND DEPRESSION IN HSCT PATIENTS AND THEIR CAREGIVERS. PRELIMINARY RESULTS OF THE 100 FIRST DAYS AFTER HSCT IN A SPANISH COHORT.</b> <i>Oral Presenter:</i> Carla Ramos-Serrano, ES	09:50 - 09:50
NP005	<b>DIGITAL SOLUTIONS FOR CRS AND ICANS GRADING</b> <i>Oral Presenter:</i> Ruth Clout, GB	09:50 - 09:50
NP006	<b>DOING MORE FOR DONORS: RESULTS OF A SERVICE IMPROVEMENT INITIATIVE</b> <i>Oral Presenter:</i> Emma Kane, GB	09:50 - 09:50
NP007	<b>MISSION: POSSIBLE - THE ESTABLISHMENT AND OPERATION OF A PALLIATIVE CARE PROJECT IN THE BONE MARROW TRANSPLANTATION UNIT</b> <i>Oral Presenter:</i> Limor Mintz-Manor, IL	09:50 - 09:50
NP008	<b>CENTRAL VENOUS CATHETER PATENCY AS A NURSING QUALITY INDICATOR? AN AUDIT EXPERIENCE DUE TO A CHANGE IN THE LOCKING SOLUTION</b> <i>Oral Presenter:</i> Isabel Salcedo, ES	09:50 - 09:50
NP009	<b>THE DEVELOPMENT OF AN AMBULATORY COMMUNITY SERVICE FOR POST HSCT PATIENTS</b> <i>Oral Presenter:</i> Rebecca Hallam, GB	09:50 - 09:50
NP010	<b>LEARNING FROM ERROR: INVOLVING EXPERT NURSES IN AN INTEGRATED AUDIT PROCESS</b> <i>Oral Presenter:</i> Barbara Loconte, CH	09:50 - 09:50
NP012	<b>PSYCHOSEXUAL FUNCTION AND RELATIONSHIPS POST HSCT - CAN WE DO BETTER?</b> <i>Oral Presenter:</i> emma thistlethwayte, GB	09:50 - 09:50
NP013	<b>FROM 2 PATIENTS RECIEVING ADVANCED HOSPITAL CARE AT HOME (AHS) IN 2018, TO OVER 40 PATIENTS IN</b>	09:50 - 09:50

**2020 - EXPERIENCES FROM OSLO UNIVERSITY HOSPITAL***Oral Presenter:* Ellen Hammering, NO

NP014	<b>QUALITY OF LIFE PATTERN IN PATIENTS WITH MULTIPLE MYELOMA INFUSED WITH CAR-T THERAPY</b> <i>Oral Presenter:</i> Cassandra Ixena Andersson-Vila, ES	09:50 - 09:50
NP015	<b>NUTRITIONAL STATUS AND QUALITY OF LIFE IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Oral Presenter:</i> Stefano Botti, IT	09:50 - 09:50
NP016	<b>PHOTOBIO-MODULATION: A PROMISING INNOVATIVE APPROACH FOR PREVENTING ORAL MUCOSITIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Oral Presenter:</i> Nicolas Stocker, FR	09:50 - 09:50
NP017	<b>PUTTING PREHABILITATION INTO PRACTICE: EVALUATION OF PRE-TRANSPLANT REFERRALS TO A SPECIALIST DIETETIC AND PHYSIOTHERAPY TELEHEALTH PREHABILITATION SERVICE IN A TERTIARY TRANSPLANT CENTRE</b> <i>Oral Presenter:</i> Shana Hall, GB	09:50 - 09:50
NP018	<b>NURSING APPOINTMENT IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Oral Presenter:</i> Lucília Carreiro, PT	09:50 - 09:50
NP019	<b>QUALITY OF LIFE: YOUR CARE, OUR CARE? IMPLEMENTATION AND THE FIRST RESULTS OF MEASURING QUALITY OF LIFE IN PATIENTS AFTER AN ALLOGENIC STEM CELL TRANSPLANTATION</b> <i>Oral Presenter:</i> Tineke Nagtegaal-de Wit, NL	09:50 - 09:50
NP020	<b>LABMT NURSES GROUP 2021 CONTINUING EDUCATION PROGRAM</b> <i>Oral Presenter:</i> Mariela Blanco, AR	09:50 - 09:50
NP021	<b>CAR-T SITE QUALIFICATION IN COVID ERA</b> <i>Oral Presenter:</i> Barbara Loconte, CH	09:50 - 09:50
NP022	<b>LIFELONG FOLLOW-UP IN ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: A PILOT SINGLE CENTER INITIATIVE IMPROVING DATA REGISTRATION</b> <i>Oral Presenter:</i> Johanna Van Hulle, BE	09:50 - 09:50
NP023	<b>THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY</b> <i>Oral Presenter:</i> Monika Ochsner, CH	09:50 - 09:50
NP025	<b>COMPARATIVE OF ALTERATIONS IN VIRGINIA HENDERSON PATTERNS IN PATIENTS UNDERGOING CART THERAPY. PILOT STUDY.</b> <i>Poster Presenter:</i> Juana García García, ES	09:50 - 09:50
NP026	<b>COMPARISON OF TYPES OF PERIPHERAL CATHETERS USED IN ALLOGENEIC DONORS DURING STEM CELLS EXTRACTION AT THE BANC DE SANG I TEIXITS OF</b>	09:50 - 09:50

	<b>BELLVITGE DURING 2019-2020</b>	
	<i>Oral Presenter:</i> Ana Isabel Torres Egea, ES	
NP027	<b>JOINING FORCES BETWEEN A PUBLIC HOSPITAL AND A THIRD SECTOR FOUNDATION TO COVER THE NECESSITY OF CAREGIVERS IN AN AT-HOME HEMATOPOIETIC STEM CELL TRANSPLANTS PROGRAM.</b>	09:50 - 09:50
	<i>Oral Presenter:</i> Cristina Gallego, ES	
NP028	<b>CLINICAL CHARACTERISTICS AND NURSING CARE IMPLEMENTED IN HAEMATOPOIETIC STEM-CELL TRANSPLANTATION RECIPIENTS WITH COVID-19: AN OBSERVATIONAL STUDY</b>	09:50 - 09:50
	<i>Oral Presenter:</i> Lidia Hurtado Ortega, ES	
NP029	<b>HSV RESISTANCE IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS</b>	09:50 - 09:50
	<i>Oral Presenter:</i> Monika Marxová, CZ	
NP030	<b>NURSING INTERVENTIONS OF THE MANAGEMENT OF TOXICITIES ASSOCIATED WITH CAR - T CELL THERAPY - A CASE SERIES</b>	09:50 - 09:50
	<i>Oral Presenter:</i> Seckin Erdal, TR	
NP031	<b>THE DEVELOPMENT OF A HEALTH CARE ASSISTANT (HCAS) AND HOUSE KEEPER (HKS) STUDY DAY</b>	09:50 - 09:50
	<i>Oral Presenter:</i> Ann-Marie Hamilton, GB	
NP032	<b>SEVERITY OF ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION; A RETROSPECTIVE STUDY</b>	09:50 - 09:50
	<i>Oral Presenter:</i> Sevgül Çil Kazan, TR	
NP034	<b>IMPLEMENTATION OF A PROTOCOL FOR THE CARE OF SKIN AND MUCOUS MEMBRANES IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	09:50 - 09:50
	<i>Oral Presenter:</i> Nuria Peña Alvarez, ES	
NP035	<b>CASE STUDY: PROCEDURE FOLLOWING LEAKAGE OF THAWED CELLS DURING INFUSION</b>	09:50 - 09:50
	<i>Oral Presenter:</i> Lyndsey Griffiths, GB	
NP036	<b>MANAGEMENT OF MELPHALAN IN THE CONDITIONING REGIMEN, VISUAL TOOL FOR NURSES.</b>	09:50 - 09:50
	<i>Oral Presenter:</i> Silvia Sangüesa Domínguez, ES	
NP037	<b>PARENTERAL NUTRITION IN PATIENTS WITH LYMPHOMAS AFTER AUTOLOGOUS TRANSPLANTATION, COMPARISON OF TEAM / BEAM REGIMENS</b>	09:50 - 09:50

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Psychological Issues**

P671	<b>PSYCHOLOGICAL NEED IN THE HAEMATOPOIETIC STEM CELL TRANSPLANT PATHWAY - WHAT DO OUR PATIENTS THINK? OUTCOMES OF A PATIENT LISTENING EVENT.</b>	09:50 - 09:50
	<i>Poster Presenter:</i> Jenna Love, GB	

P672	<b>PHYSICAL, PSYCHO-SOCIAL, AND LEARNING FUNCTIONING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN</b> <i>Poster Presenter:</i> MONIA OUEDERNI, TN	09:50 - 09:50
P673	<b>NEUROPSYCHOLOGICAL TARGETS IN THE EARLY STAGES OF REHABILITATION OF PATIENTS WITH HSCT</b> <i>Poster Presenter:</i> Alisa Volkova, RU	09:50 - 09:50
P674	<b>EXPECTATIONS OF THE MEDICAL STAFF REGARDING COOPERATION WITH CLINICAL PSYCHOLOGISTS AT THE BONE MARROW TRANSPLANT CLINIC</b> <i>Poster Presenter:</i> Alisa Volkova, RU	09:50 - 09:50
P675	<b>TITLE: SOCIODEMOGRAPHIC AND PSYCHOLOGICAL FACTORS ASSOCIATED WITH PSYCHIATRIC DIAGNOSIS BEFORE AND DURING HOSPITALIZATION FOR HSCT.</b> <i>Poster Presenter:</i> Mariana Brenda Ángeles-Basilio, MX	09:50 - 09:50
P676	<b>QUALITY OF LIFE AND SUBJECTIVE WELL-BEING IN PEDIATRIC PATIENTS AT VARIOUS STAGES OF ALLOGENEIC HSCT: FIRST RESULTS OF RUSSIAN PROSPECTIVE STUDY</b> <i>Poster Presenter:</i> Alina Khain, RU	09:50 - 09:50
P677	<b>PSYCHOLOGICAL NEED IN THE HAEMATOPOEITIC STEM CELL TRANSPLANT PATHWAY - VIEW OF THE CLINICAL TEAM</b> <i>Poster Presenter:</i> Jenna Love, GB	09:50 - 09:50
P678	<b>EVALUATION OF ANXIETY AND BURNOUT OF NURSES WORKING AT ADULT BONE MARROW TRANSPLANTATION UNIT</b> <i>Poster Presenter:</i> ELİF NAZ ARSLAN, TR	09:50 - 09:50
P679	<b>HETEROGENEOUS PSYCHOLOGICAL ASPECTS OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE</b> <i>Poster Presenter:</i> Ahmad Ibrahim, LB	09:50 - 09:50
P680	<b>HOW MODERN PSYCHOANALYSIS COULD SUPPORT MODERN MEDICINE - COMMUNICATION, TRANSLATION AND SEARCHING FOR A MEANING</b> <i>Poster Presenter:</i> Velislava Donkina, BG	09:50 - 09:50
P681	<b>NEUROCOGNITIVE FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE AND TRANSFUSION DEPENDENT THALASSEMIA</b> <i>Poster Presenter:</i> Elisabeth Kühn-Wolff, DE	09:50 - 09:50
<i>Poster Sessions</i> 09:50 - 18:00		ePoster Area
<b>Pharmacology</b>		
P683	<b>ROLE AND COMPETENCIES OF THE EBMT CLINICAL PHARMACISTS AND CLINICAL PHARMACOLOGISTS: A PAN-EUROPEAN SURVEY</b>	09:50 - 09:50

	<i>Poster Presenter:</i> Nick Duncan, GB	
P684	<b>SCREENING PHYTOCHEMICAL DRUG LIBRARY FOR IDENTIFICATION AND DEVELOPMENT OF NOVEL PHYTOCHEMICALS FOR THE PROPHYLAXIS OF ACUTE GRAFT VERSUS HOST DISEASE</b> <i>Poster Presenter:</i> Dievya Gohil, IN	09:50 - 09:50
P685	<b>GLUCOCORTICOIDS TRIGGER A CXCR4/PLC-MEDIATED CELL SURVIVAL PATHWAY INVOLVED IN RESISTANCE OF B-ACUTE LYMPHOBLASTIC LEUKEMIA</b> <i>Poster Presenter:</i> Olivier Boyer, FR	09:50 - 09:50
P686	<b>PHARMACOKINETICS AND EXPOSURE-EFFICACY RELATIONSHIP OF MARIBAVIR IN TRANSPLANT RECIPIENTS WITH REFRACTORY AND RESISTANT CYTOMEGALOVIRUS INFECTIONS</b> <i>Poster Presenter:</i> Ivy Song, US	09:50 - 09:50
P687	<b>VEDOLIZUMAB FOR PEDIATRIC PATIENTS WITH GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST-DISEASE</b> <i>Poster Presenter:</i> gefen bier, IL	09:50 - 09:50
P688	<b>SINGLE DOSE CD117-TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN COMBINATION WITH LYMPHODEPLETING ANTIBODIES ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MICE WITHOUT CHEMOTHERAPY OR RADIATION</b> <i>Poster Presenter:</i> Leanne Lanieri, US	09:50 - 09:50
P690	<b>HIGH DOSE MELPHALAN CONDITIONING IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA - A UK SURVEY OF PRACTICE</b> <i>Poster Presenter:</i> Siobhan Smith, GB	09:50 - 09:50
P691	<b>LIMITED SAMPLING IN MODEL-INFORMED PRECISION DOSING OF BUSULFAN</b> <i>Poster Presenter:</i> Adrin Dadkhah, DE	09:50 - 09:50
P692	<b>COADMINISTRATION OF REZAFUNGIN DOES NOT IMPACT CYCLOSPORINE OR MYCOPHENOLATE MOFETIL PHARMACOKINETICS</b> <i>Poster Presenter:</i> Taylor Sandison, US	09:50 - 09:50
P693	<b>AN ASSESSMENT OF INITIAL VANCOMYCIN DOSING IN PEDIATRIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Vera Pires, PT	09:50 - 09:50
P694	<b>DURATION OF ANTIFUNGAL PROPHYLAXIS AFTER HEMATOPOIETIC CELL TRANSPLANT DISCHARGE ON INVASIVE FUNGAL INFECTION OUTCOMES</b> <i>Poster Presenter:</i> Justine Abella Ross, US	09:50 - 09:50
P695	<b>LONG-TERM CLOZAPINE USE IS A RISK FACTOR FOR NEUTROPENIA IN THE POST-ENGRAFTMENT PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter:</i> Claudia Langebrake, DE	09:50 - 09:50

## Poster Sessions

09:50 - 18:00

ePoster Area

**Cellular Therapies other than CARs**

- |      |  |               |
|------|--|---------------|
| P124 | <b>UNMANIPULATED DONOR LYMPHOCYTE INFUSION (DLI) AFTER AB-T AND B-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION</b><br><i>Poster Presenter:</i> Federica Galaverna, IT  | 09:50 - 09:50 |
| P125 | <b>USE OF MESENCHYMAL STROMAL CELLS UNDER SPECIAL SITUATIONS FOR COMPLICATIONS OF ALLOGENEIC HSCT. A SINGLE CENTER EXPERIENCE.</b><br><i>Poster Presenter:</i> Rosalía Alonso Trillo, ES   | 09:50 - 09:50 |
| P126 | <b>OFF-THE-SHELF PARTIAL HLA MATCHING SARS-COV-2 ANTIGEN SPECIFIC T CELL THERAPY: A NEW POSSIBILITY FOR COVID-19 TREATMENT</b><br><i>Poster Presenter:</i> Nayoun Kim, KR  | 09:50 - 09:50 |
| P127 | <b>THE ROLE OF DONOR GAMMA DELTA T CELLS IN ACUTE MYELOID LEUKEMIA CONTROL AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</b><br><i>Poster Presenter:</i> Nelli Bejanyan, US  | 09:50 - 09:50 |
| P128 | <b>SEQUENTIAL CONDITIONING WITH FLAMSA-FLUDARABINE-BUSULFAN DOES NOT IMPROVE OUTCOMES AFTER ALLOGENEIC-STEM CELL TRANSPLANTATION WHEN COMPARED WITH TREOSULFAN-FLUDARABINE CONDITIONING IN HIGHER RISK MDS PATIENTS</b><br><i>Poster Presenter:</i> Radwan Massoud, DE | 09:50 - 09:50 |
| P129 | <b>GENE EDITING OF THE IMMUNE CHECKPOINT NKG2A ENHANCES ALLOGENIC NK CELL MEDIATED CYTOTOXICITY AGAINST PATIENT-DERIVED PRIMARY MULTIPLE MYELOMA CELLS</b><br><i>Poster Presenter:</i> Tobias Bexte, DE  | 09:50 - 09:50 |
| P130 | <b>ASSESSMENT OF THE SAFETY OF THERAPEUTIC COVID 19 SPECIFIC T CELLS USING A HUMAN SKIN EXPLANT ASSAY FOR GRAFT VERSUS HOST DISEASE</b><br><i>Poster Presenter:</i> Anne Dickinson, GB   | 09:50 - 09:50 |
| P132 | <b>CEREBROSPINAL FLUID PARAMETERS IN PATIENTS WITH PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY RECEIVING ALLOGENEIC T CELL THERAPY</b><br><i>Poster Presenter:</i> Nora Möhn, DE  | 09:50 - 09:50 |
| P133 | <b>PATIENT-TAILORED ADOPTIVE IMMUNOTHERAPY WITH EBV-SPECIFIC T CELLS FROM RELATED AND UNRELATED DONORS</b><br><i>Poster Presenter:</i> Britta Maecker-Kolhoff, DE  | 09:50 - 09:50 |
| P134 | <b>SPECTRAL FLOW CYTOMETRY OF T-CELL SUBSETS IN DONOR LYMPHOCYTE INFUSIONS REVEALS PHENOTYPICAL DIFFERENCES ASSOCIATED WITH THERAPEUTIC OUTCOME IN PATIENTS WITH MYELOID MALIGNANCIES</b><br><i>Poster Presenter:</i> Ruth Sikora, DE                                  | 09:50 - 09:50 |
| P135 | <b>THE EFFICACY OF THIRD-PARTY MESENCHYMAL STEM</b>  | 09:50 - 09:50 |



- CELLS IN STEROID-RESISTANT, SEVERE, ACUTE GRAFT VERSUS HOST DISEASE**  
*Poster Presenter:* Meltem Kurt Yuksel, TR
- P136 **RELAPSE PROPHYLAXIS POST-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AND CYCLOPHOSPHAMIDE (HAPLO/CY) BY INFUSION OF DONOR-DERIVED EXPANDED/ACTIVATED  $\gamma$  T CELLS: A PHASE I TRIAL.** 09:50 - 09:50  
*Poster Presenter:* Lawrence Lamb, US
- P137 **INFLUENCE OF T-MEMORY CELL DOSES ON POST-TRANSPLANT INFECTIONS AND GVHD RATES.** 09:50 - 09:50  
*Poster Presenter:* Poh Lin Tan, SG
- P138 **PROCESSING OF ONE TOTAL BLOOD VOLUME IS SUFFICIENT TO PERFORM EXTRACORPOREAL PHOTOPHERESIS WITH SPECTRA OPTIA CMNC PROTOCOL. A STUDY WITH FOCUS ON A PATIENT SAFETY.** 09:50 - 09:50  
*Poster Presenter:* Roman Małachowski, PL
- P139 **CLINICAL EXPERIENCE OF USING MULTIVIRUS-SPECIFIC T CELLS PRODUCED BY IFN $\gamma$ -DIRECTED IMMUNOMAGNETIC SEPARATION IN PATIENTS WITH POST-HSCT SEVERE VIRAL INFECTIONS** 09:50 - 09:50  
*Poster Presenter:* Viktoria Vedmedskia, RU
- P140 **STEM CELL THERAPY IN CHILDREN WITH NEUROLOGICAL DISEASE: ASSOCIATION BETWEEN ADVERSE EFFECTS AND TOTAL NUCLEATED CELLS PARAMETERS** 09:50 - 09:50  
*Poster Presenter:* Hernán Ramírez Durán, MX
- P141 **ADOPTIVE TRANSFER OF ALLOGENIC HPYV-1-VIRUS SPECIFIC T CELLS IMPROVES CLINICAL OUTCOME OF PATIENTS SUFFERING FROM PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY** 09:50 - 09:50  
*Poster Presenter:* Lea Grote-Levi, DE
- P142 **IMPACT OF DONOR-TO-RECIPIENT ABO MISMATCH ON OUTCOMES OF PERIPHERAL BLOOD STEM CELL-DERIVED GRAFTS HAPLOIDENTICAL STEM CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Yi Luo, CN
- P143 **INVARIANT NATURAL KILLER T CELLS PROTECT FROM CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Dominik Schneidawind, DE
- P144 **ALLOGENEIC STEM CELL TRANSPLANTATION WITH 3-DAYS BUSULFAN PLUS FLUDARABINE AS CONDITIONING REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY T- AND NK/T-CELL LYMPHOMAS** 09:50 - 09:50  
*Poster Presenter:* Ji Hyun Lee, KR
- P145 **FIBROBLAST-LIKE CELLS PRESENT IN AN APHERESIS COLLECTED HAEMATOPOIETIC PROGENITOR CELL FRACTION** 09:50 - 09:50  
*Poster Presenter:* Riana Cockeran, ZA

P146 **GRANULOCYTE TRANSFUSION IN PATIENTS WITH MUCOSITIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:50 - 09:50  
*Poster Presenter:* Ali Ünal, TR

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Experimental Transplantation and Gene Therapy**

P147 **WOLMAN CD34+ CELLS TRANSDUCED WITH CD11BLIPA LENTIVIRUS DRIVES LYSOSOMAL ACID LIPASE ENZYME EXPRESSION.** 09:50 - 09:50

*Poster Presenter:* Anthea Guha, GB

P148 **ELTROMBOPAG IN FANCONI ANEMIA PATIENTS INFUSED WITH VERY LOW NUMBERS OF GENE CORRECTED CELLS** 09:50 - 09:50

*Poster Presenter:* June Iriondo, ES

P149 **HAPLOIDENTICAL STEM-CELL TRANSPLANTATION FOR CHILDREN WITH ACUTE LEUKEMIA, USING AB+ T CELL /CD19+ B-CELL DEPLETION, A SINGLE CENTER EXPERIENCE** 09:50 - 09:50

*Poster Presenter:* Gal Dadi, IL

P150 **VENETOCLAX ADDED TO SEQUENTIAL FLAMSA + ALKYLATOR BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, A RETROSPECTIVE SINGLE CENTER CASE SERIES OF THE FLMSACLAX APPROACH** 09:50 - 09:50

*Poster Presenter:* Guido Kobbe, DE

P151 **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ADULT ONSET LEUKOENCEPHALOPATHY WITH AXONAL SPHEROIDS** 09:50 - 09:50

*Poster Presenter:* Georg-Nikolaus Franke, DE

P152 **HAPLOIDENTICAL STEM CELL TRANSPLANT FOR HAEMATOLOGICAL MALIGNANCIES: REAL WORLD EXPERIENCE FROM A DEVELOPING COUNTRY.** 09:50 - 09:50

*Poster Presenter:* Pallavi Mehta, IN*Poster Sessions*

09:50 - 18:00

ePoster Area

**Graft-versus-host Disease - Preclinical and Animal Models**

P194 **SER-155, AN INVESTIGATIONAL CULTIVATED MICROBIOME THERAPEUTIC, RATIONALLY DESIGNED TO REDUCE GASTROINTESTINAL INFLAMMATION AND PROMOTE EPITHELIAL BARRIER INTEGRITY IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION** 09:50 - 09:50

*Poster Presenter:* Elizabeth Halvorsen, US

P195 **CHRONIC GRAFT-VERSUS-HOST DISEASE IMMUNOPROFILING REVEALS T CELL CLONAL DYNAMICS THAT CORRELATE WITH DISEASE ACTIVITY: A NOVEL MOLECULAR MARKER?** 09:50 - 09:50

*Poster Presenter:* Anna Vardi, GR

P196	<b>JAK1/2 INHIBITOR RUXOLITINIB INDUCE POLYMORPHONUCLEAR MYELOID-DERIVED SUPPRESSOR CELLS MOBILIZATION AND FUNCTION VIA JAK/STAT AND MAPK/NF-KB DEPENDENT MANNER IN PROTECTING AGAINST ACUTE GRAFT-VERSUS-HOST DISEASE</b> <i>Poster Presenter: Yigeng Cao, CN</i>	09:50 - 09:50
P197	<b>SINGLE CELL TRANSCRIPTOMIC SURVEY OF THE HUMAN GVHD LANDSCAPE</b> <i>Poster Presenter: Jason Lam, GB</i>	09:50 - 09:50
P198	<b>APRAGLUTIDE DECREASES SEVERITY OF INTESTINAL DAMAGE FROM ACUTE GASTROINTESTINAL GRAFT VERSUS HOST DISEASE (GI-GVHD) FOLLOWING ALLOGENEIC TRANSPLANTATION WITHOUT IMPACTING ENGRAFTMENT</b> <i>Poster Presenter: Violetta Dimitriadou, CH</i>	09:50 - 09:50
P199	<b>APRAGLUTIDE TREATMENT REDUCES CHEMOTHERAPY-INDUCED GASTROINTESTINAL (GI) DAMAGE IN MICE AND PRESERVES CELLULAR INTEGRITY DURING CHEMOTHERAPY</b> <i>Poster Presenter: Violetta Dimitriadou, CH</i>	09:50 - 09:50
P200	<b>TREATMENT WITH APRAGLUTIDE PRESERVES THE GLOBAL HOMEOSTATIC ENVIRONMENT OF INTESTINAL MICROBIOTA DURING CHEMOTHERAPY IN MICE</b> <i>Poster Presenter: Violetta Dimitriadou, CH</i>	09:50 - 09:50
P201	<b>APRAGLUTIDE DOES NOT IMPACT ANTI-TUMOR AND IMMUNOSUPPRESSIVE EFFICACY OF CONDITIONING CHEMOTHERAPY IN MICE</b> <i>Poster Presenter: Violetta Dimitriadou, CH</i>	09:50 - 09:50

*Poster Sessions*

09:50 - 18:00

ePoster Area

**Myeloproliferative Neoplasm**

P569	<b>PARTIAL EMBOLIZATION OF SPLENIC ARTERY (PESA) - NOVEL METHOD FOR SPLEEN SIZE AND SPLENIC ACTIVITY REDUCTION IN PATIENTS WITH MYELOFIBROSIS UNDERGOING HSCT</b> <i>Poster Presenter: Patryk Sobieralski, PL</i>	09:50 - 09:50
P570	<b>DOES FIBROSIS PERSIST AFTER ALLOGENEIC HSCT IN PATIENTS WITH MYELOFIBROSIS, WHO ARE OTHERWISE NEGATIVE FOR DRIVER MUTATIONS, WITH FULL DONOR CHIMERISM?</b> <i>Poster Presenter: federica sora, IT</i>	09:50 - 09:50
P571	<b>MOLECULAR ANNOTATION OF EXTRAMEDULLARY AND BONE MARROW PRIMARY MYELOFIBROSIS RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Poster Presenter: Maria V. Barabanshikova, RU</i>	09:50 - 09:50
P572	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: OUR 15-YEARS EXPERIENCE</b>	09:50 - 09:50

	<i>Poster Presenter:</i> Lucia Rita Morais Bras, ES	
P574	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY MYELOFIBROSIS: ABOUT 6 CASES</b> <i>Poster Presenter:</i> Malek Benakli, DZ	09:50 - 09:50
<i>Poster Sessions</i>		
09:50 - 18:00		ePoster Area
<b>Statistics</b>		
P657	<b>HOW LONG IS LONG-ENOUGH? AN INVESTIGATION INTO THE RELATIONSHIP BETWEEN TRIAL MATURITY AND UNCERTAINTY IN COST-EFFECTIVENESS, THE CASE OF AXICABTAGENE CILOLEUCEL IN 3L DLBCL</b> <i>Poster Presenter:</i> Sachin Vadgama, GB	09:50 - 09:50
P658	<b>HEMATOPOIETIC STEM CELL TRANSPLANTATION IN BRAZIL: AN ANALYSIS OF THE BRAZILIAN PUBLIC HEALTHCARE SETTING DATABASE</b> <i>Poster Presenter:</i> Nicolle Queiroz Hazarbassanov, BR	09:50 - 09:50
<i>Poster Sessions</i>		
09:50 - 18:00		ePoster Area
<b>Patient Advocacy: Patients' Reported Outcome and Expectations</b>		
P663	<b>IMPROVED QUALITY OF LIFE WITH LISOCABTAGENE MARALEUCEL COMPARED WITH SALVAGE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA</b> <i>Poster Presenter:</i> Jeremy Abramson, US	09:50 - 09:50
P664	<b>PEGCETACOPLAN TREATMENT MEANINGFULLY IMPROVES QUALITY OF LIFE AND FATIGUE IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM TWO PHASE 3 CLINICAL TRIALS</b> <i>Poster Presenter:</i> Timothy Kubal, US	09:50 - 09:50
P665	<b>CHRONIC MYELOID LEUKEMIA ACCESS TO TYROSINE KINASE INHIBITORS AND POLYMERASE CHAIN REACTION TESTING. A PATIENT ADVOCACY PERSPECTIVE FROM CENTRAL-EASTERN EUROPE AND WEST ASIA REGION.</b> <i>Poster Presenter:</i> Celia Marín, CH	09:50 - 09:50
P666	<b>NEWSRINGFORME, A DIGITAL SOLUTION TO MEET TRANSPLANTED PATIENTS EXPECTATIONS IN TERMS OF SUPPORT</b> <i>Poster Presenter:</i> Emilie Robert, FR	09:50 - 09:50
P667	<b>COST-EFFECTIVENESS OF EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE IN THE AUSTRALIAN SETTING</b> <i>Poster Presenter:</i> Oscar A Mesa Zapata, GB	09:50 - 09:50
P669	<b>HEALTH-RELATED QUALITY OF LIFE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN</b>	09:50 - 09:50

**ADULT SICKLE CELL DISEASE PATIENTS***Poster Presenter:* Samer Ghazi, CA*Poster Sessions*

09:50 - 18:00

ePoster Area

**CAR-based Cellular Therapy - Preclinical**

P079	<b>ENHANCEMENT OF LONG-TERM FUNCTIONALITY OF CD19 CAR-T CELLS BY OVEREXPRESSION OF TCF-1</b> <i>Poster Presenter:</i> Hao Yao, DE	09:50 - 09:50
P080	<b>DISRUPTION OF CIN85 ENHANCES PROLIFERATION AND CYTOTOXICITY OF CD19-SPECIFIC CAR-T CELLS</b> <i>Poster Presenter:</i> Min Lin, DE	09:50 - 09:50
P081	<b>IMPACT OF SERUM-FREE MEDIA ON THE EXPANSION AND FUNCTIONALITY OF CD19.CAR T CELLS</b> <i>Poster Presenter:</i> Franziska Eberhardt, DE	09:50 - 09:50
P082	<b>THOMSEN-FRIEDENREICH ANTIGEN CD176 AS A NEW TARGET OF CAR-T CELLS TO CONTROL MULTIPLE CARCINOMAS</b> <i>Poster Presenter:</i> Agnes Bonifacius, DE	09:50 - 09:50
P083	<b>CELL THERAPY BASED ON NKG2D-CAR TRANSDUCED CYTOTOXIC CELLS AGAINST ACUTE MYELOID LEUKEMIA</b> <i>Poster Presenter:</i> Laura Córdoba, ES	09:50 - 09:50
P084	<b>COMPARISON OF SECOND AND THIRD GENERATION CAR33-T CELLS IN TERMS OF PROLIFERATION AND CYTOTOXICITY IN ACUTE MYELOID LEUKEMIA</b> <i>Poster Presenter:</i> Annika Lauk, DE	09:50 - 09:50
P085	<b>COMPARISON OF FACS AND PCR FOR DETECTION OF BCMA-CAR-T CELLS</b> <i>Poster Presenter:</i> Avinoam Reichman, DE	09:50 - 09:50
P086	<b>CD19-CAR-INKT CELL ACTIVITY IS ENHANCED BY PD-1 CHECKPOINT INHIBITION WHILE PREVENTING ALLOREACTIVITY</b> <i>Poster Presenter:</i> Dominik Schneidawind, DE	09:50 - 09:50
P087	<b>FUNCTIONALITY AND ENDURANCE OF GMP-STANDARD BCMA-CAR-T CELLS AT DIFFERENT TIMEPOINTS</b> <i>Poster Presenter:</i> Genqiao Jiang, DE	09:50 - 09:50

*Special Session*

09:50 - 18:00

On-demand Library

**SS3 - HLA - Beyond the simple allele counting***Chair:* Frantisek Mrázek, CZ*Chair:* Neema Mayor, GB

SS3-01	<b>Introduction</b> <i>Speaker:</i> Frantisek Mrázek, CZ	-
SS3-02	<b>HLA and mechanism of relapse</b> <i>Speaker:</i> Luca Vago, IT	-

SS3-03	<b>New concepts in the HLA barrier in transplantation</b> <i>Speaker:</i> Effie Petersdorf, US	-
SS3-04	<b>HLA-DP matching and expression as tool for donor selection refinement</b> <i>Speaker:</i> Esteban Arrieta-Bolaños, DE	-
SS3-05	<b>Conclusions</b> <i>Speaker:</i> Neema Mayor, GB	-

*Joint Session*

09:50 - 18:00

On-demand Library

**JS03 - Joint session EBMT-KSBMT: Optimal Unrelated donor selection regarding HLA and beyond***Chair:* Nicolaus Kröger, DE*Chair:* Hee-Je Kim, KR

JS03-01	<b>European perspective</b> <i>Speaker:</i> Alejandro Madrigal, GB	09:50 - 10:15
JS03-02	<b>Optimal selection of Unrelated donor and Cord blood units: Korean perspective</b> <i>Speaker:</i> Jae-ho Yoon, KR	10:15 - 10:40
JS03-03	<b>Panel Discussion</b>	10:40 - 10:55

*Nurses Group*

09:50 - 18:00

On-demand Library

**NG15 - Cellular Therapy beyond CAR T and HSCT**

NG15-01	<b>DLI - Donor Lymphocyte Infusion: How it works and indications</b> <i>Speaker:</i> Luděk Raida, CZ	-
NG15-02	<b>NK cells and dendritic cells as tool for immunotherapy</b> <i>Speaker:</i> Karolina Dostálová Weberová, CZ	-
NG15-03	<b>Treatment of viral infection with T-Cell (Adoptive immunotherapies)</b> <i>Speaker:</i> Robert Pytlík, CZ	-

*Special Session*

09:50 - 18:00

On-demand Library

**SS4 - Sickle Cell Anaemia***Chair:* Selim Corbacioglu, DE*Chair:* Françoise Bernaudin, FR

SS4-01	<b>Introduction</b> <i>Speaker:</i> Françoise Bernaudin, FR	09:50 - 09:55
SS4-02	<b>Sickle Cell Disease in adults: An orphan disease</b> <i>Speaker:</i> Erfan Nur, NL	09:55 - 10:10
SS4-03	<b>Gene correction: The next generation of gene therapy for Sickle Cell Disease</b> <i>Speaker:</i> Matthew Porteus, US	10:10 - 10:25

SS4-04	<b>Clonal evolution in Sickle Cell Disease</b> <i>Speaker:</i> Courtney Fitzhugh, US	10:25 - 10:40
SS4-05	<b>Conclusions</b> <i>Speaker:</i> Selim Corbacioglu, DE	10:40 - 10:50

*Special Session*

09:50 - 18:00

On-demand Library

**SS5 - Global Committee Session - Global perspective for cellular immune therapy**

SS5-01	<b>Introduction</b> <i>Speaker:</i> Norbert-Claude Gorin, FR	09:50 - 09:53
SS5-02	<b>Global evolution: The future of allogeneic stem cell transplantation: the next decade</b> <i>Speaker:</i> Huang Xiao-Jun, CN	09:53 - 10:08
SS5-03	<b>Global evolution of CAR T cells: Acute T lymphoblastic leukemia as a model</b> <i>Speaker:</i> He Huang, CN	10:08 - 10:23
SS5-04	<b>Remodeling clinical care for stem cell transplantation in a post pandemic world</b> <i>Speaker:</i> Shinichiro Okamoto, JP	10:23 - 10:38
SS5-05	<b>Navigating the road ahead for the implementation of novel Cell-based Therapies worldwide: Balancing safety with equitable access</b> <i>Speaker:</i> Mickey Koh, GB	10:38 - 10:54
SS5-06	<b>Global evolution: The future of fecal microbiotome transplantation</b> <i>Speaker:</i> Florent Malard, FR	10:54 - 11:09
SS5-07	<b>Conclusions</b> <i>Speaker:</i> Nicolaus Kröger, DE	11:09 - 11:11

*Joint Session*

09:50 - 18:00

On-demand Library

**JS04 - Joint session EBMT-WBMT: Maintaining safe access to stem cell transplantation during the pandemic**

JS04-01	<b>Adapting inpatient and outpatient clinical care: comparing experiences from transplant centres worldwide</b> <i>Speaker:</i> Adriana Seber, BR	09:50 - 10:10
JS04-02	<b>Challenges in donor selection and stem cell collection</b> <i>Speaker:</i> Nina Worel, AT	10:10 - 10:30
JS04-03	<b>Global perspective on achieving quality for cellular therapy</b> <i>Speaker:</i> Yossi Schwartz, US	10:30 - 10:50

*Special Session*

09:50 - 18:00

On-demand Library

**SS6 - How to get published**

SS6-01	<b>BMT: Official journal of the EBMT</b>	-
--------	--	---

	<i>Speaker:</i> Hillard Lazarus, US	
SS6-02	<b>How to get published</b> <i>Speaker:</i> Mohamad Mohty, FR	-
<i>Nurses Group</i>		
09:50 - 18:00		
On-demand Library		
<b>NG21 - JACIE</b>		
NG21-01	<b>JACIE: What's new for nurses?</b> <i>Speaker:</i> Tuula Rintala, GB	-
NG21-02	<b>Nursing considerations and perspective</b> <i>Speaker:</i> Marie Waller, GB	-
NG21-03	<b>Inspector's perspective</b> <i>Speaker:</i> Anne Emmett, GB	-
<i>On Demand Library</i>		
09:50 - 18:00		
On-demand Library		
<b>On-demand Library</b>		
<i>Quality Management</i>		
09:50 - 18:00		
On-demand Library		
<b>QM5 - Quality Management Abstracts session</b>		
QM5-01	<b>DEVELOPMENT OF A NURSING EDUCATION PATHWAY FOR THE INTRODUCTION OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR T) THERAPY.</b> <i>Oral Presenter:</i> Maria Gillespie, IE	09:50 - 10:05
QM5-02	<b>IMPLEMENTATION OF A STANDARDIZED THERAPEUTIC EDUCATION PROGRAM FOR PATIENTS WHO RECEIVE AN ALLO-HSCT</b> <i>Oral Presenter:</i> Carolina Bonilla, ES	10:05 - 10:20
QM5-03	<b>IMPACT ON DAYS TO TAKE BY CHANGING FROM FRESH TO CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS DURING THE COVID-19 PANDEMIC - A SINGLE CENTER STUDY</b> <i>Oral Presenter:</i> Ann-Mari Berthelsen, DK	10:20 - 10:35
QM5-04	<b>CAN REGULATORY-DRIVEN PROCESS INNOVATION OPEN THE DOOR FOR CELLULAR THERAPIES TO EMERGING MARKETS?</b> <i>Oral Presenter:</i> Gabriela Valentová, US	10:35 - 10:50
<i>Nurses Group</i>		
09:50 - 18:00		
On-demand Library		
<b>NG16 - Apheresis</b>		
NG16-01	<b>Mobilization in stem cell donors: the basics and points of attention</b> <i>Speaker:</i> Charlotte Mestdagh, BE	-
NG16-02	<b>Access challenges</b>	-



	<i>Speaker: Petra Vodičková, CZ</i>	
NG16-03	<b>Management of side effects</b> <i>Speaker: Jennifer Rose, GB</i>	-
<i>Nurses Group</i>		
09:50 - 18:00		On-demand Library
<b>NG22 - What nurses need to know about essential transplant medications</b>		
NG22-01	<b>Prophylactic medication</b> <i>Speaker: Sandra Schoenfeld, CH</i>	09:50 - 10:10
NG22-02	<b>Management of bacterial infection</b> <i>Speaker: Marta Canesi, IT</i>	10:10 - 10:24
NG22-03	<b>Anti-viral medication</b> <i>Speaker: Claudia Langebrake, DE</i>	10:24 - 10:45
NG22-04	<b>Immunosuppression</b> <i>Speaker: Jens Neefs, BE</i>	10:45 - 11:05
NG22-05	<b>Anti-fungal medication</b> <i>Speaker: Estela Moreno, ES</i>	11:05 - 11:25
NG22-06	<b>Steroids</b> <i>Speaker: Nick Duncan, GB</i>	11:25 - 11:45
<i>Nurses Group</i>		
09:50 - 18:00		On-demand Library
<b>NG17 - COVID</b>		
NG17-01	<b>Vaccination in transplant population</b> <i>Speaker: Per Ljungman, SE</i>	-
NG17-02	<b>Transplant care in the post pandemic era</b> <i>Speaker: Julia Ruiz Pato, ES</i>	-
NG17-03	<b>Workforce wellbeing</b> <i>Speaker: Regina De Jesus, GB</i>	-
<i>Special Session</i>		
09:50 - 18:00		On-demand Library
<b>SS2 - COVID-19</b>		
<i>Chair: Catherine Cordonnier, FR</i>		
<i>Chair: Ondrej Susol, CZ</i>		
SS2-01	<b>Introduction</b> <i>Speaker: Ondrej Susol, CZ</i>	09:50 - 09:55
SS2-02	<b>Prevention policies, measures and testing in the setting of allogeneic HCT</b> <i>Speaker: Adriana Balduzzi, IT</i>	09:55 - 10:10
SS2-03	<b>SARS-COV-2 vaccines for HCT recipients</b> <i>Speaker: Rafael de la Cámara, ES</i>	10:10 - 10:23
SS2-04	<b>Treatment of COVID19 after HCT</b>	10:23 - 10:38

	<i>Speaker:</i> Jan Styczynski, PL	
SS2-05	<b>Conclusions</b> <i>Speaker:</i> Catherine Cordonnier, FR	10:38 - 10:50
<i>How do I... ?</i>		
09:50 - 18:00		On-demand Library
<b>HDI6 - How Do I... improve SCT outcome in elderly or comorbid patients with malignant diseases? - Supported through an unrestricted educational grant by Medac</b>		
<i>Chair:</i> Alessandro Rambaldi, IT		
HDI6-1	<b>HSCT in the Eighth Decade</b> <i>Speaker:</i> Andrew Artz, US	-
HDI6-2	<b>QoL after allogeneic SCT in elderly patients</b> <i>Speaker:</i> Angela Scherwath, DE	-
HDI6-3	<b>How I select conditioning regimen in elderly patients</b> <i>Speaker:</i> Nico Gagelmann, DE	-
HDI6-4	<b>Q&amp;A</b>	-
<i>Nurses Group</i>		
09:50 - 18:00		On-demand Library
<b>NG20 - Research session 2: Keep Calm and Keep Researching - Examples of different methodologies in HSCT nursing research</b>		
NG20-01	<b>Variation in hydration use after reinfusion of autologous stem cells: a survey of EBMT centres</b> <i>Speaker:</i> Jantina Kortleve-Kadijk, NL	-
NG20-02	<b>The exploration of the dysgeusia in patients with allogeneic haematopoietic cell transplantation: a qualitative study</b> <i>Speaker:</i> Davide Bomben, IT <i>Speaker:</i> Valentina Bressan, IT	-
NG20-03	<b>Dressings for the central venous catheter to prevent infection in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis</b> <i>Speaker:</i> Renata Cristina de Campos Pereira Silveira, BR	-
<i>Joint Session</i>		
09:50 - 18:00		On-demand Library
<b>JS05 - Joint Session EBMT-HARMONY   Big Data innovations for bone marrow transplant professionals: Learn about the new 'tools' to rapidly select the most promising treatment for blood cancer patients.</b>		
<i>Chair:</i> Anna Sureda, ES		
<i>Chair:</i> Jesús María Hernández, ES		
	<b>Introducing the HARMONY Alliance and EBMT as Partner of the HARMONY Alliance</b>	09:50 - 09:50
JS05-01	<b>What value can Big Data technology add in the daily practice of bone marrow transplant professionals</b> <i>Speaker:</i> Anna Sureda, ES	09:50 - 09:56
JS05-02	<b>Introducing the HARMONY Alliance [HARMONY and HARMONY PLUS] - Mission, Activities and Achievements so</b>	09:56 - 10:02

	<b>far</b>	
	<i>Speaker:</i> Jesús María Hernández, ES	
	<b>Collaboration plans opportunities between EBMT and the HARMONY Alliance</b>	10:02 - 10:02
JS05-03	<b>Doing research within the HARMONY Alliance in AML: results, projects ahead, and core outcome sets development</b>	10:02 - 10:10
	<i>Speaker:</i> Lars Bullinger, DE	
JS05-04	<b>The HARMONY Machine Learning Researching Tool to predict the risk of relapse after 1st Remission in AML Patients treated without Allogeneic Haematopoietic Stem Cell Transplantation</b>	10:10 - 10:18
	<i>Speaker:</i> Marta Sobas, PL	
JS05-06	<b>The HARMONY unique data anonymization concept, OMOP common data model for harmonizing and using data, and how HARMONY could help the EBMT to amplify its relevance and envision</b>	10:26 - 10:34
	<i>Speaker:</i> Laura Tur, ES	
JS05-07	<b>The building of a new EBMT platform: Coping with the needs of widening and easing collaboration with other international registries/organisations</b>	10:34 - 10:42
	<i>Speaker:</i> Bas Middelkoop, NL	
JS05-09	<b>Expectancies of the pharmaceutical industry in a successful EBMT   HARMONY collaboration</b>	10:50 - 10:55
	<i>Speaker:</i> Frederico Calado, PT	
JS05-10	<b>Closing message of the HARMONY Patient Cluster in collaboration with the EBMT Patient Committee</b>	10:55 - 11:04
<i>Nurses Group</i>		
09:50 - 18:00		On-demand Library
<b>NG23 - Paediatrics Session - Challenges in paediatric HSCT nursing</b>		
NG23-01	<b>The experiences of pain in children during Haematopoietic Stem Cell Transplantation</b>	09:50 - 10:10
	<i>Speaker:</i> Karin Plummer, AU	
NG23-02	<b>Virtual reality on CVC management</b>	10:10 - 10:30
	<i>Speaker:</i> Elisa Piccinelli, IT	
NG23-03	<b>Pediatric nurses' perception of factors affecting negotiation of care in a pediatric stem cell transplant unit</b>	10:30 - 10:50
	<i>Speaker:</i> Simona Calza, IT	
<i>Nurses Group</i>		
09:50 - 18:00		On-demand Library
<b>NG18 - GVHD practical tips</b>		
NG18-01	<b>GVHD and the eye: update on diagnosis and management of ocular GVHD</b>	-
	<i>Speaker:</i> Dimitri Roels, BE	
NG18-02	<b>Mouth</b>	-

	<i>Speaker:</i> Nathaniel Triester, US	
NG18-03	<b>Skin</b> <i>Speaker:</i> Rubeta Matin, GB	-
<i>Nurses Group</i>		
09:50 - 18:00		On-demand Library
<b>NG19 - GVHD treatment and supportive care</b>		
NG19-01	<b>Physiotherapy guidelines for managing patients undergoing hematopoietic stem cell transplantation</b> <i>Speaker:</i> Jaleel Mohammed, GB	-
NG19-02	<b>Supportive care in GVHD</b> <i>Speaker:</i> Zinaida Peric, HR	-
NG19-03	<b>Eating well with GVHD</b> <i>Speaker:</i> Marek Hanza, CZ	-
<i>Trainee Day</i>		
10:00 - 11:15		South Hall 2A+B / Virtual Hall 5
<b>TD1 - Trainees' Day - EBMT for Trainees</b>		
<i>Chair:</i> Francesca Bonifazi, IT		
<i>Chair:</i> Nico Gagelmann, DE		
TD1-01	<b>The EBMT Trainee Survey</b> <i>Speaker:</i> Nico Gagelmann, DE <i>Speaker:</i> Claire Horgan, GB	10:00 - 10:25
TD1-02	<b>Choosing wisely: Fellowship in Transplantation and Cellular Therapy the Path for Success</b> <i>Speaker:</i> Silvy Lachance, CA	10:25 - 10:40
TD1-03	<b>Roundtable: Career development in SCT/cellular therapy</b> <i>Speaker:</i> Alexandra Gómez Arteaga, US <i>Speaker:</i> Valentín Ortiz-Maldonado, ES <i>Speaker:</i> Mizuki Watanabe, JP <i>Speaker:</i> Rafaella Muratori, BR	10:40 - 11:15
<i>Breaks</i>		
11:15 - 11:45		VH1
<b>Break, Virtual ePoster Viewing, Visit Virtual Exhibition</b>		
<i>Psy Day</i>		
11:45 - 13:00		Congress Hall / Virtual Hall 1
<b>Psy2 - Difficult conversations around blood and marrow transplantation</b>		
<i>Chair:</i> Martin Loučka, CZ		
Psy2-01	<b>How to share bad news with paediatric patients and their parents</b> <i>Speaker:</i> Bryan Sisk, US	11:45 - 12:05
Psy2-02	<b>Shared decision making for HSCT: Reality or wish?</b> <i>Speaker:</i> Hilda Mekelenkamp, NL	12:05 - 12:25
Psy2-03	<b>Patient preferences for allogeneic HSCT: How much benefit is worthwhile from the patient's perspective?</b>	12:25 - 12:45

	<i>Speaker:</i> Alix Stern, CH	
Psy2-04	<b>Discussion</b>	12:45 - 13:00
<i>Transplant and Search Coordinators Day</i>		Forum Hall / Virtual Hall 2
11:45 - 13:00		
<b>TSCD2 - EBMT-WMDA Transplant and Search Coordinators Day - A unique phenotype - what do I do?</b>		
<i>Chair:</i> Irina Evseeva, GB		
<i>Chair:</i> Sergio Querol, ES		
TSCD2-01	<b>Unique HLA phenotypes: Perspectives on the difficult search</b>	11:45 - 12:05
	<i>Speaker:</i> Valerie Stewart, US	
TSCD2-02	<b>Why be hesitant about cord blood options?</b>	12:05 - 12:25
	<i>Speaker:</i> Dunia Jawdat, SA	
TSCD2-03	<b>How TCs can help in ethnic minorities recruitment: Patient appeals</b>	12:25 - 12:45
	<i>Speaker:</i> Sabine Hildebrand, DE	
TSCD2-04	<b>QA</b>	12:45 - 13:00
<i>Pharmacists Day</i>		Panorama / Virtual Hall 3
11:45 - 13:00		
<b>Pharm2 - Panel discussion: Antiinfective prophylaxis</b>		
<i>Chair:</i> Estela Moreno, ES		
<i>Chair:</i> Agnès Bonnin, FR		
Pharm2-01	<b>Antimicrobial prophylaxis in HSCT</b>	11:45 - 12:05
	<i>Speaker:</i> Sofia Jorge, PT	
Pharm2-02	<b>Antifungal prophylaxis in HSCT</b>	12:05 - 12:25
	<i>Speaker:</i> Garbiñe Lizeaga, ES	
Pharm2-03	<b>Antiviral prophylaxis in HSCT</b>	12:25 - 12:45
	<i>Speaker:</i> Per Ljungman, SE	
Pharm2-04	<b>QA</b>	12:45 - 13:00
<i>Data Management</i>		South Hall 1A+B / Virtual Hall 4
11:45 - 13:00		
<b>DM2 - Data Management Session 2: CT Discussion Forum</b>		
<i>Chair:</i> Annelot van Amerongen, NL		
DM2-01	<b>Allo CAR Ts</b>	11:45 - 12:15
	<i>Speaker:</i> Jurgen Kuball, NL	
DM2-02	<b>Treating hematological malignancies with academic CARTs</b>	12:15 - 12:41
	<i>Speaker:</i> Alvaro Urbano-Ispizua, ES	
DM2-03	<b>Q&amp;A</b>	12:41 - 13:00

*Trainee Day*

11:45 - 13:00

South Hall 2A+B / Virtual Hall 5

**TD2 - Trainees' Day - Transplant for Trainees***Chair:* Zinaida Peric, HR*Chair:* Tiene Bauters, BE

TD2-01	<b>A difficult diagnosis of endothelial syndromes</b> <i>Speaker:</i> Ivan Moiseev, RU	11:45 - 12:05
TD2-02	<b>Drugs in transplant: Pharmacy group collaboration - Therapeutic Drug Monitoring</b> <i>Speaker:</i> Rick Admiraal, NL <i>Speaker:</i> Vera Domingos, PT	12:05 - 12:25
TD2-03	<b>CAR-T toxicity management for Trainees</b> <i>Speaker:</i> Claire Roddie, GB	12:25 - 12:40
TD2-04	<b>The nurse-doctor team in transplant</b> <i>Speaker:</i> Nico Gagelmann, DE <i>Speaker:</i> John Murray, GB	12:40 - 12:50
TD2-05	<b>QA</b>	12:50 - 13:00

*Patient, Family, and Donor Day*

11:45 - 13:00

North Hall / Virtual Hall 6

**PFD2 - Patient, Family and Donor Day: Living Beyond Bone Marrow Transplantation***Chair:* Andrea Linke, DE*Chair:* Sarah Hutton, GB

PFD2-01	<b>Introduction by the session Chairs</b>	11:45 - 11:50
PFD2-02	<b>After the stem cell transplant - dealing with fatigue</b> <i>Speaker:</i> Kirsten Wittke, DE	11:50 - 12:05
PFD2-03	<b>"After care plan" for transplant survivors?</b> <i>Speaker:</i> Francis Ayuk, DE	12:05 - 12:20
PFD2-04	<b>Return to work: Best practices from Finland</b> <i>Speaker:</i> Emma Andersson, FI	12:20 - 12:35
PFD2-05	<b>Life After Transplant - Adjusting to your 'New Normal'</b> <i>Speaker:</i> Philip Alexander, GB	12:35 - 12:50
PFD2-06	<b>QA</b>	12:50 - 13:00

*Breaks*

13:00 - 14:00

VH1

**Break, Virtual ePoster Viewing, Visit Virtual Exhibition***Patient, Family, and Donor Day*

13:10 - 13:55

North Hall / Virtual Hall 6

**PFD3 - Patient, Family and Donor Day: Lunch with Prof. Buchanan & Kate Washington - Special Lecture***Chair:* Guy Bouguet, FR

PFD3-01	<b>Nonfiction in Progress: LIVING WITH GRAFT-VERSUS-HOST DISEASE and the Family Caregiver Burnout</b>	13:10 - 13:45
---------	---	---------------

	<i>Speaker:</i> Brad Buchanan, US <i>Speaker:</i> Kate Washington, US	
PFD3-02	<b>Q&amp;A</b>	13:45 - 13:55
<i>Psy Day</i>		
14:00 - 15:15		Congress Hall / Virtual Hall 1
<b>Psy3 - How to support caregivers of HSCT patients?</b>		
<i>Chair:</i> Marie Chardon, US		
Psy3-01	<b>Longitudinal study of family caregivers' support needs during allo-HSCT</b>	14:00 - 14:20
	<i>Speaker:</i> Annika Kisch, SE	
Psy3-02	<b>How to prepare for the role of caregiver for HSCT patients?</b>	14:20 - 14:40
	<i>Speaker:</i> Jeanette Winterling, SE	
Psy3-03	<b>What is the role of religious coping in caregivers of paediatric HSCT?</b>	14:40 - 15:00
	<i>Speaker:</i> Marie Chardon, US	
Psy3-04	<b>Discussion</b>	15:00 - 15:15
<i>Transplant and Search Coordinators Day</i>		
14:00 - 15:15		Forum Hall / Virtual Hall 2
<b>TSCD3 - EBMT-WMDA Transplant and Search Coordinators Day - Panel discussion: Improving collaboration between Registry and Clinical Teams</b>		
<i>Chair:</i> Annette Rasche, DE		
<i>Chair:</i> Keith Wilson, GB		
TSCD3-01	<b>Panel discussion: How do you achieve efficient and good collaboration between the registry and clinical partners? Best practices: what works in different environments and what can the audience learn from them?</b>	14:00 - 15:00
	<i>Speaker:</i> Marisa Jack, US	
	<i>Speaker:</i> Jennifer McAtee, US	
	<i>Speaker:</i> Ann O'Leary, GB	
	<i>Speaker:</i> Juliette Lethier, GB	
	<i>Speaker:</i> Shari Denovan, GB	
	<i>Speaker:</i> Josefine Teeler, NL	
	<i>Speaker:</i> Marianne Lucassen, NL	
TSCD3-02	<b>QA</b>	15:00 - 15:15
<i>Pharmacists Day</i>		
14:00 - 15:15		Panorama / Virtual Hall 3
<b>Pharm3 - Best abstract awards</b>		
<i>Chair:</i> Vera Domingos, PT		
<i>Chair:</i> Vera Pires, PT		
Pharm3-01	<b>WEIGHT-BASED DOSING OF CICLOSPORIN A IN OBESE PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: SERUM LEVELS AND CLINICAL OUTCOMES</b>	14:00 - 14:20
	<i>Oral Presenter:</i> Midori Nakagaki, AU	
Pharm3-02	<b>POPULATION PHARMACOKINETICS OF BUSULFAN AND ITS METABOLITE SULFOLANE IN PATIENTS WITH</b>	14:20 - 14:40

**MYELOFIBROSIS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

*Oral Presenter:* Adrin Dadkhah, DE

Pharm3-03	<b>THE SAFETY, FEASIBILITY, AND EFFICACY OF GANCICLOVIR PROPHYLAXIS THROUGH DAY +100 IN PEDIATRIC ALLOSCT RECIPIENTS: BONE MARROW SUPPRESSION SECONDARY TO GANCICLOVIR MAY LIMIT EFFECTIVENESS</b>	14:40 - 15:00
	<i>Oral Presenter:</i> Liana Klejmont, US	
Pharm3-04	<b>Q&amp;A</b>	15:00 - 15:15

*Data Management*

14:00 - 15:15

South Hall 1A+B / Virtual Hall 4

**DM3 - Data Management Session 3**

*Chair:* Paula Busto, NL

DM3-01	<b>Update of the EBMT and JACIE project on Benchmarking of survival outcomes</b>	14:00 - 14:40
	<i>Speaker:</i> Riccardo Saccardi, IT	
	<i>Speaker:</i> John Snowden, GB	
DM3-02	<b>Q&amp;A - part I</b>	14:40 - 14:50
DM3-03	<b>Data Protection</b>	14:50 - 15:13
	<i>Speaker:</i> Iris Bargalló, ES	
DM3-04	<b>Q&amp;A - part II</b>	15:13 - 15:15

*Lab Technicians*

14:00 - 15:15

South Hall 2A+B / Virtual Hall 5

**LT1 - Lab Technicians Day - Specialised cell processing**

*Chair:* Britta Eiz-Vesper, DE

LT1-01	<b>CART manufacturing in academic setting: technical aspects and performance</b>	14:00 - 14:20
	<i>Speaker:</i> Marta Español Rego, ES	
LT1-02	<b>GMP-compliant manufacturing TEGs (abT cells Engineered to express a gdTCR)</b>	14:20 - 14:40
	<i>Speaker:</i> Trudy Straetemans, NL	
LT1-03	<b>Gene corrected autologous CD34-stem cell product manufacturing</b>	14:40 - 15:00
	<i>Speaker:</i> Karin Pike-Overzet, NL	
LT1-04	<b>QA</b>	15:00 - 15:15

*Patient, Family, and Donor Day*

14:00 - 15:15

North Hall / Virtual Hall 6

**PF4 - Patient, Family and Donor Day: New therapies - New Hopes?**

*Chair:* Ellen Kramer, NL

*Chair:* Hans Scheurer, NL

PF4-01	<b>Introduction by the session Chairs</b>	14:00 - 14:05
--------	---	---------------



PFD4-02	<b>GVHD new approaches: Current status and future directions</b> <i>Speaker:</i> Zinaida Peric, HR	14:05 - 14:25
PFD4-03	<b>Latest CAR T cell therapy developments: new indications and progress in previous indications</b> <i>Speaker:</i> Andreas Mackensen, DE	14:25 - 14:40
PFD4-04	<b>Improving the CAR-T therapy patient and carer experience</b> <i>Speaker:</i> Lorna Warwick, CA	14:40 - 14:55
PFD4-05	<b>QA</b>	14:55 - 15:15

*Breaks*

15:15 - 15:45

VH1

**Break, Virtual ePoster Viewing, Visit Virtual Exhibition***Psy Day*

15:45 - 17:00

Congress Hall / Virtual Hall 1

**Psy4 - Panel discussion: How to integrate palliative care and blood and marrow transplantation medicine?***Chair:* Martin Loučka, CZ

Psy4-01	<b>Panel discussion</b> <i>Speaker:</i> Areej Al-Jawahri, US <i>Speaker:</i> Anne Pralong, DE <i>Speaker:</i> Steffen Simon, DE <i>Speaker:</i> Mario Luppi, IT	15:45 - 17:00
---------	---	---------------

*Transplant and Search Coordinators Day*

15:45 - 17:00

Forum Hall / Virtual Hall 2

**TSCD4 - EBMT-WMDA Transplant and Search Coordinators Day - Lessons to share***Chair:* Valerie Stewart, US*Chair:* Annika Kisch, SE

TSCD4-01	<b>Reporting SEAR/SPEAR - a tool to share lessons learnt</b> <i>Speaker:</i> Thilo Mengling, DE	15:45 - 16:05
TSCD4-02	<b>Search, Match &amp; Connect - tips and tricks on your match list</b> <i>Speaker:</i> Alicia Venter, NL	16:05 - 16:25
TSCD4-03	<b>What has changed in unrelated transplants since 2020?</b> <i>Speaker:</i> Isabel Sanchez-Ortega, ES	16:25 - 16:44
TSCD4-04	<b>QA</b>	16:44 - 17:00

*Pharmacists Day*

15:45 - 17:00

Panorama / Virtual Hall 3

**Pharm4 - Quality and education***Chair:* Katerina Nezvalova-Henriksen, NO*Chair:* Rick Admiraal, NL

Pharm4-01	<b>JACIE for pharmacists: update 8th Edition</b> <i>Speaker:</i> Tiene Bauters, BE	15:45 - 16:05
Pharm4-02	<b>Results survey</b>	16:05 - 16:25

	<i>Speaker:</i> Nick Duncan, GB	
Pharm4-03	<b>Development of the UKBMT pharmacist training passport and e-learning programmes</b> <i>Speaker:</i> Nick Duncan, GB	16:25 - 16:45
Pharm4-04	<b>QA</b>	16:45 - 17:00
<i>Data Management</i>		
15:45 - 17:00		South Hall 1A+B / Virtual Hall 4
<b>DM4 - Data Management Session 4</b>		
<i>Chair:</i> Carina Gross, NL		
DM4-01	<b>Donor choice in pediatric haploidentical HSCT</b> <i>Speaker:</i> Hany Ariffin, MY	15:45 - 16:15
DM4-02	<b>Q&amp;A - part I</b>	16:15 - 16:20
DM4-03	<b>Minor sibling donors: A challenge for nurses</b> <i>Speaker:</i> Eugenia Trigos, ES	16:20 - 16:41
DM4-04	<b>Q&amp;A - part II</b>	16:41 - 16:46
DM4-05	<b>Closing and farewell</b> <i>Speaker:</i> Bas Middelkoop, NL	16:46 - 17:00
<i>Lab Technicians</i>		
15:45 - 17:00		South Hall 2A+B / Virtual Hall 5
<b>LT2 - Lab Technicians Day - Immune monitoring post cell therapy</b>		
<i>Chair:</i> Harry Dolstra, NL		
LT2-01	<b>Immune monitoring post allo-transplants</b> <i>Speaker:</i> Madalena Noviello, IT	15:45 - 16:05
LT2-02	<b>Immune monitoring of patients treated with CAR T cells</b> <i>Speaker:</i> Sophie Caillat-Zucman, FR	16:05 - 16:25
LT2-03	<b>Immune monitoring of COVID immune responses in cell therapy patients</b> <i>Speaker:</i> Marcus Buggert, SE	16:25 - 16:45
LT2-04	<b>QA</b>	16:45 - 17:00
<i>Patient, Family, and Donor Day</i>		
15:45 - 17:00		North Hall / Virtual Hall 6
<b>PFD5 - Patient, Family and Donor Day: Registries matter</b>		
<i>Chair:</i> Guy Bouguet, FR		
<i>Chair:</i> Natacha Bolaños, ES		
PFD5-01	<b>Introduction by the Chairs</b>	15:45 - 15:50
PFD5-02	<b>Do we still need a bone marrow donor registry?</b> <i>Speaker:</i> Anne-Pierre Pickaert, FR	15:50 - 16:05
PFD5-03	<b>Securing marrow registry diversity: overcoming cultural, religious and sexual orientation barriers</b> <i>Speaker:</i> Rebecca Pritchard, GB	16:05 - 16:20

PFD5-04	<b>The EBMT registry: what happens to patients medical data, challenges and opportunities</b> <i>Speaker:</i> Annelot van Amerongen, NL	16:20 - 16:35
PFD5-05	<b>QA</b>	16:35 - 16:50
PFD5-06	<b>Closing and farewell</b> <i>Speaker:</i> Bregje Verhoeven, NL <i>Speaker:</i> Mohamad Mohty, FR <i>Speaker:</i> Natacha Bolaños, ES	16:50 - 17:00
<i>Meet the Expert</i> 17:15 - 18:15		MTE
<b>MTE-05 - Meet the Expert 5</b>		
MTE-05	<b>Fertility preservation 2022: A must for all survivors below the age of 40</b> <i>Speaker:</i> Tamara Diesch, CH	17:15 - 18:15
<i>Meet the Expert</i> 17:15 - 18:15		MTE
<b>Meet the Expert Sessions</b>		
<i>Meet the Expert</i> 17:15 - 18:15		MTE
<b>MTE-04 - Meet the Expert 4</b>		
MTE-04	<b>Allo-HCT in Myelofibrosis - Current and future trends</b> <i>Speaker:</i> Donal McLornan, GB	17:15 - 18:15
<i>Meet the Expert</i> 17:15 - 18:15		MTE
<b>MTE-03 - Meet the Expert 3</b>		
MTE-03	<b>Mycobacterial infections</b> <i>Speaker:</i> Anne Bergeron, CH	17:15 - 18:15
<i>Meet the Expert</i> 17:15 - 18:15		MTE
<b>MTE-02 - Meet the Expert 2</b>		
MTE-02	<b>Therapy of fungal infections</b> <i>Speaker:</i> Dina Averbuch, IL	17:15 - 18:15
<i>Meet the Expert</i> 17:15 - 18:15		MTE
<b>MTE-01 - Meet the Expert 1</b>		
MTE-01	<b>B Cell Signaling: Pathways Toward Prevention of Chronic GVHD</b> <i>Speaker:</i> Stefanie Sarantopoulos, US	17:15 - 18:15

**Sunday, 20. March 2022***Non-Profit Symposium*

08:30 - 10:00

Congress Hall / Virtual Hall 1

**IS01 - GMMG Symposium***Chair:* Katja Weisel, DE*Chair:* Hans Salwender, DE

IS01-01	<b>Role of Cellular therapy in multiple myeloma</b> <i>Speaker:</i> Christof Scheid, DE	08:30 - 08:43
IS01-02	<b>Efficacy and future application strategies of antibody treatment in multiple myeloma</b> <i>Speaker:</i> Hartmut Goldschmidt, DE	08:43 - 08:56
IS01-03	<b>Therapeutic developments for refractory multiple myeloma</b> <i>Speaker:</i> Marc Raab, DE	08:56 - 09:09
IS01-04	<b>Treatment of high risk multiple myeloma</b> <i>Speaker:</i> Katja Weisel, DE	09:09 - 09:22
IS01-05	<b>Therapy of newly-diagnosed, non-transplant eligible multiple myeloma patients</b> <i>Speaker:</i> Maximilian Merz, DE	09:22 - 09:35
IS01-06	<b>Update in Amyloidosis</b> <i>Speaker:</i> Stefan Schönland, DE	09:35 - 09:48
IS01-07	<b>Q&amp;A</b>	09:48 - 10:00

*Non-Profit Symposium*

08:30 - 10:00

Forum Hall / Virtual Hall 2

**IS02 - Allogeneic hematopoietic stem cell transplantation for non-malignant haematological disease | SFGM-TC- Non profit Symposium***Chair:* Jean-Hugues Dalle, FR*Chair:* Charlotte Jubert, FR

IS02-01	<b>First line treatment of severe aplastic anemia in 2022</b> <i>Speaker:</i> Antonio Risitano, IT	08:30 - 09:00
IS02-02	<b>Sickle cell disease &amp; allogeneic hematopoietic stem cell transplantation</b> <i>Speaker:</i> Nathalie Dhedin, FR	09:00 - 09:30
IS02-03	<b>Thalassemia &amp; cell therapy</b> <i>Speaker:</i> Borje Andersson, US	09:30 - 10:00

*Non-Profit Symposium*

08:30 - 10:00

South Hall 1A+B / Virtual Hall 4

**IS03 - The latest advances in hematology and stem cell transplantation: an update | Sorbonne University (ATERHIT) non-profit symposium***Chair:* Mohamad Mohty, FR

IS03-01	<b>Introduction</b> <i>Speaker:</i> Mohamad Mohty, FR	08:30 - 08:31
IS03-02	<b>MRD in AML</b>	08:31 - 08:48

	<i>Speaker:</i> Arnon Nagler, IL	
IS03-03	<b>Modulation of the microbiota in HSCT</b> <i>Speaker:</i> Florent Malard, FR	08:48 - 09:04
IS03-04	<b>CAR-T cells in ALL</b> <i>Speaker:</i> Eolia Brissot, FR	09:04 - 09:26
IS03-05	<b>CAR T cells versus ASCT in DLBCL</b> <i>Speaker:</i> Remy Duléry, FR	09:26 - 09:41
IS03-06	<b>CAR T cells in multiple myeloma</b> <i>Speaker:</i> Mohamad Mohty, FR	09:41 - 10:00

*Nurses Group*

08:30 - 10:00

North Hall / Virtual Hall 6

**NG01 - Nurses Education Day 1: Supporting a patient through transplant***Chair:* Klara Kabatová-Maxová, CZ*Chair:* Kathy Goris, BE

NG01-01	<b>Pre-transplant information session: what to include</b> <i>Speaker:</i> Emma Kane, GB	08:30 - 08:55
NG01-02	<b>Preparing our paediatric patient with a non-malignant disease</b> <i>Speaker:</i> Marina Ben-Izhak, IL	08:55 - 09:20
NG01-03	<b>Preparing our adult patient with a non-malignant and chemotherapy naive disease</b> <i>Speaker:</i> Tessa Kerre, BE	09:20 - 09:45
NG01-04	<b>QA</b>	09:45 - 10:00

*Poster Sessions*

08:30 - 19:15

ePoster Area

**ePoster Viewing***On Demand Library*

08:30 - 19:15

On-demand Library

**On-demand Library***Breaks*

10:00 - 10:30

North Hall / Virtual Hall 6

**Break, ePoster Viewing, Visit Exhibition***Industry Symposium*

10:30 - 12:00

Congress Hall / Virtual Hall 1

**IS04 - The evolving CAR T treatment paradigm in lymphoma - BMS Industry Symposium***Chair:* Anna Sureda, ES

IS04-01	<b>Welcome and Introduction</b> <i>Speaker:</i> Anna Sureda, ES	10:30 - 10:35
IS04-02	<b>CAR T cell therapy for second line LBCL and earlier: future perspectives</b>	10:35 - 10:55

	<i>Speaker:</i> Stephan Mielke, SE	
IS04-03	<b>CAR T cell therapy implementation in LBCL: third line and later</b> <i>Speaker:</i> Anna Sureda, ES	10:55 - 11:15
IS04-04	<b>How to optimize CAR T cell therapy in LBCL</b> <i>Speaker:</i> Christian Chabannon, FR	11:15 - 11:35
IS04-05	<b>Q&amp;A and discussion. Closing remarks.</b>	11:35 - 12:00

*Industry Symposium*

10:30 - 12:00

Forum Hall / Virtual Hall 2

**IS05 - What's new in GVHD in 2022: tackling the unmet needs from prophylaxis to treatment - Sanofi Industry Symposium***Chair:* Mohamad Mohty, FR*Chair:* Didier Blaise, FR

IS05-01	<b>ATG versus post-cyclophosphamide for GVHD prophylaxis</b> <i>Speaker:</i> Mohamad Mohty, FR	10:30 - 10:51
IS05-02	<b>Update on the pathophysiology of chronic GVHD</b> <i>Speaker:</i> Ernst Holler, DE	10:51 - 11:11
IS05-03	<b>Frontline management of chronic GVHD</b> <i>Speaker:</i> Florent Malard, FR	11:11 - 11:25
IS05-04	<b>Management of refractory chronic GVHD</b> <i>Speaker:</i> Aleksandr Lazaryan, US	11:25 - 11:45
IS05-05	<b>Role of physical exercise in chronic GVHD management</b> <i>Speaker:</i> Bipin N Savani, US	11:45 - 11:56
IS05-06	<b>Q&amp;A</b>	11:56 - 12:00

*Industry Symposium*

10:30 - 12:00

Panorama / Virtual Hall 3

**IS07 - Role of C3 inhibition in PNH - Sobi Industry Symposium***Chair:* Jens Panse, DE

IS07-01	<b>Introduction</b> <i>Speaker:</i> Jens Panse, DE	10:30 - 10:40
IS07-02	<b>Roundtable discussion</b> <i>Speaker:</i> Jens Panse, DE <i>Speaker:</i> Régis Peffault de Latour, FR <i>Speaker:</i> Richard Kelly, GB <i>Speaker:</i> Antonio Risitano, IT	10:40 - 10:40
IS07-02-01	<b>Charting the waters of PNH</b>	10:40 - 11:00
IS07-02-02	<b>Where the dam is breaking</b>	11:00 - 11:20
IS07-02-03	<b>Benefits of stemming the tide upstream</b>	11:20 - 11:40
IS07-03	<b>Live Q&amp;A with the audience</b>	11:40 - 12:00

*Industry Symposium*

10:30 - 12:00

South Hall 1A+B / Virtual Hall 4

**IS06 - Looking deep into complexities of Multiple Myeloma (MM): How to decide the treatment and measure the outcomes? - Pfizer Industry Symposium***Chair:* Roman Hájek, CZ

IS06-01	<b>Introduction</b> <i>Speaker:</i> Roman Hájek, CZ	10:30 - 10:35
IS06-02	<b>Current MM treatment landscape</b> <i>Speaker:</i> Hartmut Goldschmidt, DE	10:35 - 10:58
IS06-03	<b>Role of transplantation in MM treatment</b> <i>Speaker:</i> Sergio Giralt, US	10:58 - 11:20
IS06-04	<b>Emerging therapeutic landscape with novel targets</b> <i>Speaker:</i> Elena Zamagni, IT	11:20 - 11:40
IS06-05	<b>Q&amp;A and closing remarks</b>	11:40 - 12:00

*Industry Symposium*

10:30 - 12:00

South Hall 2A+B / Virtual Hall 5

**IS08 - Understanding the Role of the Lectin Pathway of Complement in HSCT-TMA - Omeros Industry Symposium***Chair:* Alessandro Rambaldi, IT

IS08-01	<b>Welcome and Introductions</b> <i>Speaker:</i> Alessandro Rambaldi, IT	10:30 - 10:35
IS08-02	<b>Elucidating the Lectin Pathway's Role in Endothelial Injury Syndromes and HSCT-TMA</b> <i>Speaker:</i> Eleni Gavriilaki, GR	10:35 - 11:00
IS08-03	<b>Identifying the HSCT-TMA Patient: Current Challenges and Available Resources</b> <i>Speaker:</i> Olaf Penack, DE	11:00 - 11:25
IS08-04	<b>Applying Real World and Clinical Trial Evidence in Support of Lectin Pathway Inhibition for the Treatment of HSCT-TMA</b> <i>Speaker:</i> Alessandro Rambaldi, IT	11:25 - 11:50
IS08-05	<b>Q&amp;A</b>	11:50 - 12:00

*Nurses Group*

10:30 - 12:00

North Hall / Virtual Hall 6

**NG02 - Nurses Education Day 2: Supporting a patient through transplant***Chair:* Klara Kabatová-Maxová, CZ*Chair:* Kathy Goris, BE

NG02-01	<b>Donor selection</b> <i>Speaker:</i> Katerina Steinerová, CZ	10:30 - 10:55
NG02-02	<b>Supportive care of the unrelated donor</b> <i>Speaker:</i> Rachel Miller, GB	10:55 - 11:20
NG02-03	<b>Supportive care of the minor donor</b> <i>Speaker:</i> Daphna Hutt, IL	11:20 - 11:45

NG02-04 **QA** 11:45 - 12:00

*Breaks*

12:00 - 12:30

North Hall / Virtual Hall 6

**Break, ePoster Viewing, Visit Exhibition**

*Industry Symposium*

12:30 - 14:00

Congress Hall / Virtual Hall 1

**IS09 - 5 years and counting: Building survival in lymphomas with CAR T | Gilead-Kite**

**Industry Symposium**

*Chair: Marek Trněný, CZ*

IS09-01 **Introduction and CAR T overview** 12:30 - 12:35  
*Speaker: Marek Trněný, CZ*

IS09-02 **Survival in R/R DLBCL with CAR T: How long can we go?** 12:35 - 13:10  
*Speaker: Jason Westin, US*  
*Speaker: Andy Davies, GB*

IS09-04 **Optimising for survival with CAR T in R/R MCL** 13:10 - 13:40  
*Speaker: Tom van Meerten, NL*  
*Speaker: Ana Marín Niebla, ES*

IS09-05 **Live audience Q&A** 13:40 - 13:58

IS09-06 **Summary and close** 13:58 - 14:00

*Industry Symposium*

12:30 - 14:00

Forum Hall / Virtual Hall 2

**IS10 - Unmet needs in GvHD management: a new future within reach - Novartis Industry Symposium**

*Chair: Nicolaus Kröger, DE*

IS10-01 **Welcome and introduction** 12:30 - 12:33

IS10-02 **Challenges in managing acute GvHD** 12:33 - 12:43  
*Speaker: Nicolaus Kröger, DE*

IS10-03 **Challenges in managing chronic GvHD** 12:43 - 12:53  
*Speaker: Tsila Zuckerman, IL*

IS10-04 **Panel discussion and live Q&A: challenges in managing GvHD** 12:53 - 13:03  
*Speaker: Nicolaus Kröger, DE*

IS10-05 **First-line treatment in GvHD** 13:03 - 13:13  
*Speaker: Robert Zeiser, DE*

IS10-06 **Panel discussion and live Q&A: unmet needs in GvHD** 13:13 - 13:28  
*Speaker: Nicolaus Kröger, DE*

IS10-07 **Interpreting GvHD trials: design and outcomes** 13:28 - 13:43  
*Speaker: Mohamad Mohty, FR*

IS10-07 **Panel discussion and live Q&A: a new future within reach?** 13:43 - 13:58  
*Speaker: Mohamad Mohty, FR*



IS10-08	<b>Concluding remarks</b>	13:58 - 14:00
---------	---------------------------	---------------

*Industry Symposium*

12:30 - 14:00

Panorama / Virtual Hall 3

**IS12 - Diagnosis and outcomes of HSCT-TMA: practical lessons from the experts - Alexion****Industry Symposium**

Chair: Donald Bunjes, DE

IS12-01	<b>Introduction</b>	12:30 - 12:43
---------	---------------------	---------------

*Speaker:* Donald Bunjes, DE

IS12-02	<b>Interactive discussion of risk factors and signs of HSCT-TMA:</b>	12:43 - 12:43
---------	--	---------------

IS12-02-A	<b>Insights from the paediatric field</b>	12:43 - 13:18
-----------	---	---------------

*Speaker:* Sonata Jodele, US

IS12-02-B	<b>Similarities and differences in adults</b>	13:18 - 13:28
-----------	---	---------------

*Speaker:* Donald Bunjes, DE

IS12-03	<b>Q&amp;A</b>	13:28 - 14:00
---------	----------------	---------------

*Industry Symposium*

12:30 - 14:00

South Hall 1A+B / Virtual Hall 4

**IS11 - Optimizing New Options for the Treatment of Cytomegalovirus in HSCT Recipients - Takeda/Medscape Industry Symposium**

Chair: Johan Maertens, BE

IS11-01	<b>Welcome and Introductions</b>	12:30 - 12:35
---------	----------------------------------	---------------

*Speaker:* Johan Maertens, BE

IS11-02	<b>The Landscape of CMV in HSCT Including Those With R/R CMV</b>	12:35 - 13:00
---------	--	---------------

*Speaker:* Johan Maertens, BE*Speaker:* Rafael Duarte, ES

IS11-03	<b>New Therapies Data Updates</b>	13:00 - 13:15
---------	-----------------------------------	---------------

*Speaker:* Roy F. Chemaly, US

IS11-04	<b>Patient Cases 1 and 2: Who Is the Refractory/Resistant Patient?</b>	13:15 - 13:35
---------	--	---------------

*Speaker:* Genovefa Papanicolaou, US

IS11-05	<b>Panel Discussion: Future of New Therapies and Q&amp;A Session</b>	13:35 - 13:58
---------	--	---------------

IS11-06	<b>Concluding Remarks</b>	13:58 - 14:00
---------	---------------------------	---------------

*Speaker:* Johan Maertens, BE*Industry Symposium*

12:30 - 14:00

South Hall 2A+B / Virtual Hall 5

**IS13 - Cell therapy: revolutionary ideas improving today's practices - Miltenyi Biotec Industry Symposium**

Chair: Andrew Gennery, GB

IS13-01	<b>Welcome &amp; introduction</b>	12:30 - 12:37
---------	-----------------------------------	---------------

*Speaker:* Andrew Gennery, GB

IS13-02	<b>CD45RA+ TN-depletion of PBSC grafts for prevention of chronic GVHD</b> <i>Speaker:</i> Marie Bleakley, US	12:37 - 12:55
IS13-03	<b>TCR<math>\alpha\beta</math>/CD19 T- and B-cell Depleted HSCT in Primary Immunodeficiencies</b> <i>Speaker:</i> Andrew Gennery, GB	12:55 - 13:09
IS13-04	<b>Feasibility and efficacy of CD45RA depleted donor lymphocytes infusion after haploidentical transplantation with post-transplantation cyclophosphamide</b> <i>Speaker:</i> Luca Castagna, IT	13:09 - 13:27
IS13-05	<b>The many faces of CAR-T clinical application in childhood leukemia</b> <i>Speaker:</i> Michael Maschan, RU	13:27 - 13:45
IS13-06	<b>Questions &amp; Answers</b>	13:45 - 14:00

*Nurses Group*

12:30 - 14:00

North Hall / Virtual Hall 6

**NG03 - Nurses Education Day 3: Supporting a patient through transplant***Chair:* Klara Kabatová-Maxová, CZ*Chair:* Kathy Goris, BE

NG03-01	<b>Discharge: What you patient needs to know</b> <i>Speaker:</i> Marijke Quaghebeur, BE	12:30 - 12:50
NG03-02	<b>Psychological care of patients post-transplant (coping)</b> <i>Speaker:</i> Hannah De Messemaeker, BE	12:50 - 13:10
NG03-03	<b>Patient testimony on discharge</b> <i>Speaker:</i> Anne-Pierre Pickaert, FR	13:10 - 13:30
NG03-04	<b>Patient empowerment through recovery and beyond</b> <i>Speaker:</i> Lynn Leppla, CH	13:30 - 13:50
NG03-05	<b>QA</b>	13:50 - 14:00

*Breaks*

14:00 - 14:30

North Hall / Virtual Hall 6

**Break, ePoster Viewing, Visit Exhibition***Industry Symposium*

14:30 - 16:00

Congress Hall / Virtual Hall 1

**IS14 - Recent advancements in immune therapies for multiple myeloma - BMS Industry Symposium***Chair:* Michel Delforge, BE

IS14-01	<b>Welcome and introduction</b> <i>Speaker:</i> Michel Delforge, BE	14:30 - 14:35
IS14-02	<b>Redirecting the immune system: the era of CAR T cell therapies</b> <i>Speaker:</i> Michel Delforge, BE	14:35 - 14:55
IS14-03	<b>Emerging targets and treatment modalities in RRMM</b>	14:55 - 15:10

	<i>Speaker:</i> Paula Rodríguez Otero, ES	
IS14-04	<b>Advances in cereblon E3 ligase modulation as a therapeutic mediator for protein degradation</b> <i>Speaker:</i> Niels van de Donk, NL	15:10 - 15:30
IS14-05	<b>Emerging clinical data of CELMoD® agents</b> <i>Speaker:</i> Sagar Lonial, US	15:30 - 15:45
IS14-06	<b>Discussion and Q&amp;A</b>	15:45 - 16:00

*Industry Symposium*

14:30 - 16:00

Forum Hall / Virtual Hall 2

**IS15 - Optimizing antifungal treatment options in neutropenic haematology patients | Gilead Industry Symposium***Chair:* Johan Maertens, BE

IS15-01	<b>Welcome, introduction and overview of agenda</b> <i>Speaker:</i> Johan Maertens, BE	14:30 - 14:35
IS15-02	<b>Changing epidemiology of breakthrough fungal infections</b> <i>Speaker:</i> Livio Pagano, IT	14:35 - 15:00
IS15-03	<b>Important factors to consider when initiating the early treatment of IFIs</b> <i>Speaker:</i> Rafael Duarte, ES	15:00 - 15:25
IS15-04	<b>Managing the risk of drug-drug interactions between new haematology treatments and antifungal agents</b> <i>Speaker:</i> Johan Maertens, BE	15:25 - 15:50
IS15-05	<b>Conclusions and Q&amp;A</b>	15:50 - 16:00

*Industry Symposium*

14:30 - 16:00

South Hall 1A+B / Virtual Hall 4

**IS29 - mRNA technology: addressing a spectrum of unmet needs in vulnerable populations - Moderna Industry Symposium***Chair:* Rafael de la Cámara, ES

IS29-01	<b>Welcome and Introduction</b> <i>Speaker:</i> Rafael de la Cámara, ES	14:30 - 14:40
IS29-02	<b>mRNA Science in Response to a Pandemic</b> <i>Speaker:</i> Andrea Carfi, US	14:40 - 15:00
IS29-03	<b>Immune Responses to COVID-19 mRNA Vaccines in Immunocompromised Populations</b> <i>Speaker:</i> Paul Moss, GB	15:00 - 15:20
IS29-04	<b>Challenging Infections in Immunocompromised Patients - Preventative Approaches</b> <i>Speaker:</i> Per Ljungman, SE	15:20 - 15:40
IS29-05	<b>Panel Discussion and Live Q&amp;A</b>	15:40 - 16:00

*Industry Symposium*

14:30 - 16:00

South Hall 2A+B / Virtual Hall 5

**IS17 - Advances in the management of Hodgkin lymphoma and implications from emerging RWE in consolidation therapy following ASCT | Takeda Industry Symposium***Chair:* Martin Hutchings, DK

IS17-01	<b>Welcome and introductions</b> <i>Speaker:</i> Martin Hutchings, DK	14:30 - 14:35
IS17-02	<b>Perspectives in newly diagnosed advanced Hodgkin lymphoma</b> <i>Speaker:</i> Ramón García-Sanz, ES	14:35 - 15:00
IS17-03	<b>Post-ASCT consolidation strategies in Hodgkin lymphoma</b> <i>Speaker:</i> Martin Hutchings, DK	15:00 - 15:10
IS17-04	<b>Real-world evidence supporting post-ASCT consolidation in Hodgkin lymphoma</b> <i>Speaker:</i> Stefano Luminari, IT	15:10 - 15:30
IS17-05	<b>Panel discussion and Q&amp;A</b>	15:30 - 15:55
IS17-06	<b>Summary and close</b> <i>Speaker:</i> Martin Hutchings, DK	15:55 - 16:00

*Nurses Group*

14:30 - 16:00

North Hall / Virtual Hall 6

**NG04 - Nurses Education Day 4: Supporting a patient through transplant***Chair:* Klara Kabatová-Maxová, CZ*Chair:* Kathy Goris, BE

NG04-01	<b>Isolation syndrome</b> <i>Speaker:</i> Valentina Biagioli, IT	14:30 - 14:50
NG04-02	<b>Drivers and barriers to ambulatory transplantation</b> <i>Speaker:</i> Sabine Valenta, CH	14:50 - 15:10
NG04-03	<b>Patients in ambulatory transplant</b> <i>Speaker:</i> Cristina Gallego, ES	15:10 - 15:30
NG04-04	<b>Debate: Pros and cons to ambulatory transplant care</b> <i>Speaker:</i> John Murray, GB	15:30 - 16:00

*Breaks*

16:00 - 16:30

North Hall / Virtual Hall 6

**Break, ePoster Viewing, Visit Exhibition***Industry Symposium*

16:30 - 18:00

Congress Hall / Virtual Hall 1

**IS18 - Will transplant continue to be the SoC in R/R DLBCL? | Gilead-Kite Industry Symposium***Chair:* John Gribben, GB

IS18-01	<b>Introduction</b> <i>Speaker:</i> John Gribben, GB	16:30 - 16:35
IS18-02	<b>Summary of SoC treatment paradigm in R/R DLBCL with emphasis on transplant eligible (TE) vs. transplant</b>	16:35 - 16:45

	<b>ineligible (TI) patients</b>	
	<i>Speaker:</i> John Gribben, GB	
IS18-03	<b>Will the SoC change in R/R DLBCL?</b>	16:45 - 17:05
IS18-03-01	<b>No, the SOC will not change in 2L</b>	17:05 - 17:05
	<i>Speaker:</i> Keith Wilson, GB	
IS18-03-02	<b>Yes, the SOC will evolve in the upcoming years</b>	17:05 - 17:05
	<i>Speaker:</i> Jason Westin, US	
IS18-04	<b>Live audience Q&amp;A</b>	17:05 - 17:20
IS18-05	<b>Is transplant eligibility the same as CAR T eligibility?</b>	17:20 - 17:40
IS18-04-02	<b>Yes</b>	17:40 - 17:40
	<i>Speaker:</i> Nicolaus Kröger, DE	
IS18-04-01	<b>No</b>	17:40 - 17:40
	<i>Speaker:</i> Roberta Di Blasi, IT	
IS18-06	<b>Live audience Q&amp;A</b>	17:40 - 17:55
IS18-07	<b>Summary and close - TE vs TI in the future?</b>	17:55 - 18:00
	<i>Speaker:</i> John Gribben, GB	

*Industry Symposium*

16:30 - 18:00

Forum Hall / Virtual Hall 2

**IS19 - Making the most of ASCT in patients with newly-diagnosed multiple myeloma - Janssen Industry Symposium***Chair:* Mohamad Mohty, FR

IS19-01	<b>Welcome and introduction</b>	16:30 - 16:35
IS19-02	<b>Current treatment guidelines for managing patients with transplant eligible MM</b>	16:35 - 16:55
	<i>Speaker:</i> Elena Zamagni, IT	
IS19-03	<b>Optimizing induction, consolidation, and maintenance therapies for patients with MM receiving an ASCT?</b>	16:55 - 17:15
	<i>Speaker:</i> Mohamad Mohty, FR	
IS19-04	<b>Front-line treatment of patients with high-risk MM and the role of minimal residual disease</b>	17:15 - 17:35
	<i>Speaker:</i> Martin Kaiser, GB	
IS19-05	<b>Panel discussion with Q&amp;A</b>	17:35 - 17:55
IS19-06	<b>Closing remarks</b>	17:55 - 18:00

*Industry Symposium*

16:30 - 18:00

Panorama / Virtual Hall 3

**IS21 - CMV in HSCT: Breaking down barriers to improve patient outcomes - MSD Symposium***Chair:* Per Ljungman, SE*Chair:* Rafael de la Cámara, ES

IS21-01	<b>Welcome and introduction</b>	16:30 - 16:35
---------	---------------------------------	---------------

IS21-02	<b>Relevance of CMV in the post-transplant setting: Evolving new evidence</b> <i>Speaker:</i> Genovefa Papanicolaou, US	16:35 - 16:55
IS21-03	<b>Progress in CMV management: Real life experiences</b> <i>Speaker:</i> Matthias Stelljes, DE	16:55 - 17:15
IS21-04	<b>CMV in HSCT: What does the future hold?</b> <i>Speaker:</i> Dionysios Neofytos, CH	17:15 - 17:35
IS21-05	<b>Panel Q&amp;A</b>	17:35 - 17:55
IS21-06	<b>Closing remarks</b>	17:55 - 18:00

*Industry Symposium*

16:30 - 18:00

South Hall 1A+B / Virtual Hall 4

**IS20 - Real-world data, pharmacoeconomics and treatment combination in GvHD: A focus on ECP | Therakos Industry Symposium***Chair:* Hildegard Greinix, AT

IS20-01	<b>Introduction</b> <i>Speaker:</i> Hildegard Greinix, AT	16:30 - 16:35
IS20-02	<b>Real-world treatment patterns and outcomes in cGvHD patients treated with ECP - a retrospective study in Sweden</b> <i>Speaker:</i> Gösta Berlin, SE	16:35 - 17:00
IS20-03	<b>ECP vs other therapies for steroid-refractory cGvHD in adult patients: pharmacoeconomic assessment from a Spanish hospital perspective</b> <i>Speaker:</i> Rebeca Rodríguez Veiga, ES	17:00 - 17:25
IS20-04	<b>Clinical experiences and potential mechanisms of ECP alone or in combinational approaches in GvHD</b> <i>Speaker:</i> Robert Zeiser, DE	17:25 - 17:50
IS20-05	<b>Q&amp;A</b>	17:50 - 18:00

*Industry Symposium*

16:30 - 18:00

South Hall 2A+B / Virtual Hall 5

**IS22 - The past, present and future of haemoglobinopathy care - Vertex Industry Symposium***Chair:* Anna Sureda, ES

IS22-1	<b>Opening video</b>	16:30 - 16:31
IS22-2	<b>Welcome and introduction</b> <i>Speaker:</i> Anna Sureda, ES	16:31 - 16:39
IS22-3	<b>Stem cell transplantation in an era of innovation: current limitations and future potential opportunities in transfusion-dependent <math>\beta</math>-thalassemia</b> <i>Speaker:</i> Josu de la Fuente, GB	16:39 - 16:51
IS22-4	<b>Scientific exchange with Q&amp;A - I</b> <i>Speaker:</i> Josu de la Fuente, GB	16:51 - 16:58
IS22-5	<b>Stem cell transplantation in an era of innovation: current limitations and future potential opportunities in sickle cell</b>	16:58 - 17:10

	<b>disease</b>	
	<i>Speaker:</i> Françoise Bernaudin, FR	
IS22-6	<b>Scientific exchange with Q&amp;A - II</b>	17:10 - 17:17
	<i>Speaker:</i> Françoise Bernaudin, FR	
IS22-7	<b>Patient care: the journey ahead</b>	17:17 - 17:29
	<i>Speaker:</i> Maria Domenica Cappellini, IT	
IS22-8	<b>Scientific exchange with Q&amp;A - III</b>	17:29 - 17:36
	<i>Speaker:</i> Maria Domenica Cappellini, IT	
IS22-9	<b>Scientific exchange with panel discussion and Q&amp;A</b>	17:36 - 17:58
IS22-10	<b>Chair's close of symposium</b>	17:58 - 18:00
<i>General</i>		
18:15 - 19:30		Congress Hall / Virtual Hall 1
<b>GS1 - Opening Ceremony</b>		
<i>Chair:</i> Nicolaus Kröger, DE		
<i>Chair:</i> Petr Sedláček, CZ		
<i>Chair:</i> Pavel Jindra, CZ		
GS1-01	<b>Welcome</b>	18:15 - 18:20
	<i>Speaker:</i> Nicolaus Kröger, DE	
GS1-02	<b>Welcome and introduction to the conference</b>	18:20 - 18:24
	<i>Speaker:</i> Pavel Jindra, CZ	
GS1-03	<b>Welcome from the Nurses Group</b>	18:24 - 18:28
	<i>Speaker:</i> Michelle Kenyon, GB	
GS1-04	<b>Welcome note from the Patient Advocacy Committee</b>	18:28 - 18:32
	<i>Speaker:</i> Bregje Verhoeven, NL	
GS1-05	<b>Honorary Member Awards and Clinical Achievement Award 2022</b>	18:32 - 18:57
	<i>Speaker:</i> Judith Marsh, GB	
	<i>Speaker:</i> Fred Falkenburg, NL	
	<i>Speaker:</i> Noel Milpied, FR	
	<i>Speaker:</i> Richard Burt, US	
GS1-06	<b>Special THANK YOU from the EBMT &amp; Introduction of next EBMT President</b>	18:57 - 19:02
	<i>Speaker:</i> Nicolaus Kröger, DE	
GS1-07	<b>Introduction of the Keynote speaker</b>	19:02 - 19:05
	<i>Speaker:</i> Petr Sedláček, CZ	
GS1-08	<b>Keynote Lecture: allo-HCT in Paediatric Acute Lymphoblastic Leukaemia, state of art</b>	19:05 - 19:30
	<i>Speaker:</i> Christina Peters, AT	

**Monday, 21. March 2022***Meetings*

07:00 - 08:50

Congress Hall / Virtual Hall 1

**Infectious Diseases Working Party Business Meeting***Chair:* Rafael de la Cámara, ES*Meetings*

07:00 - 08:50

South Hall 1A+B / Virtual Hall 4

**Chronic Malignancies Working Party Business Meeting***Chair:* Ibrahim Yakoub-Agha, FR*Meetings*

07:00 - 08:50

South Hall 2A+B / Virtual Hall 5

**Autoimmune Diseases Working Party Business Meeting***Chair:* Raffaella Greco, IT*Poster Sessions*

07:00 - 18:45

ePoster Area

**ePoster Viewing***On Demand Library*

07:00 - 18:45

On-demand Library

**On-demand Library***Working Party Session*

09:00 - 10:15

Congress Hall / Virtual Hall 1

**IDWP - Infectious Diseases Working Party session***Chair:* Rafael de la Cámara, ES*Chair:* Dina Averbuch, IL

IDWP-01	<b>The most important articles on infections in HSCT recipients published during the last 2 years</b> <i>Speaker:</i> Malgorzata Mikulska, IT	09:00 - 09:20
IDWP-02	<b>What is new in the field of antifungals?</b> <i>Speaker:</i> Johan Maertens, BE	09:20 - 09:40
IDWP-03	<b>Is antibacterial/antifungal/antiviral prophylaxis needed in CART therapy?</b> <i>Speaker:</i> Lidia Gil, PL	09:40 - 10:00
IDWP-04	<b>Q&amp;A</b>	10:00 - 10:15

*Cell Therapy*

09:00 - 10:15

Forum Hall / Virtual Hall 2

**CTD1 - Cell Therapy Day 1: Immune monitoring post therapeutic intervention***Chair:* Nina Worel, AT*Chair:* Luca Vago, IT

CTD1-01	<b>T-cell reconstitution and clinical outcome after allogeneic hematopoietic cell transplantation</b> <i>Speaker:</i> Marina Cavazzana, FR	09:00 - 09:20
---------	---	---------------



CTD1-02	<b>Monitoring of CMV infection and disease after allogeneic hematopoietic cell transplantation</b> <i>Speaker:</i> Raffaella Greco, IT	09:20 - 09:40
CTD1-03	<b>Impact of conditioning regimens on immune reconstitution</b> <i>Speaker:</i> Moniek de Witte, NL	09:40 - 10:00
CTD1-04	<b>Q&amp;A</b>	10:00 - 10:15

*Nurses Group*

09:00 - 10:15

Panorama / Virtual Hall 3

**NG05 - Nurses Programme Opening Session***Chair:* Michelle Kenyon, GB

NG05-01	<b>Welcome and overview</b> <i>Speaker:</i> Michelle Kenyon, GB	09:00 - 09:05
NG05-02	<b>Welcome to Prague</b> <i>Speaker:</i> Klara Kabatová-Maxová, CZ	09:05 - 09:10
NG05-03	<b>Presentation of the NG Honorary Members 2022 and the 14th Distinguished Merit Award</b> <i>Speaker:</i> Michelle Kenyon, GB	09:10 - 09:15
NG05-04	<b>ICN Keynote lecture - Nurses leading and responding to the global health agenda</b> <i>Speaker:</i> Howard Catton, CH	09:15 - 09:45
NG05-05	<b>Worldwide evolution of CAR T: Landing in Czech Republic</b> <i>Speaker:</i> Jan Vydra, CZ	09:45 - 10:15

*How do I... ?*

09:00 - 10:15

South Hall 1A+B / Virtual Hall 4

**HDI1 - How Do I... treat chronic GVHD? - Supported through an unrestricted educational grant by Sanofi***Chair:* Nicolaus Kröger, DE

HDI1-01	<b>How do I prevent cGVHD?</b> <i>Speaker:</i> José Antonio Pérez Simón, ES	09:00 - 09:20
HDI1-02	<b>How I use ECP in the treatment of cGVHD</b> <i>Speaker:</i> Corey Cutler, US	09:20 - 09:40
HDI1-03	<b>How do I select drugs/treatment for second line therapy in cGVHD?</b> <i>Speaker:</i> Daniel Wolff, DE	09:40 - 10:00
HDI1-04	<b>QA</b>	10:00 - 10:15

*Patient Advocacy Sessions*

09:00 - 10:15

South Hall 2A+B / Virtual Hall 5

**PA1 - Patient Advocacy: From gaps to bridges - The future of patient advocacy in Central and Eastern Europe***Chair:* Natacha Bolaños, ES*Chair:* Sarah Hutton, GB

PA1-01	<b>Introduction by the Chairs</b>	09:00 - 09:05
--------	-----------------------------------	---------------

PA1-02	<b>Facilitators and Barriers to Patient Advocacy</b> <i>Speaker:</i> Tamas Bereczky, DE	09:05 - 09:15
PA1-03	<b>CZ patient Advocacy Experience - What is needed?</b> <i>Speaker:</i> Jana Pelouchova, CZ	09:15 - 09:25
PA1-04	<b>Special round table discussion: Ukrainian crisis; coordination of international support for lymphoma and BMT patients</b> <i>Speaker:</i> Natacha Bolaños, ES <i>Speaker:</i> Irina Kriachok, UA <i>Speaker:</i> Anita Kienesberger, AT <i>Speaker:</i> Tamas Bereczky, DE <i>Speaker:</i> Jana Pelouchova, CZ	09:25 - 10:15

*Oral Session*  
09:00 - 10:15

North Hall / Virtual Hall 6

**OS01 - Oral session 1: Lymphoma, CLL, and multiple myeloma**

*Chair:* Tomáš Jelínek, CZ

*Chair:* Charalampia Kyriakou, GB

OS01-01	<b>CORD BLOOD TRANSPLANTATION FOR ADULT LYMPHOID NEOPLASMS IN EUROPE AND JAPAN: A COLLABORATIVE STUDY BETWEEN EUROCORD/LWP-EBMT AND JSTCT/JDCHCT</b> <i>Oral Presenter:</i> Mizuki Watanabe, JP	09:00 - 09:09
OS01-02	<b>QUANTIFICATION OF MRD AT 10<sup>-5</sup> BY FLOW IN THE STEM CELL GRAFT CORRELATES WITH MARROW MRD AND PFS FOLLOWING AHCT AMONG PATIENTS DIAGNOSED WITH MM</b> <i>Oral Presenter:</i> Guldane Cengiz Seval, TR	09:09 - 09:18
OS01-03	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCTS) FOR NON-HODGKIN LYMPHOMA (NHL)S: OUTCOMES AT THE NATIONAL CANCER CENTER HOSPITAL (NCCH) OF JAPAN</b> <i>Oral Presenter:</i> Mizuki Watanabe, JP	09:18 - 09:27
OS01-04	<b>AN EARLY POST-TRANSPLANT RELAPSE PREDICTION SCORE IN MULTIPLE MYELOMA PATIENTS: A LARGE COHORT STUDY FROM CHRONIC MALIGNANCIES WORKING PARTY OF EBMT</b> <i>Oral Presenter:</i> Meral Beksac, TR	09:27 - 09:36
OS01-05	<b>INTERNATIONAL DIFFERENCES IN BASELINE CHARACTERISTICS AND PRACTICE PATTERNS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS UNDERGOING UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION</b> <i>Oral Presenter:</i> Laurent Garderet, FR	09:36 - 09:45
OS01-06	<b>OUTCOMES OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) IN ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)</b> <i>Oral Presenter:</i> Pashna Munshi, US	09:45 - 09:54
OS01-07	<b>HLA COMPATIBILITY RELEVANCE IN LYMPHOMAS USING POST-TRANSPLANT CYCLOPHOSPHAMIDE: MUD VS</b>	09:54 - 10:03

**HAPLOIDENTICAL DONORS***Oral Presenter:* Alberto Mussetti, ES

- OS01-08      **OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) IN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)**      10:03 - 10:12  
*Oral Presenter:* Mehdi Hamadani, US

*Educational*

09:00 - 10:00

Terrace 2A

**E1 - AML and allogeneic HCT: for whom, how, and when?***Chair:* Jiri Mayer, CZ*Chair:* Eolia Brissot, FR

- E1-01      **Introduction**      09:00 - 09:05  
*Speaker:* Jiri Mayer, CZ
- E1-02      **Stratified use of allogeneic HCT in the initial management of AML**      09:05 - 09:20  
*Speaker:* Felicitas Thol, DE
- E1-03      **Allogeneic HCT in high-risk AML patients. The value of achieving CR?**      09:20 - 09:35  
*Speaker:* Charles Craddock, GB
- E1-04      **Prophylaxis, early intervention, and treatment of relapse after HCT**      09:35 - 09:50  
*Speaker:* Martin Bornhaeuser, DE
- E1-05      **Conclusions**      09:50 - 10:00  
*Speaker:* Eolia Brissot, FR

*Workshop*

09:00 - 10:00

Terrace 2B

**W1 - How to perform alternative donor transplant in non-malignant disease***Chair:* Markéta Bloomfield, CZ*Chair:* Bénédicte Neven, FR

- W1-01      **Introduction**      09:00 - 09:05  
*Speaker:* Markéta Bloomfield, CZ
- W1-02      **Haploidentical HSCT in primary immune deficiencies**      09:05 - 09:20  
*Speaker:* Mary Slatter, GB
- W1-03      **Haploidentical HSCT in constitutional SAA**      09:20 - 09:35  
*Speaker:* Carmem Bonfim, BR
- W1-04      **Cord blood HSCT in metabolic diseases**      09:35 - 09:50  
*Speaker:* Rob Wynn, GB
- W1-05      **Conclusions**      09:50 - 10:00  
*Speaker:* Bénédicte Neven, FR

*Breaks*

10:15 - 10:45

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition**

*Working Party Session*

10:45 - 12:00

Congress Hall / Virtual Hall 1

**CMWP - Chronic Malignancies Working Party session***Chair:* Ibrahim Yakoub-Agha, FR*Chair:* Patrick Hayden, IE

CMWP-01	<b>One year of VEXAS: what we know and where we are going</b> <i>Speaker:</i> Carmelo Gurnari, US	10:45 - 11:10
CMWP-02	<b>Blast Phase MPN - new developments</b> <i>Speaker:</i> Guillermo Ortí, ES	11:10 - 11:35
CMWP-03	<b>EBMT scoring system for early relapse after auto-HCT in MM patients</b> <i>Speaker:</i> Meral Beksac, TR	11:35 - 12:00

*Cell Therapy*

10:45 - 11:45

Forum Hall / Virtual Hall 2

**CTD2 - Cell therapy Day 2: Clinical monitoring post therapeutic intervention***Chair:* Christian Chabannon, FR

CTD2-01	<b>Neurological safety of CAR T-cells</b> <i>Speaker:</i> Antoine Carpentier, FR	10:45 - 11:00
CTD2-02	<b>Safety and feasibility of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSc) in severe systemic sclerosis (SSc) refractory to conventional immunosuppressive therapy</b> <i>Speaker:</i> Dominique Farge, FR	11:00 - 11:15
CTD2-03	<b>Assessing the risk of secondary malignancies after gene therapy for globin disorders</b> <i>Speaker:</i> Emanuele Angelucci, IT	11:15 - 11:30
CTD2-04	<b>Q&amp;A</b>	11:30 - 11:45

*Nurses Group*

10:45 - 12:00

Panorama / Virtual Hall 3

**NG06 - Infections***Chair:* Sophie Van Lancker, BE*Chair:* Monika Marxova, CZ

NG06-01	<b>Viral infections post allogeneic stem cell transplantation</b> <i>Speaker:</i> Laura Ricketts, GB	10:45 - 11:05
NG06-02	<b>Invasive fungal infections</b> <i>Speaker:</i> Milan Navrátil, CZ	11:05 - 11:25
NG06-03	<b>Rare infections</b> <i>Speaker:</i> Tomas Kabut, CZ	11:25 - 11:45
NG06-04	<b>QA</b>	11:45 - 12:00

*How do I... ?*

10:45 - 12:00

South Hall 1A+B / Virtual Hall 4

**HDI2 - How Do I... manage multiple facets of GVHD treatment? A focus on ECP - Supported through an unrestricted educational grant by Therakos-Mallinckrodt***Chair:* Petr Sedláček, CZ

HDI2-01	<b>When do I use ECP in the treatment of paediatric acute or chronic GvHD?</b> <i>Speaker:</i> Andrew Gennery, GB	10:45 - 11:05
HDI2-02	<b>When and why do I combine ECP with immunosuppressive agents in the treatment of acute and chronic GVHD?</b> <i>Speaker:</i> Zinaida Peric, HR	11:05 - 11:25
HDI2-03	<b>When do I use and when do I avoid ECP in the treatment of GVHD?</b> <i>Speaker:</i> Hildegard Greinix, AT	11:25 - 11:45
HDI2-04	<b>QA</b>	11:45 - 12:00

*Patient Advocacy Sessions*

10:45 - 12:00

South Hall 2A+B / Virtual Hall 5

**PA2 - Patient Advocacy: The Dilemma: Will CAR-T therapy replace BMT - What is the real outcome and impact***Chair:* Andrea Linke, DE*Chair:* Guy Bouguet, FR

PA2-01	<b>Introduction by the Chairs</b>	10:45 - 10:49
PA2-02	<b>Patient perspective</b> <i>Speaker:</i> Jonathan Clark, NL	10:49 - 10:58
PA2-03	<b>Payer perspective</b> <i>Speaker:</i> Marcin Czech, PL	10:58 - 11:07
PA2-04	<b>Clinician perspective</b> <i>Speaker:</i> Meletios A. Dimopoulos, GR	11:07 - 11:16
PA2-05	<b>Economist perspective</b> <i>Speaker:</i> Frederick Thielen, NL	11:16 - 11:25
PA2-06	<b>Roundtable Panel Discussion</b>	11:25 - 12:00

*Oral Session*

10:45 - 12:00

North Hall / Virtual Hall 6

**OS02 - Oral session 2: Inborn errors, immunodeficiency***Chair:* Ansgar Schulz, DE*Chair:* Despina Moshous, FR

OS02-01	<b>PILOT STUDY ON MEMORY T-CELL ADDBACK AFTER TCRA/CD19 DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH NON-SCID INBORN ERRORS OF IMMUNITY</b> <i>Oral Presenter:</i> Su Han Lum, GB	10:45 - 10:54
OS02-02	<b>OUTCOME OF CHILDREN WITH WISKOTT-ALDRICH SYNDROME (WAS) GIVEN TCRA/CD19 DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FROM AN HLA-</b>	10:54 - 11:03

	<b>HAPLOIDENTICAL RELATIVE</b>	
	<i>Oral Presenter:</i> Mattia Algeri, IT	
OS02-03	<b>IN DEPTH IMMUNE PROFILING OF IL2RG DEFICIENT PATIENT 50 YEARS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION REVEALS A DIVERSE NAIVE BUT OLIGOCLONAL MEMORY T CELL COMPARTMENT</b>	11:03 - 11:12
	<i>Oral Presenter:</i> Janine E. Melsen, NL	
OS02-04	<b>HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ARPC1B DEFICIENCY</b>	11:12 - 11:21
	<i>Oral Presenter:</i> Stefano Giardino, IT	
OS02-05	<b>INDIVIDUALIZED ALEMTUZUMAB DOSING FOR INDUCTION OF DISEASE REMISSION PRIOR TO HSCT IN CHILDREN WITH HLH</b>	11:21 - 11:30
	<i>Oral Presenter:</i> Federica R. Achini-Gutzwiller, CH	
OS02-06	<b>TARGETED, MYELOABLATIVE BUSULFAN IS WELL TOLERATED IN INFANTS WITH HURLER SYNDROME</b>	11:30 - 11:39
	<i>Oral Presenter:</i> Goutomi Chatterjee, GB	
OS02-07	<b>EXCELLENT OUTCOMES AFTER HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE IN 25 PATIENTS WITH WISKOTT-ALDRICH SYNDROME</b>	11:39 - 11:48
	<i>Oral Presenter:</i> Carmem Bonfim, BR	
OS02-08	<b>CD3+ TCRAB/CD19+ DEPLETED HAPLOIDENTICAL HAEMATOPOIETIC CELL TRANSPLANTATION AS A SALVAGE STRATEGY FOR GRAFT FAILURE OR REFRACTORY GRAFT VERSUS HOST DISEASE IN INBORN ERRORS OF IMMUNITY</b>	11:48 - 11:57
	<i>Oral Presenter:</i> Subramaniam Ramanathan, GB	

*Educational*

10:45 - 11:46

Terrace 2A

**E2 - Precise medicine in paediatric leukaemia***Chair:* Jan Starý, CZ*Chair:* Birgitte Strahm, DE

E2-01	<b>Introduction</b>	10:45 - 10:50
	<i>Speaker:</i> Jan Starý, CZ	
E2-02	<b>Genetics, epigenetics or HbF as biomarker: how to stratify therapy in JMML</b>	10:50 - 11:05
	<i>Speaker:</i> Charlotte Niemeyer, DE	
E2-03	<b>Therapeutic options for early relapse of ALL: advantages and limitations</b>	11:05 - 11:25
	<i>Speaker:</i> Franco Locatelli, IT	
E2-04	<b>Therapeutic options for individual therapy in pediatric AML</b>	11:25 - 11:41
	<i>Speaker:</i> Patrick Schlegel, AU	
E2-05	<b>Conclusions</b>	11:41 - 11:50
	<i>Speaker:</i> Birgitte Strahm, DE	

<i>Workshop</i>		
10:45 - 11:45		Terrace 2B
<b>W2 - Current place of cellular therapy in multiple myeloma</b>		
<i>Chair:</i> Marta Krejčí, CZ		
<i>Chair:</i> He Huang, CN		
W2-01	<b>Introduction</b>	10:45 - 10:50
	<i>Speaker:</i> Marta Krejčí, CZ	
W2-02	<b>Efficacy and outcome of modern standard treatment vs. ASCT in newly diagnosed multiple myeloma patients</b>	10:50 - 11:05
	<i>Speaker:</i> Meral Beksac, TR	
W2-03	<b>CAR T cell therapy as replacement or supplement of ASCT as part of consolidation in newly diagnosed multiple myeloma patients? Pros and cons</b>	11:05 - 11:20
	<i>Speaker:</i> Roman Hájek, CZ	
W2-04	<b>Current role of allogeneic SCT in multiple myeloma in the context of new drugs and cellular therapies?</b>	11:20 - 11:35
	<i>Speaker:</i> Nicolaus Kröger, DE	
W2-05	<b>Conclusions</b>	11:35 - 11:45
	<i>Speaker:</i> He Huang, CN	
<i>Educational</i>		
11:50 - 12:45		Terrace 2A
<b>E3 - CAR T cell therapy for leukaemia and lymphoma</b>		
<i>Chair:</i> Frantisek Folber, CZ		
E3-01	<b>Introduction</b>	11:50 - 11:55
	<i>Speaker:</i> Frantisek Folber, CZ	
E3-02	<b>CAR T cell therapy for lymphoma</b>	11:55 - 12:10
	<i>Speaker:</i> Marie Jose Kersten, NL	
E3-04	<b>Management of CAR T cell toxicities</b>	12:25 - 12:40
	<i>Speaker:</i> Marion Subklewe, DE	
<i>Workshop</i>		
11:50 - 12:47		Terrace 2B
<b>W3 - Autoimmune Diseases</b>		
<i>Chair:</i> Tomáš Kozák, CZ		
<i>Chair:</i> Riccardo Saccardi, IT		
W3-01	<b>Introduction</b>	11:50 - 11:55
	<i>Speaker:</i> Tomáš Kozák, CZ	
W3-02	<b>Autologous HSCT in MS</b>	11:55 - 12:10
	<i>Speaker:</i> Joachim Burman, SE	
W3-03	<b>Autologous HSCT in SSc</b>	12:10 - 12:27
	<i>Speaker:</i> Dominique Farge, FR	
W3-04	<b>Allogeneic HSCT in ADs</b>	12:27 - 12:42
	<i>Speaker:</i> Keith Sullivan, US	
W3-05	<b>Conclusions</b>	12:42 - 12:47

*Speaker:* Riccardo Saccardi, IT

*Breaks*

12:00 - 12:45

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition**

*Industry Symposium*

12:45 - 13:45

Congress Hall / Virtual Hall 1

**IS23 - Start your engines: is transplant still the heart of the MM treatment circuit? - Sanofi (Genzyme) Industry Symposium**

*Chair:* Ivan Spicka, CZ

IS23-01	<b>Welcome and introduction</b> <i>Speaker:</i> Ivan Spicka, CZ	12:45 - 12:50
IS23-02	<b>Will supercharged new regimens leave old practices in the dust?</b> <i>Speaker:</i> Katja Weisel, DE	12:50 - 13:05
IS23-03	<b>The race is on: How do subsequent therapies perform post-transplant?</b> <i>Speaker:</i> Mohamad Mohty, FR	13:05 - 13:20
IS23-04	<b>Tuning treatments for modern practice: Case studies</b> <i>Speaker:</i> Xavier Leleu, FR	13:20 - 13:35
IS23-05	<b>Panel discussion with Q&amp;A and concluding remarks</b>	13:35 - 13:45

*Industry Symposium*

12:45 - 13:45

Forum Hall / Virtual Hall 2

**IS24 - Here, Now, and Next: Perspectives on the role of CAR-T Cell Therapy in Lymphomas - Novartis Industry Symposium**

*Chair:* Catherine Thieblemont, FR

IS24-01	<b>Introductions and Opening Remarks</b> <i>Speaker:</i> Catherine Thieblemont, FR	12:45 - 12:48
IS24-02	<b>Now and Next in r/r DLBCL: Optimizing patient journey</b>	12:48 - 12:48
IS24-02-01	<b>Discussing efficacy and safety of CAR-T cell therapies across pivotal clinical trials and real-world settings</b> <i>Speaker:</i> Ulrich Jäger, AT <i>Speaker:</i> Marion Subklewe, DE	12:48 - 13:03
IS24-02-02	<b>Exploring key considerations and experiences around the process of identifying patients with r/r DLBCL for CAR-T cell therapy</b> <i>Speaker:</i> Catherine Thieblemont, FR <i>Speaker:</i> Ulrich Jäger, AT <i>Speaker:</i> Marion Subklewe, DE	13:03 - 13:28
IS24-03	<b>Live Q&amp;A</b> <i>Speaker:</i> Catherine Thieblemont, FR <i>Speaker:</i> Ulrich Jäger, AT <i>Speaker:</i> Marion Subklewe, DE	13:28 - 13:43
IS24-04	<b>Closing remarks</b>	13:43 - 13:45



*Speaker:* Catherine Thieblemont, FR

*Industry Symposium*

12:45 - 13:45

Panorama / Virtual Hall 3

**IS26 - Delivering ECP to every patient | Therakos Industry Symposium**

*Chair:* Michelle Kenyon, GB

IS26-01	<b>Introduction</b> <i>Speaker:</i> Michelle Kenyon, GB	12:45 - 12:50
IS26-02	<b>ECP service improvement in a nurse-led clinic</b> <i>Speaker:</i> Manda Mootien, GB <i>Speaker:</i> Sukran Saglam, GB	12:50 - 13:20
IS26-03	<b>Delivering integrated Therakos ECP technology - Experiences from Zagreb, Croatia</b> <i>Speaker:</i> Ines Bojanic, HR	13:20 - 13:40
IS26-04	<b>Q&amp;A</b>	13:40 - 13:45

*Special Session*

12:45 - 13:45

South Hall 2A+B / Virtual Hall 5

**SS1 - Equality, Diversity and Inclusion Session**

*Chair:* Andreu Gusi, ES

*Chair:* Silvia Montoto, GB

SS1-01	<b>Impact of COVID in gender inequality in research</b> <i>Speaker:</i> Pavel Ovseiko, GB	12:45 - 13:00
SS1-02	<b>Intersectionality in haematology and impact on patients</b> <i>Speaker:</i> Nada Hamad, AU	13:00 - 13:15
SS1-03	<b>Trainees' views on EDI and inequality experiences</b> <i>Speaker:</i> Nico Gagelmann, DE <i>Speaker:</i> Claire Horgan, GB	13:15 - 13:30
SS1-04	<b>Q&amp;A</b>	13:30 - 13:45

*Statistics*

12:45 - 13:45

North Hall / Virtual Hall 6

**Stats1 - Statistics Workshop**

*Chair:* Liesbeth de Wreede, NL

Stats1-1a	<b>How to adjust for confounding in a comparative analysis, and how to select variables in a Cox multivariable model</b> <i>Speaker:</i> Jacques-Emmanuel Galimard, FR	12:45 - 13:00
Stats1-1b	<b>How to adjust for confounding in a comparative analysis, and how to select variables in a Cox multivariable model</b> <i>Speaker:</i> Zinaida Peric, HR	13:00 - 13:15
Stats1-1c	<b>How to adjust for confounding in a comparative analysis, and how to select variables in a Cox multivariable model</b> <i>Speaker:</i> Christophe Peczynski, FR	13:15 - 13:30
Stats1-2	<b>QA</b>	13:30 - 13:45

*Industry Symposium*

12:45 - 13:45

MTE

**MTE-S-01 - Meet the Expert lunch session on Allogeneic T-cell immunotherapies for EBV+Post-Transplant Lymphoproliferative Disease by Pierre Fabre**

MTE-S-01-1	<b>Introduction</b> <i>Speaker:</i> Pierre Fabre, FR	12:45 - 12:50
MTE-S-01-2	<b>State of the art knowledge on EBV+ PTLD</b> <i>Speaker:</i> Daan Dierickx, BE	12:50 - 13:10
MTE-S-01-3	<b>Allogeneic T-cell immunotherapies for EBV+ PTLD</b> <i>Speaker:</i> Sylvain Choquet, FR	13:10 - 13:30
MTE-S-01-QA	<b>Audience Questions &amp; Answers</b>	13:30 - 13:45

*Breaks*

13:45 - 14:15

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition***General*

14:15 - 15:45

Congress Hall / Virtual Hall 1

**GS2 - Presidential Symposium***Chair:* Nicolaus Kröger, DE*Chair:* Petr Sedláček, CZ*Chair:* Pavel Jindra, CZ

GS2-01	<b>Van Bakkum Award - Introduction</b> <i>Speaker:</i> Nicolaus Kröger, DE	14:15 - 14:18
GS2-02	<b>LISOCABTAGENE MARALEUCEL VERSUS STANDARD OF CARE (SALVAGE CHEMOTHERAPY FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION) AS SECOND-LINE THERAPY IN RELAPSED/REFRACTORY LBCL: TRANSFORM RESULTS</b> <i>Oral Presenter:</i> Jeremy Abramson, US	14:18 - 14:33
GS2-03	<b>Basic Science Award - Introduction</b> <i>Speaker:</i> Petr Sedláček, CZ	14:33 - 14:36
GS2-04	<b>MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIAL RECOVERY VIA THE STING PATHWAY IN MICE AND MEN AND PROTECT FROM GRAFT-VERSUS-HOST DISEASE</b> <i>Oral Presenter:</i> Sascha Götttert, DE	14:36 - 14:51
GS2-05	<b>DEFIBROTIDE TREATMENT IN PAEDIATRIC AND ADULT PATIENTS WITH SEVERE/VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): RESULTS FROM THE DEFIFRANCE STUDY</b> <i>Oral Presenter:</i> Mohamad Mohty, FR	14:51 - 15:00
GS2-06	<b>OUTCOMES OF ALLOGENEIC HCT IN PATIENTS WITH HODGKIN LYMPHOMA IN THE ERA OF CHECKPOINT INHIBITORS: A JOINT CIBMTR AND EBMT ANALYSIS.</b> <i>Oral Presenter:</i> Miguel Angel Perales, US	15:00 - 15:09
GS2-07	<b>LATE EFFECTS AFTER HEMATOPOIETIC STEM CELL</b>	15:09 - 15:18

**TRANSPLANTATION IN PATIENTS WITH HLH: A HISTIOCYTE SOCIETY, PDWP, IEWP AND TCWP EBMT STUDY**

*Oral Presenter:* Kanchan Rao, GB

GS2-08 **LONG TERM OUTCOMES AND RELATIVE MORTALITY IN SURVIVORS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: AN ANALYSIS FROM THE ALWP OF THE EBMT** 15:18 - 15:27

*Oral Presenter:* Vivek Patel, US

GS2-09 **POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ALL TREATED IN CR1 WITH ALLO-HCT FROM MATCHED UNRELATED DONORS. A STUDY FROM ALWP OF THE EBMT** 15:27 - 15:36

*Oral Presenter:* Sebastian Giebel, PL

GS2-10 **ENGINEERING T-CELLS TO PREVENT GRAFT-VERSUS-HOST DISEASE AND LEUKEMIA RELAPSE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION** 15:36 - 15:45

*Oral Presenter:* Feiyan Mo, US

*Nurses Group*

14:15 - 15:45

Panorama / Virtual Hall 3

**NG07 - Oral session: Abstract finalists**

*Chair:* Annika Kisch, SE

*Chair:* Eliška Kropáčková, CZ

NG07-01 **INITIAL TRAINING PROGRAM FOR NURSES IN HEMATOPOIETIC CELLULAR THERAPY PROVIDED BY A NATIONWIDE PLATFORM IN SPAIN** 14:15 - 14:30

*Oral Presenter:* Julia Ruiz Pato, ES

NG07-02 **COMPLIANCE EVALUATION OF THE TRANSPLANTATION UNITS BASED ON THE DECISIONS TAKEN DURING TURKEY HEMATOPOIETIC STEM CELL TRANSPLANTATION NURSING CONSENSUS** 14:30 - 14:45

*Oral Presenter:* Seckin Erdal, TR

NG07-03 **PERSON-CENTRED SUPPORT FOR FAMILY CAREGIVERS IN THE CONTEXT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - FEASIBILITY OF A REMOTELY DELIVERED INTERVENTION** 14:45 - 15:00

*Oral Presenter:* Jeanette Winterling, SE

NG07-04 **SKIN CARE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA AND TREOSULFAN** 15:00 - 15:15

*Oral Presenter:* Kim van der Niet, NL

NG07-05 **SIMILAR NUTRITION SUPPORT PRACTICES BUT DIFFERENT OPINIONS TOWARD GASTROSTOMY USE IN UNITED KINGDOM PEDIATRIC BONE MARROW TRANSPLANT CENTERS** 15:15 - 15:30

*Oral Presenter:* James Evans, GB

NG07-6 **QA** 15:30 - 15:45

*Educational*

14:15 - 15:15

Terrace 2A

**E4 - The older patients in HSCT***Chair:* Rafael Duarte, ES*Chair:* Miriam Lanska, CZ

E4-01	<b>Introduction</b> <i>Speaker:</i> Miriam Lanska, CZ	14:15 - 14:20
E4-02	<b>Elderly candidates for HSCT: how to assess their eligibility?</b> <i>Speaker:</i> Maximilian Christopeit, DE	14:20 - 14:35
E4-03	<b>The results of allogeneic HSCT for myeloid malignancies in the elderly</b> <i>Speaker:</i> Maria Thérèse Rubio, FR	14:35 - 14:50
E4-04	<b>Geriatric complications among older patients</b> <i>Speaker:</i> Andrew Artz, US	14:50 - 15:05
E4-05	<b>Conclusions</b> <i>Speaker:</i> Rafael Duarte, ES	15:05 - 15:15

*Workshop*

14:15 - 15:15

Terrace 2B

**W4 - Critical care in HCT recipients***Chair:* Jan Vydra, CZ*Chair:* Colombe Saillard, FR

W4-01	<b>Introduction</b> <i>Speaker:</i> Jan Vydra, CZ	14:15 - 14:20
W4-02	<b>Respiratory failure after hematopoietic cell transplantation</b> <i>Speaker:</i> Boris Boell, DE	14:20 - 14:35
W4-03	<b>Severe sepsis and septic shock in immunocompromised patients</b> <i>Speaker:</i> Martin Balík, CZ	14:35 - 14:50
W4-04	<b>Which patients should go to intensive care?</b> <i>Speaker:</i> Thomas Staudinger, AT	14:50 - 15:05
W4-05	<b>Conclusions</b> <i>Speaker:</i> Colombe Saillard, FR	15:05 - 15:15

*Breaks*

15:45 - 16:15

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition***Industrial Theatre*

15:50 - 16:10

North Hall / Virtual Hall 6

**IT3 - Industry Theatre: Idecabtagene vicleucel for the treatment of patients with relapsed and refractory multiple myeloma | Bristol Myers Squibb**

IT3-01	<b>Idecabtagene vicleucel for the treatment of patients with relapsed and refractory multiple myeloma</b> <i>Speaker:</i> Katja Weisel, DE	15:50 - 16:10
--------	---	---------------

*Plenary Session*

16:15 - 17:30

Congress Hall / Virtual Hall 1

**P1 - Cord blood transplantation - do we still need it?***Chair:* Petr Sedláček, CZ*Chair:* Jaime Sanz Caballer, ES

P1-01	<b>State of the art in Cord Blood Transplantation in Europe</b> <i>Speaker:</i> Éliane Gluckman, FR	16:15 - 16:35
P1-02	<b>Emerging uses of cord blood in regenerative medicine</b> <i>Speaker:</i> Jessica Sun, US	16:35 - 16:55
P1-03	<b>Clinical benefits of ex vivo progenitor cell expansion for cord blood transplantation</b> <i>Speaker:</i> Guillermo Sanz, ES	16:55 - 17:15
P1-04	<b>QA</b>	17:15 - 17:30

*Cell Therapy*

16:15 - 17:30

Forum Hall / Virtual Hall 2

**CTD3 - Cell Therapy Day 3: GoCART updates***Chair:* Jurgen Kuball, NL*Chair:* Chiara Bonini, IT

CTD3-01	<b>WP Data harmonization: revision of the EBMT Cellular Therapy Form</b> <i>Speaker:</i> Christian Chabannon, FR	16:15 - 16:25
CTD3-02	<b>WP Standards of Care: Harmonisation site qualification processes</b> <i>Speaker:</i> Nina Worel, AT	16:25 - 16:35
CTD3-03	<b>WP Education</b> <i>Speaker:</i> Osman Ahmed, SA <i>Speaker:</i> Michelle Kenyon, GB	16:35 - 16:45
CTD3-05	<b>WP Scientific Excellence: Presentation selected study proposals</b> <i>Speaker:</i> Bertram Glass, DE <i>Speaker:</i> Sebastian Giebel, PL <i>Speaker:</i> Valentín Ortiz-Maldonado, ES <i>Speaker:</i> Matteo Doglio, IT	16:45 - 17:05
CTD3-07	<b>Update status Governance Charter</b> <i>Speaker:</i> Sofie Terwel, NL	17:05 - 17:10
CTD3-08	<b>QA</b> <i>Speaker:</i> Nicolaus Kröger, DE <i>Speaker:</i> John Gribben, GB <i>Speaker:</i> Martin Dreyling, DE <i>Speaker:</i> Andreu Gusi, ES	17:10 - 17:30

*How do I... ?*

16:15 - 17:30

Panorama / Virtual Hall 3

**HDI3 - Nurse's How Do I... best support MM patients in my practice? - Supported through an unrestricted educational grant by Janssen***Chair:* John Murray, GB*Chair:* Marijke Quaghebeur, BE

HDI3-01	<b>Supporting my patients to live well with myeloma - managing fatigue, memory loss and psychological wellbeing</b> <i>Speaker:</i> Maaïke de Ruijter, NL	16:15 - 16:35
HDI3-02	<b>Supporting my patients to live well with myeloma - managing side effects of treatment including PN</b> <i>Speaker:</i> Matthias Hellberg-Naegel, CH	16:35 - 16:55
HDI3-03	<b>Being supported to live well with myeloma - what works for me and what matters to me</b> <i>Speaker:</i> Pavel Šplechta, CZ	16:55 - 17:15
	<b>Q&amp;A</b>	17:15 - 17:30

*Oral Session*

16:15 - 17:30

South Hall 1A+B / Virtual Hall 4

**OS03 - Oral session 3: Various diseases: myeloproliferative neoplasm and myelodysplastic syndrome***Chair:* Marie Robin, FR*Chair:* Thomas Schroeder, DE

OS03-01	<b>ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT FOR BLAST PHASE OF PHILADELPHIA-CHROMOSOME NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A RETROSPECTIVE STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT</b> <i>Oral Presenter:</i> Guillermo Ortí, ES	16:15 - 16:24
OS03-02	<b>OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC NEUTROPHILIC LEUKEMIA: A COMBINED CIBMTR/EBMT ANALYSIS</b> <i>Oral Presenter:</i> Bhagirathbhai Dholaria, US	16:24 - 16:33
OS03-03	<b>UNRELATED AND HAPLOIDENTICAL DONOR ALLO-HCT FOR CML WITH POST TRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT</b> <i>Oral Presenter:</i> Guillermo Ortí, ES	16:33 - 16:42
OS03-04	<b>IMPACT OF REDUCED INTENSITY HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS IN ACCELERATED-PHASE AND THE ROLE OF BLASTS</b> <i>Oral Presenter:</i> Nico Gagelmann, DE	16:42 - 16:51
OS03-05	<b>IMPACT OF HIGH RISK MOLECULAR MUTATIONS AFTER ALLOGENIC TRANSPLANTATION IN MYELOFIBROSIS: LONG TERM RESULTS OF A PROSPECTIVE GITMO CLINICAL TRIAL</b> <i>Oral Presenter:</i> Silvia Salmoiraghi, IT	16:51 - 17:00
OS03-06	<b>OUTCOME OF ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION IN EOSINOPHILIC DISORDERS: A RETROSPECTIVE STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT</b> <i>Oral Presenter:</i> Donal McLornan, GB	17:00 - 17:09
OS03-07	<b>ALLOGENEIC TRANSPLANTATION FOR PH+ CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS FROM THE EBMT CHRONIC MALIGNANCIES WORKING PARTY</b>	17:09 - 17:18

**(EBMT-CMWP) COMPARING OUTCOMES ACCORDING TO DONOR TYPE***Oral Presenter:* Francesco Onida, IT

OS03-08	<b>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME UNCLASSIFIABLE - A RETROSPECTIVE STUDY ON BEHALF OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT</b>	17:18 - 17:27
	<i>Oral Presenter:</i> Joanna Drozd-Sokolowska, PL	

*How do I... ?*

16:15 - 17:30

South Hall 2A+B / Virtual Hall 5

**HDI4 - How Do I... best implement CAR T cell therapy in DLBCL? From patient eligibility to long term follow up - Supported through an unrestricted educational grant by BMS***Chair:* Anna Sureda, ES

HDI4-01	<b>How do I select the right DLBCL patient for CAR T cell therapy?</b>	16:15 - 16:35
	<i>Speaker:</i> Avichai Shimoni, IL	
HDI4-02	<b>How do I manage short and long term toxicities of CAR T cell therapy?</b>	16:35 - 16:55
	<i>Speaker:</i> Claire Roddie, GB	
HDI4-03	<b>How do I manage the patients with CAR T cell therapy failure?</b>	16:55 - 17:15
	<i>Speaker:</i> Michael Byrne, US	
HDI4-04	<b>QA</b>	17:15 - 17:30

*Working Party Session*

16:15 - 17:30

North Hall / Virtual Hall 6

**ADWP - Autoimmune Diseases Working Party session***Chair:* Raffaella Greco, IT*Chair:* Tobias Alexander, DE

ADWP-01	<b>Summary of ADWP database activity</b>	16:15 - 16:25
	<i>Speaker:</i> Raffaella Greco, IT	
	<i>Speaker:</i> Tobias Alexander, DE	
	<i>Speaker:</i> Manuela Badoglio, FR	
ADWP-02	<b>Changing a chronic autoimmune disease into a one-time reversible illness</b>	16:25 - 16:35
	<i>Speaker:</i> Richard Burt, US	
ADWP-03	<b>Transplant indications and patient selection in severe crohn's disease</b>	16:35 - 16:50
	<i>Speaker:</i> Elena Ricart, ES	
ADWP-04	<b>Transplant indications and patient selection in SSc</b>	16:50 - 17:05
	<i>Speaker:</i> Nicoletta Del Papa, IT	
ADWP-05	<b>Indications and patient selection in autologous haematopoietic stem cell transplantation in MS</b>	17:05 - 17:20
	<i>Speaker:</i> Basil Sharrack, GB	
ADWP-06	<b>Q&amp;A</b>	17:20 - 17:30

*Educational*

16:15 - 17:15

Terrace 2A

**E5 - Tools for risk stratification of GVHD***Chair:* Michal Karas, CZ*Chair:* Ernst Holler, DE

E5-01	<b>Introduction</b> <i>Speaker:</i> Michal Karas, CZ	16:15 - 16:18
E5-02	<b>MAGIC consortium assessment</b> <i>Speaker:</i> Francis Ayuk, DE	16:18 - 16:33
E5-03	<b>Minnesota GVHD risk score for acute GVHD</b> <i>Speaker:</i> Daniel Weisdorf, US	16:33 - 16:44
E5-04	<b>Risk stratification for Chronic GVHD</b> <i>Speaker:</i> Stephanie Lee, US	16:44 - 16:59
E5-05	<b>Conclusions</b> <i>Speaker:</i> Ernst Holler, DE	16:59 - 17:04

*Workshop*

16:15 - 17:15

Terrace 2B

**W5 - Palliative care after BMT***Chair:* Michelle Kenyon, GB

W5-02	<b>Quality of life and dying after BMT</b> <i>Speaker:</i> Angela Scherwath, DE	16:20 - 16:35
W5-03	<b>When to initiate palliative care after BMT</b> <i>Speaker:</i> William Krüger, DE	16:35 - 16:50
W5-04	<b>Palliative care in children after BMT</b> <i>Speaker:</i> Marta Verna, IT	16:50 - 17:05
W5-05	<b>Conclusions</b> <i>Speaker:</i> Michelle Kenyon, GB	17:05 - 17:15

*Breaks*

17:30 - 17:45

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition***Oral Session*

17:45 - 18:45

Congress Hall / Virtual Hall 1

**AA1 - EBMT Talks: Best Abstracts***Chair:* Anna Sureda, ES*Chair:* Petr Sedláček, CZ

**VAN BEKKUM AWARD - LISOCABTAGENE MARALEUCEL  
VERSUS STANDARD OF CARE (SALVAGE CHEMOTHERAPY  
FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND  
AUTOLOGOUS STEM CELL TRANSPLANTATION) AS  
SECOND-LINE THERAPY IN RELAPSED/REFRACTORY  
LBCL: TRANSFORM RESULTS**

*Oral Presenter:* Jeremy Abramson, US

**BASIC SCIENCE AWARD - MICROBIAL-DERIVED  
METABOLITES INDUCE EPITHELIAL RECOVERY VIA THE**



**STING PATHWAY IN MICE AND MEN AND PROTECT FROM GRAFT-VERSUS-HOST DISEASE**

*Oral Presenter:* Sascha Göttert, DE

**JON J. VAN ROOD AWARD - INVARIANT NATURAL KILLER T-CELL SUBSETS HAVE DIVERSE GRAFT-VERSUS-HOST-DISEASE-PREVENTING AND ANTITUMOR EFFECTS**

*Oral Presenter:* Kristina Maas-Bauer, DE

**JIAN-JIAN LUAN AWARD - DAY+7 ANTI CD19-CAR-T BLOOD CONCENTRATIONS IDENTIFY ULTRA-HIGH-RISK GROUP FOR EARLY PROGRESSION OF DISEASE IN PATIENTS WITH STABLE/PROGRESSIVE DLBCL AT LYMPHODEPLETION**

*Oral Presenter:* Ron Ram, IL

**PRESIDENTIAL ABSTRACT - DEFIBROTIDE TREATMENT IN PAEDIATRIC AND ADULT PATIENTS WITH SEVERE/VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): RESULTS FROM THE DEFIFRANCE STUDY**

*Oral Presenter:* Mohamad Mohty, FR

**PRESIDENTIAL ABSTRACT - OUTCOMES OF ALLOGENEIC HCT IN PATIENTS WITH HODGKIN LYMPHOMA IN THE ERA OF CHECKPOINT INHIBITORS: A JOINT CIBMTR AND EBMT ANALYSIS.**

*Oral Presenter:* Miguel Angel Perales, US

**PRESIDENTIAL ABSTRACT - LATE EFFECTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HLH: A HISTIOCYTE SOCIETY, PDWP, IEWP AND TCWP EBMT STUDY**

*Speaker:* Kanchan Rao, GB

**PRESIDENTIAL ABSTRACT - LONG TERM OUTCOMES AND RELATIVE MORTALITY IN SURVIVORS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: AN ANALYSIS FROM THE ALWP OF THE EBMT**

*Oral Presenter:* Vivek Patel, US

**PRESIDENTIAL ABSTRACT - POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ALL TREATED IN CR1 WITH ALLO-HCT FROM MATCHED UNRELATED DONORS. A STUDY FROM ALWP OF THE EBMT**

*Oral Presenter:* Sebastian Giebel, PL

**PRESIDENTIAL ABSTRACT - ENGINEERING T-CELLS TO PREVENT GRAFT-VERSUS-HOST DISEASE AND LEUKEMIA RELAPSE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION**

*Oral Presenter:* Feiyan Mo, US

*Meet the Expert*

17:45 - 18:45

MTE

**MTE-10 - Meet the Expert 10**

MTE-10

**Management of CAR T cell toxicities**

17:45 - 18:45

*Speaker:* Philipp Wohlfarth, AT

*Meet the Expert*

17:45 - 18:45

MTE

**MTE-08 - Meet the Expert 8**

MTE-08

**Management of myeloma relapse after HSCT**

17:45 - 18:45

*Speaker:* Roman Hájek, CZ

*Meet the Expert*

17:45 - 18:45

MTE

**Meet the Expert Sessions**

*Meet the Expert*

17:45 - 18:45

MTE

**MTE-09 - Meet the Expert 9**

MTE-09

**Novel viral infections in immunocompromised patients**

17:45 - 18:45

*Speaker:* Marie von Lilienfeld-Toal, DE

*Meet the Expert*

17:45 - 18:45

MTE

**MTE-06 - Meet the Expert 6**

MTE-06

**How to select the best haploidentical donor in PTCY platform**

17:45 - 18:45

*Speaker:* Nina Worel, AT

*Meet the Expert*

17:45 - 18:45

MTE

**MTE-07 - Meet the Expert 7**

MTE-07

**Patient optimization for CAR T therapy: benefit vs. risk of toxicity**

17:45 - 18:45

*Speaker:* Matthew Frigault, US

**Tuesday, 22. March 2022***Meetings*

07:00 - 08:50

Forum Hall / Virtual Hall 2

**Transplant Complications Working Party Business Meeting***Chair:* Zinaida Peric, HR*Poster Sessions*

07:00 - 18:15

ePoster Area

**ePoster Viewing***On Demand Library*

07:00 - 18:15

On-demand Library

**On-demand Library***Meetings*

08:00 - 08:50

Panorama / Virtual Hall 3

**NGBM - Nurses Group Business Meeting***Chair:* Daphna Hutt, IL*Chair:* Michelle Kenyon, GB

NGBM-01	<b>Introduction</b>	08:00 - 08:05
NGBM-02	<b>President report</b>	08:05 - 08:15
NGBM-03	<b>Research Committee update</b> <i>Speaker:</i> Annika Kisch, SE	08:15 - 08:25
NGBM-04	<b>Scientific Committee update</b> <i>Speaker:</i> Kathy Goris, BE	08:25 - 08:30
NGBM-05	<b>Paediatric Committee update</b> <i>Speaker:</i> Hilda Mekelenkamp, NL	08:30 - 08:35
NGBM-06	<b>Global Education Committee update</b> <i>Speaker:</i> Eugenia Trigos, ES	08:35 - 08:40
NGBM-07	<b>Discussion</b>	08:40 - 08:50

*Quality Management*

08:00 - 09:00

MTE

**QM MTE-05 - Quality Management Meet the Expert 5**

QM MTE-05	<b>Outcome analysis and benchmarking &amp; Validation and verification</b> <i>Speaker:</i> Mara Magri, IT <i>Speaker:</i> Kim Orchard, GB	08:00 - 09:00
-----------	---	---------------

*Quality Management*

08:00 - 09:00

MTE

**QM MTE - Quality Management Meet the Expert**

*Quality Management*

08:00 - 09:00

MTE

**QM MTE-04 - Quality Management Meet the Expert 4**QM MTE-04      **Maintaining the QM program & Personnel Competency**      08:00 - 09:00*Speaker:* Phuong Huynh, BE*Speaker:* Sarah Holtby, GB*Quality Management*

08:00 - 09:00

MTE

**QM MTE-02 - Quality Management Meet the Expert 2**QM MTE-02      **Audits & Document development and control**      08:00 - 09:00*Speaker:* Julie Dolva, NO*Speaker:* Renza Monteleone, IT*Quality Management*

08:00 - 09:00

MTE

**QM MTE-03 - Quality Management Meet the Expert 3**QM MTE-03      **Adverse events & CAPA**      08:00 - 09:00*Speaker:* Anne Emmett, GB*Quality Management*

08:00 - 09:00

MTE

**QM MTE-01 - Quality Management Meet the Expert 1**QM MTE-01      **Risk & Change Management**      08:00 - 09:00*Speaker:* Olga López, ES*Speaker:* Dieter Klarmann, DE*Working Party Session*

09:00 - 10:15

Congress Hall / Virtual Hall 1

**ALWP - Acute Leukaemia Working Party session - Advances in ALL therapy***Chair:* Mohamad Mohty, FR*Chair:* Sebastian Giebel, PLALWP-01      **Introduction**      09:00 - 09:10*Speaker:* Mohamad Mohty, FRALWP-02      **Progress in allo-HCT for ALL**      09:10 - 09:22*Speaker:* Ali Bazarbachi, LBALWP-03      **MRD-driven HSCT for ALL**      09:22 - 09:34*Speaker:* Arnon Nagler, ILALWP-04      **Management of Philadelphia positive ALL**      09:34 - 09:46*Speaker:* Sebastian Giebel, PLALWP-05      **Role of bispecific antibodies**      09:46 - 09:58*Speaker:* Eolia Brissot, FRALWP-06      **CAR T cell therapy for relapsed/refractory B-ALL**      09:58 - 10:10*Speaker:* Jordan Gauthier, USALWP-07      **Q&A - Conclusion**      10:10 - 10:15

Speaker: Mohamad Mohty, FR

Oral Session

09:00 - 10:15

Forum Hall / Virtual Hall 2

**OS04 - Oral session 4: Infectious complications I**

Chair: Andriyana Bankova, CH

Chair: Oliver Cornely, DE

- |         |  |               |
|---------|--|---------------|
| OS04-01 | <p><b>CAUSES OF DEATHS AFTER HEMATOPOIETIC CELL TRANSPLANTATION IN THE CONTEXT OF LETHAL INFECTIOUS COMPLICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT COD-2 STUDY</b></p> <p><i>Oral Presenter:</i> Jan Styczynski, PL</p>   | 09:00 - 09:09 |
| OS04-02 | <p><b>LISTERIA INFECTION IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: AN INTERNATIONAL CASE-CONTROL STUDY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT</b></p> <p><i>Oral Presenter:</i> Dina Averbuch, IL</p>   | 09:09 - 09:18 |
| OS04-03 | <p><b>MARIBAVIR VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CMV INFECTION (WITH/WITHOUT RESISTANCE) IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: SUBGROUP SAFETY ANALYSIS OF A PHASE 3 STUDY</b></p> <p><i>Oral Presenter:</i> Catherine Cordonnier, FR</p>                    | 09:18 - 09:27 |
| OS04-04 | <p><b>POSOLEUCEL, MULTIVIRUS-SPECIFIC T-CELL (VST) THERAPY, FOR PREVENTION OF CLINICALLY SIGNIFICANT VIRAL INFECTIONS IN ALLOGENEIC TRANSPLANT RECIPIENTS: PERSISTENCE OF VSTS IN AN OPEN-LABEL PHASE 2 TRIAL</b></p> <p><i>Oral Presenter:</i> Sanjeet Singh Dadwal, US</p>           | 09:27 - 09:36 |
| OS04-05 | <p><b>SAFETY AND IMMUNOGENICITY OF HIGH-DOSE INFLUENZA VACCINE IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS</b></p> <p><i>Oral Presenter:</i> Natasha Halasa, US</p>  | 09:36 - 09:45 |
| OS04-06 | <p><b>EASIX FOR PREDICTION OF SEPSIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION</b></p> <p><i>Oral Presenter:</i> Felix Korell, DE</p>   | 09:45 - 09:54 |
| OS04-07 | <p><b>REAL-WORLD OUTCOMES ASSOCIATED WITH LETERMIVIR USE FOR CYTOMEGALOVIRUS (CMV) PRIMARY PROPHYLAXIS IN ALLOGENEIC-HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES</b></p> <p><i>Oral Presenter:</i> Roy F. Chemaly, US</p> | 09:54 - 10:03 |
| OS04-08 | <p><b>UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN METAPNEUMOVIRUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION</b></p> <p><i>Oral Presenter:</i> José Luis Piñana, ES</p>   | 10:03 - 10:12 |

*Nurses Group*

09:00 - 10:15

Panorama / Virtual Hall 3

**NG08 - Disease management***Chair:* Iris Agreiter, IE

NG08-01	<b>AML</b> <i>Speaker:</i> Victoria Potter, GB	09:00 - 09:20
NG08-02	<b>Myeloma</b> <i>Speaker:</i> Nicolas Kint, BE	09:20 - 09:40
NG08-03	<b>Short overview of Bispecifics and CART-cell therapy in Lymphoma and Myeloma</b> <i>Speaker:</i> Ciel De Vriendt, BE	09:40 - 10:00
NG08-04	<b>QA</b>	10:00 - 10:15

*Paediatric Day*

09:00 - 10:15

South Hall 1A+B / Virtual Hall 4

**Paed1 - Paediatrics Diseases Working Party Session***Chair:* Selim Corbacioglu, DE*Chair:* Petr Sedláček, CZ

Paed1-01	<b>Dietrich Niethammer Obituary</b> <i>Speaker:</i> Peter Bader, DE	09:00 - 09:05
Paed1-02	<b>Dietrich Niethammer Award</b> <i>Speaker:</i> Selim Corbacioglu, DE <i>Speaker:</i> Christina Peters, AT	09:05 - 09:10
Paed1-03	<b>Towards Predictable Immune Reconstitution</b> <i>Speaker:</i> Jaap Jan Boelens, US	09:10 - 09:20
Paed1-04	<b>Haploidentical HSCT in Thalassemia with novel conditioning regimen</b> <i>Speaker:</i> Suradej Hongeng, TH	09:20 - 09:30
Paed1-05	<b>Update: Idiopathic Pneumonia Syndrome</b> <i>Speaker:</i> Kenneth Cooke, US	09:30 - 09:40
Paed1-06	<b>Development of novel anti-CD45 drug conjugates as targeted conditioning for SCT and gene therapy</b> <i>Speaker:</i> Persis Amrolia, GB	09:40 - 09:50
Paed1-07	<b>Prospective Multi-center Study of Paediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS): POEM Update</b> <i>Speaker:</i> Kris Mahadeo, US	09:50 - 10:00
Paed1-08	<b>QA</b>	10:00 - 10:15

*Oral Session*

09:00 - 10:15

South Hall 2A+B / Virtual Hall 5

**OS05 - Oral session 5: Non-infectious early and late complications***Chair:* Enric Carreras, ES*Chair:* Claire Horgan, GB

OS05-01	<b>INCREASED EARLY CARDIAC TOXICITY IN PATIENTS</b>	09:00 - 09:09
---------	---	---------------

**UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION COMBINED WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE**

*Oral Presenter:* Amanda I Perez-Valencia, ES

- |         |  |               |
|---------|--|---------------|
| OS05-02 | <b>INCIDENCE, SEVERITY, MANAGEMENT AND OUTCOME OF SINUSOIDAL OBSTRUCTION SYNDROME/VENO-OCCLUSIVE DISEASE (SOS/VOD) IN ALLOGENEIC HSCT IN ADULT PATIENTS: A RETROSPECTIVE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY STUDY</b> | 09:09 - 09:18 |
|         | <i>Oral Presenter:</i> Tapani Ruutu, FI  |               |
| OS05-03 | <b>LIVER STIFFNESS ASSESSED BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION PREDICTS GRAFT-VERSUS-HOST DISEASE AND NON-RELAPSE MORTALITY</b>  | 09:18 - 09:27 |
|         | <i>Oral Presenter:</i> Alba Cabirta, ES  |               |
| OS05-04 | <b>TOWARD IMPROVING DIAGNOSTIC CRITERIA FOR TA-TMA: INTERIM ANALYSIS OF A MULTI-CENTER RETROSPECTIVE REVIEW BY THE TA-TMA WORKING GROUP</b>  | 09:27 - 09:36 |
|         | <i>Oral Presenter:</i> Rafael Duarte, ES   |               |
| OS05-05 | <b>EASIX AND MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY BY THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY</b>   | 09:36 - 09:45 |
|         | <i>Oral Presenter:</i> Olaf Penack, DE   |               |
| OS05-06 | <b>SECOND TRANSPLANTATION FOR GRAFT FAILURE AFTER HAPLOIDENTICAL HSCT: A SURVEY BY THE TRANSPLANT COMPLICATIONS WORKING PARTY OF THE EBMT</b>  | 09:45 - 09:54 |
|         | <i>Oral Presenter:</i> Nadira Duraković, HR  |               |
| OS05-07 | <b>CYTOKINE RELEASE SYNDROME AFTER PERIPHERAL BLOOD HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: TIME OF ONSET MATTERS</b>  | 09:54 - 10:03 |
|         | <i>Oral Presenter:</i> Alberto Hernández Sánchez, ES   |               |
| OS05-08 | <b>SAFETY AND EFFICACY OF DEFIBROTIDE IN LATE-ONSET VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT) FROM THE DEFIFRANCE REGISTRY STUDY</b>                    | 10:03 - 10:15 |
|         | <i>Oral Presenter:</i> Mohamad Mohty, FR   |               |

*Quality Management*

09:00 - 10:15

North Hall / Virtual Hall 6

**QM1 - Center's Session**

*Chair:* Laura Medina, ES

- |        |  |               |
|--------|--|---------------|
| QM1-01 | <b>Accreditation Processes</b>           | 09:00 - 09:20 |
|        | <i>Speaker:</i> Carla Sánchez, ES        |               |
|        | <i>Speaker:</i> Pietro Merli, IT         |               |
|        | <i>Speaker:</i> Vincenzo Iaconianni, IT  |               |
| QM1-02 | <b>Basic quality management concepts</b> | 09:20 - 09:30 |
|        | <i>Speaker:</i> Songül Tepebasi, TR      |               |

QM1-03	<b>Labeling &amp; Traceability</b> <i>Speaker: İlknur Kozanoglu, TR</i>	09:30 - 10:00
QM1-04	<b>QA</b>	10:00 - 10:15

*Educational*  
09:00 - 10:00

Terrace 2A

**E6 - Biology and treatment of chronic GVHD***Chair: Pavel Žák, CZ**Chair: Hildegard Greinix, AT*

E6-01	<b>Introduction</b> <i>Speaker: Pavel Žák, CZ</i>	09:00 - 09:05
E6-02	<b>Novel insights into the biology of chronic GVHD</b> <i>Speaker: Bruce Blazar, US</i>	09:05 - 09:19
E6-03	<b>Update of NIH cGvHD conference 2020</b> <i>Speaker: Steve Pavletic, US</i>	09:19 - 09:34
E6-04	<b>Sclerotic organ manifestations</b> <i>Speaker: Zinaida Peric, HR</i>	09:34 - 09:50
E6-05	<b>Conclusions</b> <i>Speaker: Hildegard Greinix, AT</i>	09:50 - 10:00

*Educational*  
09:00 - 10:01

Terrace 2B

**E7 - Lymphomas***Chair: Marek Trněný, CZ**Chair: Bertram Glass, DE*

E7-01	<b>Introduction</b> <i>Speaker: Marek Trněný, CZ</i>	09:00 - 09:05
E7-02	<b>The place of transplantation in Hodgkin Lymphoma in the context of targeted immunotherapy (CPI, MoAb conjugates)</b> <i>Speaker: Anna Sureda, ES</i>	09:05 - 09:21
E7-03	<b>Time to redefine the role of auto/allo SCT in DLBCL in the context of CAR-T?</b> <i>Speaker: Silvia Montoto, GB</i>	09:21 - 09:36
E7-04	<b>Cellular therapies in the management of Mantle cell lymphoma</b> <i>Speaker: Avichai Shimoni, IL</i>	09:36 - 09:51
E7-05	<b>Conclusions</b> <i>Speaker: Bertram Glass, DE</i>	09:51 - 10:01

*Breaks*  
10:15 - 10:45

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition**



*Industrial Theatre*

10:20 - 10:40

North Hall / Virtual Hall 6

**IT4 - Industry Theatre - Breaking news in PNH treatment: how to improve life with C3i | Sobi**

IT4-01	<b>Changing clinical PNH practice - from innovation to trial findings</b>	10:20 - 10:20
IT4-01-01	<b>MoA, Key data/features/ 'message' of Aspaveli, QoL data (plus intro and closing statement for after Ilene)</b> <i>Speaker:</i> Pete Hillmen, GB	10:20 - 10:27
IT4-02	<b>Making a difference for people living with PNH</b>	10:27 - 10:27
IT4-02-01	<b>Real world experience patient cases (x2). Priority for case: Hb 10-12, suffers from anaemia.</b> <i>Speaker:</i> Ilene Weitz, US <i>Speaker:</i> Brian Mulherin, US	10:27 - 10:34

*Working Party Session*

10:45 - 12:00

Congress Hall / Virtual Hall 1

**CTIWP - Cellular Therapy and Immunobiology Working Party session***Chair:* Christian Chabannon, FR

CTIWP-01	<b>CTIWP Activities: End of mandate statement</b> <i>Speaker:</i> Christian Chabannon, FR	10:45 - 11:05
CTIWP-02	<b>Presentation of the Jon van Rood Award</b>	11:05 - 11:08
CTIWP-03	<b>INVARIANT NATURAL KILLER T-CELL SUBSETS HAVE DIVERSE GRAFT-VERSUS-HOST-DISEASE-PREVENTING AND ANTITUMOR EFFECTS</b> <i>Oral Presenter:</i> Kristina Maas-Bauer, DE	11:08 - 11:25
CTIWP-04	<b>Keynote lecture: Gene therapy options for globin disorders</b> <i>Speaker:</i> Franco Locatelli, IT	11:25 - 11:45
CTIWP-05	<b>Q&amp;A</b>	11:45 - 12:00

*Oral Session*

10:45 - 12:00

Forum Hall / Virtual Hall 2

**OS06 - Oral session 6: Infectious complications II, COVID***Chair:* Malgorzata Mikulska, IT*Chair:* Jan Styczynski, PL

OS06-01	<b>HUMORAL IMMUNE RESPONSE AND KINETICS FOLLOWING DUAL VACCINATION WITH BNT162B2 IN PATIENTS AFTER ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION</b> <i>Oral Presenter:</i> Stefanie Munder, DE	10:45 - 10:54
OS06-02	<b>COVID-19 INFECTION OF HSCT RECIPIENTS IS ASSOCIATED WITH HIGH MORTALITY BUT NO DETECTABLE CYTOKINE STORM AT PRESENTATION.</b> <i>Oral Presenter:</i> Giovanna Lucchini, GB	10:54 - 11:03
OS06-03	<b>ANTIBODY RESPONSE TO A THIRD SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</b>	11:03 - 11:12

*Oral Presenter: Andriyana Bankova, CH*

OS06-04	<b>REDUCED IMMUNOGENICITY OF A THIRD COVID-19 VACCINATION IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION</b>	11:12 - 11:21
	<i>Oral Presenter: Sigrun Einarsdottir, SE</i>	
OS06-05	<b>DYNAMICS OF ANTIBODY RESPONSE TO BNT162B2 MRNA COVID-19 VACCINE IN RECIPIENTS OF HEMATOPOIETIC STEM CELL TRANSPLANT COMPARED TO HEALTHY CONTROLS: A LONGITUDINAL PROSPECTIVE STUDY</b>	11:21 - 11:30
	<i>Oral Presenter: Francesco Saraceni, IT</i>	
OS06-06	<b>LONGITUDINAL STUDY OF THE HUMORAL AND CELLULAR RESPONSE DEVELOPED IN ALLOSCT PATIENTS DURING A TWO-DOSE VACCINATION SCHEDULE AGAINST COVID-19</b>	11:30 - 11:39
	<i>Oral Presenter: Magdalena Corona de Lapuerta, ES</i>	
OS06-07	<b>EVALUATION OF T AND B LYMPHOCYTES SUBSETS AFTER TWO DOSES OF BNT162B2 ANTI-SARS-COV-2 MRNA VACCINATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS.</b>	11:39 - 11:48
	<i>Oral Presenter: Immacolata Attolico, IT</i>	
OS06-08	<b>ANTIVIRAL T-CELL FREQUENCIES IN A HEALTHY POPULATION: REFERENCE VALUES FOR EVALUATING ANTIVIRAL IMMUNE CELL PROFILES IN IMMUNOCOMPROMISED PATIENTS</b>	11:48 - 11:57
	<i>Oral Presenter: Agnes Bonifacius, DE</i>	

*Nurses Group*

10:45 - 12:00

Panorama / Virtual Hall 3

**NG09 - Research session 1: Best nursing research abstracts***Chair: Isabel Salcedo, ES**Chair: Sabine Valenta, CH*

NG09-01	<b>REHABILITATION OF PATIENTS UNDERGOING ALLOGENEIC NON-MYELOABLATIVE STEM CELL TRANSPLANTATION: A SINGLE ARM LONGITUDINAL STUDY</b>	10:45 - 11:05
	<i>Oral Presenter: Astrid Lindman, DK</i>	
NG09-02	<b>INFORMAL CAREGIVER OF THE HSCT RECIPIENT: PROFILE, MENTAL HEALTH AND QUALITY OF LIFE IMPACT. PRELIMINARY RESULTS IN A THIRD-LEVEL SPANISH HOSPITAL</b>	11:05 - 11:25
	<i>Oral Presenter: Arianna Rosich-Soteras, ES</i>	
NG09-03	<b>VIRTUAL REALITY IN BONE MARROW BIOPSY AND ASPIRATION: SAFETY AND USER EXPERIENCE</b>	11:25 - 11:45
	<i>Oral Presenter: Marthe Bellens, BE</i>	
NG09-04	<b>QA</b>	11:45 - 12:00

*Paediatric Day*

10:45 - 12:00

South Hall 1A+B / Virtual Hall 4

**Paed2 - Inborn Errors Working Party session***Chair:* Bénédicte Neven, FR*Chair:* Rob Wynn, GB

Paed2-01	<b>HSCT in HLH: Challenges and progress</b> <i>Speaker:</i> Despina Moshous, FR	10:45 - 11:05
Paed2-02	<b>Update on the biological and clinical outcome of ex-vivo gene therapy for MPSI Hurler patients</b> <i>Speaker:</i> Maria Esther Bernardo, IT	11:05 - 11:25
Paed2-03	<b>How can we approach HSCT in AYAs with inborn errors of immunity?</b> <i>Speaker:</i> Michael Albert, DE	11:25 - 11:45
Paed2-04	<b>QA</b>	11:45 - 12:00

*How do I... ?*

10:45 - 12:00

South Hall 2A+B / Virtual Hall 5

**HDI5 - How Do I... conduct effective differential diagnosis of VOD from other post-HSCT complications? - This session is supported by Jazz Pharmaceuticals. Jazz Pharmaceuticals have suggested this topic and have had no subsequent involvement in the development, content or organisation of this session.**

*Chair:* Pavel Jindra, CZ

HDI5-01	<b>How do I use imaging techniques?</b> <i>Speaker:</i> Francesca Bonifazi, IT	10:45 - 11:05
HDI5-02	<b>How do we use biomarkers?</b> <i>Speaker:</i> Thomas Luft, DE	11:05 - 11:25
HDI5-03	<b>How do I diagnose VOD in paediatric patients?</b> <i>Speaker:</i> Selim Corbacioglu, DE	11:25 - 11:45
	<b>QA</b>	11:45 - 12:00

*Quality Management*

10:45 - 12:00

North Hall / Virtual Hall 6

**QM2 - 8th Edition of the Standards***Chair:* Isabel Sanchez-Ortega, ES

QM2-01	<b>Clinical standards</b> <i>Speaker:</i> Kim Orchard, GB	10:45 - 10:57
QM2-02	<b>Collections Standards</b> <i>Speaker:</i> Nina Worel, AT	10:57 - 11:09
QM2-03	<b>Processing Standards</b> <i>Speaker:</i> Ivan van Riet, BE	11:09 - 11:21
QM2-04	<b>Quality Management Standards</b> <i>Speaker:</i> Anne Emmett, GB	11:21 - 11:33
QM2-05	<b>Immune Effector Cells Standards</b> <i>Speaker:</i> Riccardo Saccardi, IT	11:33 - 11:45
QM2-06	<b>QA</b>	11:45 - 12:00

*Educational*

10:45 - 11:45

Terrace 2A

**E8 - Biology and treatment of acute GVHD***Chair:* Luděk Raida, CZ*Chair:* Olaf Penack, DE

E8-01	<b>Introduction</b> <i>Speaker:</i> Luděk Raida, CZ	10:45 - 10:50
E8-02	<b>Endothelial dysfunction in aGVHD</b> <i>Speaker:</i> Thomas Luft, DE	10:50 - 11:05
E8-03	<b>Novel insights into the biology of steroid-refractory gastrointestinal</b> <i>Speaker:</i> Shernan Holtan, US	11:05 - 11:20
E8-04	<b>Biology-driven recent approaches to the treatment of aGVHD</b> <i>Speaker:</i> Robert Zeiser, DE	11:20 - 11:35
E8-05	<b>Conclusions</b> <i>Speaker:</i> Olaf Penack, DE	11:35 - 11:45

*Joint Session*

10:45 - 12:15

Terrace 2B

**JS01 - Joint session EBMT - ASTCT - CIBMTR - APBMT - LABMT: Access to novel cell therapies such as CAR T Cells: challenges and strategies***Chair:* Brenda Sandmaier, US*Chair:* John Wingard, US*Chair:* Shinichiro Okamoto, JP*Chair:* Gregorio Jaimovich, AR*Chair:* Nicolaus Kröger, DE

JS01-01	<b>US perspective (ASTCT)</b> <i>Speaker:</i> Miguel Angel Perales, US	10:45 - 11:00
JS01-02	<b>CIBMTR perspective</b> <i>Speaker:</i> Jeffery Auletta, US	11:00 - 11:15
JS01-03	<b>European perspective</b> <i>Speaker:</i> Christian Chabannon, FR	11:15 - 11:30
JS01-04	<b>Asian perspective</b> <i>Speaker:</i> Shinichiro Okamoto, JP	11:30 - 11:45
JS01-05	<b>Latin America perspective</b> <i>Speaker:</i> Nelson Hamerschlak, BR	11:45 - 12:00
JS01-06	<b>Discussion</b>	12:00 - 12:15

*Workshop*

11:50 - 12:45

Terrace 2A

**W6 - Can we limit infectious complications in transplant setting?***Chair:* Vanda Chrenkova, CZ*Chair:* Jan Styczynski, PL

W6-01	<b>Introduction</b> <i>Speaker:</i> Vanda Chrenkova, CZ	11:50 - 11:55
-------	--	---------------

W6-02	<b>Current diagnosis and management of invasive fungal diseases</b> <i>Speaker:</i> Malgorzata Mikulska, IT	11:55 - 12:10
W6-03	<b>Pneumonia after transplantation</b> <i>Speaker:</i> Montserrat Rovira, ES	12:10 - 12:25
W6-04	<b>Rare infections after transplantation</b> <i>Speaker:</i> Montserrat Rovira, ES	12:25 - 12:40
W6-05	<b>Conclusions</b> <i>Speaker:</i> Jan Styczynski, PL	12:40 - 12:45

*Breaks*

12:00 - 12:45

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition***Industry Symposium*

12:45 - 13:45

Congress Hall / Virtual Hall 1

**IS27 - State of the art update for managing patients with relapsed/refractory (RRMM) multiple myeloma and future potential of cellular therapies - Janssen Industry Symposium***Chair:* Mohamad Mohty, FR

IS27-01	<b>Welcome and introduction</b>	12:45 - 12:50
IS27-02	<b>Current treatment options for managing patients with relapsed refractory multiple myeloma</b> <i>Speaker:</i> Paula Rodríguez Otero, ES	12:50 - 13:10
IS27-03	<b>Future directions for triple-class exposed patients with MM</b> <i>Speaker:</i> Niels van de Donk, NL	13:10 - 13:30
IS27-04	<b>Panel discussion with Q&amp;A</b>	13:30 - 13:45

*Industry Symposium*

12:45 - 13:45

Forum Hall / Virtual Hall 2

**IS28 - Prophylaxis versus diagnostic-driven therapy: Best-practice approaches for treating IMD in haematology patients - Pfizer Industry Symposium***Chair:* Alexander Schauwvlieghe, BE

IS28-01	<b>Welcome and introduction</b> <i>Speaker:</i> Alexander Schauwvlieghe, BE	12:45 - 12:50
IS28-02	<b>Aspergillosis in the hematology unit from an ID perspective: Early suspicion and diagnostic-driven management</b> <i>Speaker:</i> Isabel Ruiz-Camps, ES	12:50 - 13:05
IS28-03	<b>Aspergillosis in the haematology unit: Complex patients and prophylaxis</b> <i>Speaker:</i> Alexander Schauwvlieghe, BE	13:05 - 13:20
IS28-04	<b>The changing therapeutic landscape of IMD: The role of existing and upcoming antifungals</b> <i>Speaker:</i> Cornelia Lass-Flörl, AT	13:20 - 13:36
IS28-05	<b>Discussion, Q&amp;A and close</b>	13:36 - 13:45

*Statistics*

12:45 - 13:45

South Hall 2A+B / Virtual Hall 5

**Stats2 - Statistical Symposium***Chair:* Ariane Boumendil, FR*Chair:* Hein Putter, NL

Stats2-1	<b>Answering causal questions with observational data</b> <i>Speaker:</i> Saskia Le Cessie, NL	12:45 - 13:00
Stats2-2	<b>Design, analysis and description issues in haematological studies</b> <i>Speaker:</i> Richard Szydlo, GB	13:00 - 13:15
Stats2-3	<b>Towards cGRFS and other new endpoints: problems and solutions</b> <i>Speaker:</i> Liesbeth de Wreede, NL	13:15 - 13:30
Stats2-4	<b>QA</b>	13:30 - 13:45

*Quality Management*

12:45 - 13:45

North Hall / Virtual Hall 6

**QM3 - Boot camp on Accreditation for IEC***Chair:* Alvaro Urbano-Ispizua, ES

QM3-01	<b>IEC Collection Perspective</b> <i>Speaker:</i> Miquel Lozano, ES	12:45 - 13:00
QM3-02	<b>IEC - Processing Perspective</b> <i>Speaker:</i> Sandra Loaiza, GB	13:00 - 13:15
QM3-03	<b>IEC Clinical Perspective</b> <i>Speaker:</i> Robin Sanderson, GB	13:15 - 13:30
QM3-04	<b>QA</b>	13:30 - 13:45

*Industry Symposium*

12:45 - 13:45

MTE

**MTE-S-02 - Meet the Expert lunch session by Therakos-Mallinckrodt***Chair:* Zinaida Peric, HR

MTE-S-02-01	<b>Case study discussion - combinatorial strategies using ECP in the treatment of GvHD</b> <i>Speaker:</i> Zinaida Peric, HR	12:45 - 13:45
-------------	---	---------------

*Breaks*

13:45 - 14:15

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition***Plenary Session*

14:15 - 15:30

Congress Hall / Virtual Hall 1

**P2 - Optimisation of transplant outcome by modifiable pre- and peri-transplant variables***Chair:* Petr Cetkovský, CZ*Chair:* Frédéric Baron, BE

P2-01	<b>GVHD prophylaxis: post-transplant CY versus ATG, where do we stand?</b>	14:15 - 14:35
-------	--	---------------

	<i>Speaker:</i> Mohamad Mohty, FR	
P2-02	<b>Stem cell and donor source - return to the bone marrow or cord blood: for whom and when?</b> <i>Speaker:</i> Udo Holtick, DE	14:35 - 14:55
P2-03	<b>Conditioning &amp; relapse prevention: is there sufficient evidence for personalized conditioning and posttransplant maintenance therapy?</b> <i>Speaker:</i> Francesca Bonifazi, IT	14:55 - 15:15
P2-04	<b>QA</b>	15:15 - 15:30

*Oral Session*  
14:15 - 15:30

Forum Hall / Virtual Hall 2

**OS07 - Oral session 7: MRD, chimerism, relapse, and immune reconstitution**

*Chair:* Desiree Kunadt, DE

*Chair:* Katrine Kielsen, DK

OS07-01	<b>MEASURABLE-RESIDUAL DISEASE GUIDED TREATMENT WITH AZACITIDINE IN MDS/AML PATIENTS AT IMMINENT RISK OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: RESULTS OF THE PROSPECTIVE RELAZA2 TRIAL</b> <i>Oral Presenter:</i> Uwe Platzbecker, DE	14:15 - 14:24
OS07-02	<b>LATE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA - A RETROSPECTIVE STUDY FROM THE FRENCH SOCIETY FOR STEM CELL TRANSPLANTATION (SFGM-TC)</b> <i>Oral Presenter:</i> Eléonore Kaphan, FR	14:24 - 14:33
OS07-03	<b>AZACITIDINE, LENALIDOMIDE AND DLI AS SALVAGE THERAPY FOR MDS, AML AND CMML RELAPSE AFTER ALLOGENEIC SCT - FINAL RESULTS OF THE PROSPECTIVE AZALENA-TRIAL (NCT02472691)</b> <i>Oral Presenter:</i> Thomas Schroeder, DE	14:33 - 14:42
OS07-04	<b>COMBINING BLINATUMOMAB AND DONOR LYMPHOCYTE INFUSION IN B-ALL PATIENTS RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY OF THE SFGM-TC.</b> <i>Oral Presenter:</i> Paul Chauvet, FR	14:42 - 14:51
OS07-05	<b>TABELECLEUCEL FOR EPSTEIN-BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL (HCT) OR SOLID ORGAN TRANSPLANT (SOT) AFTER FAILURE OF RITUXIMAB +/- CHEMOTHERAPY (ALLELE)</b> <i>Oral Presenter:</i> Susan Prockop, US	14:51 - 15:00
OS07-06	<b>GENOMIC DYSFUNCTION OF HUMAN LEUKOCYTE ANTIGEN DIVERSITY AS DRIVER OF POST-TRANSPLANT ACUTE MYELOID LEUKEMIA RECURRENCE</b> <i>Oral Presenter:</i> Simona Pagliuca, FR	15:00 - 15:09
OS07-07	<b>PROSPECTIVE PHASE II STUDY OF PREEMPTIVE CHIMERISM-DRIVEN REDUCTION OF IMMUNOSUPPRESSION AFTER NON-MYELOABLATIVE CONDITIONING – SUBANALYSIS OF PATIENTS WITH</b>	15:09 - 15:18

**MYELOID NEOPLASMS - EUDRACT #: 2007-002420-15***Oral Presenter:* Saskia Hell, DE

- OS07-08      **THE IMMUNOLOGICAL SYNOPSIS OF ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: PLEIOTROPY OF IMMUNE ESCAPE**      15:18 - 15:27  
*Oral Presenter:* Simona Pagliuca, FR

*Nurses Group*

14:15 - 15:30

Panorama / Virtual Hall 3

**NG10 - Paediatrics Session - Communication challenges in paediatric HSCT nursing***Chair:* Hilda Mekelenkamp, NL*Chair:* Marjola Gjergji, IT

- NG10-01      **Words as medicine**      14:15 - 14:35  
*Speaker:* Renee Gregson, NL
- NG10-02      **QA - part I**      14:35 - 14:40
- NG10-03      **Communication over language barriers - Examples from paediatric oncology**      14:40 - 15:00  
*Speaker:* Pernilla Pergert, SE
- NG10-04      **QA - part II**      15:00 - 15:05
- NG10-05      **Debate**      15:05 - 15:30  
*Speaker:* Hilda Mekelenkamp, NL  
*Speaker:* Eugenia Trigoso, ES  
*Speaker:* Marjola Gjergji, IT

*Paediatric Day*

14:15 - 15:30

South Hall 1A+B / Virtual Hall 4

**Paed3 - Paediatric Diseases Oral Session***Chair:* Selim Corbacioglu, DE*Chair:* Jean-Hugues Dalle, FR

- Paed3-05      **DECISION-MAKING ABOUT HSCT IN PATIENTS WITH HEMOGLOBINOPATHIES, A PDPW/IEWP SCENARIO-BASED SURVEY ON PHYSICIANS' PERSPECTIVES.**      14:15 - 14:23  
*Oral Presenter:* Hilda Mekelenkamp, NL
- Paed3-01      **EFFECT OF KIR MISMATCH AND NK CELL DOSE ON THE INCIDENCE OF LEUKEMIA RELAPSE AFTER ALFA/BETA T CELL-DEPLETED HAPLO HSCT**      14:23 - 14:31  
*Oral Presenter:* Svetlana Glushkova, RU
- Paed3-02      **MATCHED UNRELATED DONOR TRANSPLANTATION WITH ATG VERSUS HAPLOIDENTICAL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN WITH ACUTE MYELOID LEUKEMIA: A STUDY ON BEHALF OF THE PDWP-EBMT**      14:31 - 14:39  
*Oral Presenter:* Annalisa Ruggeri, IT
- Paed3-03      **PREDICTORS OF LONG TERM RESPONSE WITH CD28-BASED CD19 CAR T-CELLS IN CHILDREN AND YOUNG ADULTS WITH B-ALL**      14:39 - 14:47  
*Oral Presenter:* Elad Jacoby, IL



Paed3-04	<b>T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A COMPARISON OF TRANSPLANT OUTCOMES BETWEEN CD3+/CD19+ AND TCRAB+/CD19+ DEPLETION PLATFORMS.</b> <i>Oral Presenter:</i> MARTA GONZALEZ VICENT, ES	14:47 - 14:55
Paed3-06	<b>IN CHILDREN WITH SICKLE CELL ANEMIA AND HYPERSPLENISM, PARTIAL VERSUS TOTAL SPLENECTOMY BEFORE STEM CELL TRANSPLANTATION PRESERVES SPLEEN FUNCTION</b> <i>Oral Presenter:</i> Françoise Bernaudin, FR	14:55 - 15:03
Paed3-07	<b>IMPACT OF INCLUDING ABATACEPT FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMOGLOBINOPATHY.</b> <i>Oral Presenter:</i> Niketa Shah, US	15:03 - 15:11
Paed3-08	<b>100 HEMATOPOIETIC CELL TRANSPLANTS FOR SICKLE CELL DISEASE: LESSONS LEARNT</b> <i>Oral Presenter:</i> Gaurav Kharya, IN	15:11 - 15:19
Paed3-09	<b>HLA IDENTICAL RELATED CORD BLOOD TRANSPLANTATION FOR PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA AND SICKLE CELL DISEASE</b> <i>Oral Presenter:</i> Vanderson Rocha, BR	15:19 - 15:27

*General*

14:15 - 15:15

South Hall 2A+B / Virtual Hall 5

**GS3 - General Assembly***Chair:* Nicolaus Kröger, DE*Chair:* Harry Dolstra, NL*Chair:* John Snowden, GB

GS3-01	<b>President's Report</b> <i>Speaker:</i> Nicolaus Kröger, DE	14:15 - 14:40
GS3-02	<b>Treasurer's Financial Report</b> <i>Speaker:</i> Harry Dolstra, NL	14:40 - 14:50
GS3-03	<b>Secretary's Report</b> <i>Speaker:</i> John Snowden, GB	14:50 - 15:00
GS3-04	<b>Election Results 2022</b> <i>Speaker:</i> John Snowden, GB	15:00 - 15:05
GS3-05	<b>Outgoing Board members</b> <i>Speaker:</i> Nicolaus Kröger, DE	15:05 - 15:10
GS3-06	<b>QA</b>	15:10 - 15:15

*Quality Management*

14:15 - 15:30

North Hall / Virtual Hall 6

**QM4 - Inspectors Session***Chair:* Ivana Ferrero, IT

QM4-01	<b>JACIE Activity &amp; Updates on the impact of COVID</b> <i>Speaker:</i> Raquel Espada, ES	14:15 - 14:25
--------	---	---------------

QM4-02a	<b>Inspectors experience inspecting the different accreditation processes: Virtual Inspections</b> <i>Speaker:</i> Frédéric Bernard, FR	14:25 - 14:32
QM4-02b	<b>The Jacie inspection through the eyes of an inspector: On-Site and Hybrid Inspections</b> <i>Speaker:</i> Victoria Bordon, BE	14:32 - 14:39
QM4-02c	<b>Inspectors experience inspecting the different accreditation processes: Short Process</b> <i>Speaker:</i> Korinne Di Leo, IT	14:39 - 14:45
QM4-03	<b>Volunteers update</b> <i>Speaker:</i> Anna Pasztor, ES	14:45 - 14:55
QM4-04	<b>JACIE &amp; Data safety</b> <i>Speaker:</i> Iris Bargalló, ES	14:55 - 15:05
QM4-05	<b>Presentation of the QMC</b> <i>Speaker:</i> Renza Monteleone, IT	15:05 - 15:10
QM4-06	<b>Presentation of the JIC</b> <i>Speaker:</i> Tuula Rintala, GB	15:10 - 15:15
QM4-07	<b>QA</b>	15:15 - 15:30

*Educational*

14:15 - 15:15

Terrace 2A

**E9 - Autologous immune cells in cellular therapy***Chair:* Robert Pytlík, CZ*Chair:* Annalisa Ruggeri, IT

E9-01	<b>Introduction</b> <i>Speaker:</i> Robert Pytlík, CZ	14:15 - 14:20
E9-02	<b>Use of autologous cells as a source for the cellular therapies for malignant diseases</b> <i>Speaker:</i> Christian Chabannon, FR	14:20 - 14:35
E9-03	<b>Potential of NK cells for the relapse control</b> <i>Speaker:</i> Monika Holubová, CZ	14:35 - 14:50
E9-04	<b>Dendritic Cell-Based Immunotherapy for AML</b> <i>Speaker:</i> Sébastien Anguille, BE	14:50 - 15:05
E9-05	<b>Conclusions</b> <i>Speaker:</i> Annalisa Ruggeri, IT	15:05 - 15:15

*Workshop*

14:15 - 15:15

Terrace 2B

**W7 - ABC of immune system I***Chair:* Adam Kuba, CZ*Chair:* Satu Mustjoki, FI

W7-01	<b>Introduction</b> <i>Speaker:</i> Adam Kuba, CZ	14:15 - 14:20
W7-02	<b>Mucosa-associated immune system</b>	14:20 - 14:35

	<i>Speaker:</i> Ronjon Chakraverty, GB	
W7-03	<b>Role of GIT virome in immune response</b> <i>Speaker:</i> Jerome Legoff, FR	14:35 - 14:50
W7-04	<b>Microbiota and mucosal immunity effects on HSCT outcomes</b> <i>Speaker:</i> Marcel van den Brink, US	14:50 - 15:05
W7-05	<b>Conclusions</b> <i>Speaker:</i> Satu Mustjoki, FI	15:05 - 15:15

*Breaks*

15:30 - 16:00

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition***Industrial Theatre*

15:35 - 15:55

North Hall / Virtual Hall 6

**IT6 - Industry Theatre: A 1-year Experience of the Multi-Procedural Amicus Blue™ Online ECP System in Routine Use by Fresenius Kabi**

IT6_1	<b>A 1-year Experience of the Multi-Procedural Amicus Blue™ Online ECP System in Routine Use</b> <i>Speaker:</i> Tarik Kanouni, FR	15:35 - 15:35
-------	---	---------------

*Plenary Session*

16:00 - 17:15

Congress Hall / Virtual Hall 1

**P3 - Does achievement of MRD-negative disease after HSCT improve survival?***Chair:* Michael Doubek, CZ*Chair:* Nicolaus Kröger, DE

P3-01	<b>Acute myeloid leukemia</b> <i>Speaker:</i> Arnon Nagler, IL	16:00 - 16:20
P3-02	<b>Acute lymphoblastic leukemia</b> <i>Speaker:</i> Nicola Gökbuget, DE	16:20 - 16:40
P3-03	<b>Myeloma</b> <i>Speaker:</i> Francesca Gay, IT	16:40 - 17:00
P3-04	<b>QA</b>	17:00 - 17:15

*Working Party Session*

16:00 - 17:15

Forum Hall / Virtual Hall 2

**TCWP - Transplant Complications Working Party session***Chair:* Zinaida Peric, HR*Chair:* Ivan Moiseev, RU

TCWP-1	<b>Endothelial syndromes in HSCT and Cellular therapy</b> <i>Speaker:</i> Christian Koenecke, DE	16:00 - 16:15
TCWP-2	<b>Current Clinical Practice in Chronic GVHD</b> <i>Speaker:</i> Olaf Penack, DE	16:15 - 16:30
TCWP-3	<b>Late Effects in HSCT Survivors - What's new</b> <i>Speaker:</i> Hélène Schoemans, BE	16:30 - 16:45

TCWP-4	<b>Modern Technological Approaches in HSCT complications</b> <i>Speaker:</i> Grzegorz Basak, PL	16:45 - 17:00
TCWP-5 D	<b>Discussion</b>	17:00 - 17:15

*Nurses Group*

16:00 - 17:15

Panorama / Virtual Hall 3

**NG11 - How do I... Understand blood counts?***Chair:* Teija Schröder, FI*Chair:* Petra Vodičková, CZ

NG11-01	<b>Liver diseases in laboratory. What are the main findings in haematology patients?</b> <i>Speaker:</i> Katerina Steinerová, CZ	16:00 - 16:15
NG11-02	<b>Renal diseases in the laboratory. What are the main findings in haematology patients?</b> <i>Speaker:</i> Tereza Dekojová, CZ	16:15 - 16:30
NG11-03	<b>Full blood counts</b> <i>Speaker:</i> Alexandra Jungová, CZ	16:30 - 16:45
NG11-04	<b>Crossmatching</b> <i>Speaker:</i> Veronika Bergerová, CZ	16:45 - 17:00
NG11-05	<b>QA</b>	17:00 - 17:15

*Paediatric Day*

16:00 - 17:15

South Hall 1A+B / Virtual Hall 4

**Paed4 - Inborn Errors Oral Session***Chair:* Bénédicte Neven, FR*Chair:* Michael Albert, DE

Paed4-01	<b>A RANDOMISED CLINICAL PHASE 2 TRIAL TO COMPARE TREOSULFAN WITH BUSULFAN BASED CONDITIONING PRIOR TO ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH NON-MALIGNANT DISEASES.</b> <i>Oral Presenter:</i> Karl-Walter Sykora, DE	16:00 - 16:09
Paed4-02	<b>AUTOIMMUNE CYTOPENIA AFTER HAEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH INBORN ERRORS OF IMMUNITY: A MULTICENTRE RETROSPECTIVE COHORT ANALYSIS</b> <i>Oral Presenter:</i> Su Han Lum, GB	16:09 - 16:18
Paed4-03	<b>RADIO-IMMUNOTHERAPY WITH <sup>90</sup>YTTRIUM LABELLED ANTI-CD66 MONOCLONAL ANTIBODY IN CHILDREN WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA: A UK PHASE 1 STUDY</b> <i>Oral Presenter:</i> Robert Chiesa, GB	16:18 - 16:27
Paed4-04	<b>POPULATION PHARMACOKINETIC ANALYSIS OF ALEMTUZUMAB IN CHILDREN WITH NON-MALIGNANT DISEASES UNDERGOING ALLOGENEIC HSCT: TOWARDS MODEL INFORMED PRECISION DOSING</b> <i>Oral Presenter:</i> Federica R. Achini-Gutzwiller, CH	16:27 - 16:36

Paed4-05	<b>PREPAD: PREDICTING PATIENT DEATH AFTER ALLOHSCT FOR INBORN ERRORS USING MACHINE LEARNING, AN IEWP STUDY</b> <i>Oral Presenter:</i> Erik G J von Asmuth, NL	16:36 - 16:45
Paed4-06	<b>ALTERNATIVE DONOR STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN 37 CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY (SCID)</b> <i>Oral Presenter:</i> Rafaella Muratori, BR	16:45 - 16:54
Paed4-07	<b>HSCT OUTCOME IN HYPOMORPHIC RAG DEFICIENCIES: AN IEWP/PIDTC STUDY</b> <i>Oral Presenter:</i> Catharina Schuetz, DE	16:54 - 17:03
Paed4-08	<b>CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELL GENE THERAPY IN MPSIIIA</b> <i>Oral Presenter:</i> Jane Louise Kinsella, GB	17:03 - 17:12

*Oral Session*

16:00 - 17:15

South Hall 2A+B / Virtual Hall 5

**OS08 - Oral session 8: CAR-T I***Chair:* Maria-Luisa Schubert, DE*Chair:* Frantisek Folber, CZ

OS08-01	<b>LONG-TERM FOLLOW-UP ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL)</b> <i>Oral Presenter:</i> Julio Chavez, US	16:00 - 16:09
OS08-02	<b>PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): 1-YEAR FOLLOW-UP OF ZUMA-1 COHORT 6 (C6)</b> <i>Oral Presenter:</i> Olalekan O. Oluwole, US	16:09 - 16:18
OS08-03	<b>PRIMARY CD33-CAR-NK CELLS EFFICIENTLY TARGET ACUTE MYELOID LEUKEMIA</b> <i>Oral Presenter:</i> Nawid Albinger, DE	16:18 - 16:27
OS08-04	<b>STEM CELL BOOST FOR PERSISTENT CYTOPENIA AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A GERMAN LYMPHOMA ALLIANCE (GLA) STUDY</b> <i>Oral Presenter:</i> Nico Gagelmann, DE	16:27 - 16:36
OS08-05	<b>SUPERIORITY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN SECOND-LINE (2L) LARGE B-CELL LYMPHOMA (LBCL) IN THE ELDERLY</b> <i>Oral Presenter:</i> Tom van Meerten, NL	16:36 - 16:45
OS08-06	<b>ENHANCING SLAMF7 CAR T CELL PRODUCTION BY PREVENTION OF FATRICIDE</b> <i>Oral Presenter:</i> Sabrina Prommersberger, DE	16:45 - 16:54
OS08-07	<b>TWO-YEAR FOLLOW-UP OF TRANSCEND NHL 001 (TRANSCEND), A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL(LISO-CEL) IN RELAPSED</b>	16:54 - 17:03

**OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMAS (LBCL)**

*Oral Presenter:* Jeremy Abramson, US

- OS08-08      **ALLOGENEIC CD19-CAR T CELLS: A PROMISING TREATMENT FOR PEDIATRIC PATIENTS WITH HIGHLY REFRACTORY BCP-ALL RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT (ALLO-HSCT)**      17:03 - 17:12  
*Oral Presenter:* Francesca Del Bufalo, IT

*Oral Session*

16:00 - 17:15

North Hall / Virtual Hall 6

**OS09 - Oral session 9: Cellular therapies other than CARs, cell-based immune therapies, stem cell engineering**

*Chair:* Monika Holubová, CZ

*Chair:* Eva Wagner, DE

- OS09-01      **OFF-THE-SHELF INVARIANT NATURAL KILLER T CELL IMMUNOTHERAPY IS FEASIBLE, SAFE AND PROMOTES REGULATORY AND CYTOTOXIC HOST IMMUNE CELLS IN THE DOG**      16:00 - 16:09  
*Oral Presenter:* Antonia Rotolo, US
- OS09-02      **EXPANSION OF PHENOTYPICALLY SENESCENT CD57+ CD8 T CELLS IS ASSOCIATED WITH IMPAIRED IMMUNOCOMPETENCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**      16:09 - 16:18  
*Oral Presenter:* Sarah Morin, CH
- OS09-03      **MULTISTATE ANALYSIS OF ALLOGENEIC HSCT IN PATIENTS  $\geq$  70 YEARS COMPARED TO POPULATION MORTALITY BASED ON THE GERMAN REGISTRY FOR STEM CELL TRANSPLANTATION (DRST)**      16:18 - 16:27  
*Oral Presenter:* Jan Frederic Weller, DE
- OS09-04      **A PHASE 1/2A STUDY OF DECIDUAL STROMAL CELLS FOR THE TREATMENT OF COVID-19 ARDS.**      16:27 - 16:36  
*Oral Presenter:* Igor Novitzky-Basso, CA
- OS09-05      **THE IMPACT OF DONOR-SPECIFIC ANTIBODIES PRESENCE ON THE OUTCOME POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SURVEY FROM A SINGLE CENTER.**      16:36 - 16:45  
*Oral Presenter:* Sabrina Giammarco, IT
- OS09-06      **UM171 EXPANSION OF SMALL CORD BLOODS PROVIDES ACCESS TO SAFE TRANSPLANTATION FOR DONORLESS PATIENTS WITH EXCELLENT LONGTERM FOLLOW-UP**      16:45 - 16:54  
*Oral Presenter:* Sandra Cohen, CA
- OS09-07      **GRAFT ENGINEERING: HOW LONG CAN YOU WAIT, HOW LOW CAN YOU GO, AND PANDEMIC READINESS**      16:54 - 17:03  
*Oral Presenter:* Kasper Westinga, NL
- OS09-08      **MECHANISMS OF T CELL TOLERANCE AFTER PT-CY HAPLOTRANSPLANTATION**      17:03 - 17:12  
*Oral Presenter:* Paul Szabolcs, US

*Educational*

16:00 - 17:00

Terrace 2A

**E10 - MDS/MPN/SAA***Chair:* Anna Jonášová, CZ*Chair:* Nicolaus Kröger, DE

E10-01	<b>Introduction</b> <i>Speaker:</i> Anna Jonášová, CZ	16:00 - 16:05
E10-02	<b>Transplantations for PMF and secondary MF: current algorithm and results</b> <i>Speaker:</i> Juan Carlos Hernández-Boluda, ES	16:05 - 16:20
E10-03	<b>Current transplant algorithm for MDS</b> <i>Speaker:</i> Marie Robin, FR	16:20 - 16:35
E10-04	<b>SAA - the results with new new transplant and non-transplant approaches</b> <i>Speaker:</i> Andrea Bacigalupo, IT	16:35 - 16:50
E10-05	<b>Conclusions</b> <i>Speaker:</i> Nicolaus Kröger, DE	16:50 - 17:00

*Workshop*

16:00 - 17:00

Terrace 2B

**W8 - ABC of immune system II***Chair:* Edgar Faber, CZ*Chair:* Milan Raška, CZ

W8-01	<b>Introduction</b> <i>Speaker:</i> Milan Raška, CZ	16:00 - 16:05
W8-02	<b>Identification of essential pathways for CAR-T cytotoxicity</b> <i>Speaker:</i> Satu Mustjoki, FI	16:05 - 16:20
W8-03	<b>Manipulation of regulatory T cell populations in transplantation tolerance</b> <i>Speaker:</i> Cristiano Scotta, GB	16:20 - 16:35
W8-04	<b>Immunomodulation in BMT: Interferons and Cytokines. Lessons from Clinical Immunology</b> <i>Speaker:</i> Emma Morris, GB	16:35 - 16:50
W8-05	<b>Conclusions</b> <i>Speaker:</i> Edgar Faber, CZ	16:50 - 17:00

*Industrial Theatre*

17:30 - 18:00

North Hall / Virtual Hall 6

**IT5 - Kites commitment to manufacturing excellence: Inside CAR T manufacturing | Industry Theatre: Gilead***Chair:* Charles Calderaro, US

IT5-01	<b>Introduction</b> <i>Speaker:</i> Charles Calderaro, US	17:30 - 17:33
IT5-02	<b>Inside Kite's manufacturing for cellular therapies</b> <i>Speaker:</i> Charles Calderaro, US	17:33 - 17:53
IT5-03	<b>Live audience Q&amp;A</b>	17:53 - 17:58

	<i>Speaker:</i> Charles Calderaro, US	
IT5-04	<b>Close</b> <i>Speaker:</i> Charles Calderaro, US	17:58 - 18:00
	<i>Meet the Expert</i> 17:30 - 18:30	MTE
<b>MTE-13 - Meet the Expert 13</b>		
MTE-13	<b>Donor selection: HLA and beyond</b> <i>Speaker:</i> Ann-Margaret Little, GB	17:30 - 18:30
	<i>Meet the Expert</i> 17:30 - 18:30	MTE
<b>MTE-14 - Meet the Expert 14</b>		
MTE-14	<b>COVID-19 in HCT candidates and patients in the post-vaccine era</b> <i>Speaker:</i> Per Ljungman, SE	17:30 - 18:30
	<i>Meet the Expert</i> 17:30 - 18:30	MTE
<b>Meet the Expert Sessions</b>		
	<i>Meet the Expert</i> 17:30 - 18:30	MTE
<b>MTE-15 - Meet the Expert 15</b>		
MTE-15	<b>Vaccinations</b> <i>Speaker:</i> Catherine Cordonnier, FR	17:30 - 18:30
	<i>Meet the Expert</i> 17:30 - 18:30	MTE
<b>MTE-11 - Meet the Expert 11</b>		
MTE-11	<b>Indications for allo-HCT in lymphoid malignancies</b> <i>Speaker:</i> Bertram Glass, DE	17:30 - 18:30



**Wednesday, 23. March 2022***Working Party Session*

09:00 - 10:15

Congress Hall / Virtual Hall 1

**SAAWP - Severe Aplastic Anaemia Working Party session***Chair:* Beatrice Drexler, CH*Chair:* Alicia Rovo, CH

SAAWP-01	<b>Somatic mutations in acquired aplastic anemia: what do we learn from the RACE trial?</b> <i>Speaker:</i> Austin Kulasekararaj, GB	09:00 - 09:20
SAAWP-02	<b>Current standard of IST in SAA in Europe in the EPAG era?</b> <i>Speaker:</i> Antonio Risitano, IT	09:20 - 09:40
SAAWP-03	<b>Transplantation modalities in acquired aplastic anemia: any change?</b> <i>Speaker:</i> Régis Peffault de Latour, FR	09:40 - 10:00
SAAWP-04	<b>QA</b>	10:00 - 10:15

*Working Party Session*

09:00 - 10:15

Forum Hall / Virtual Hall 2

**LWP - Lymphoma Working Party session***Chair:* Bertram Glass, DE

LWP-01	<b>Report of the Chairman on activities 2021 and upcoming new projects</b> <i>Speaker:</i> Bertram Glass, DE	09:00 - 09:15
LWP-02	<b>Jian-Jian Luan Award - Introduction</b>	09:15 - 09:17
LWP-03	<b>DAY+7 ANTI CD19-CAR-T BLOOD CONCENTRATIONS IDENTIFY ULTRA-HIGH-RISK GROUP FOR EARLY PROGRESSION OF DISEASE IN PATIENTS WITH STABLE/PROGRESSIVE DLBCL AT LYMPHODEPLETION</b> <i>Oral Presenter:</i> Ron Ram, IL	09:17 - 09:40
LWP-04	<b>Scientific Debate : Any role for autologous transplantation in lymphoma? - Or will CAR T-cells do the job?</b> <i>Speaker:</i> Catherine Thieblemont, FR <i>Speaker:</i> Marek Trněný, CZ	09:40 - 10:15

*Nurses Group*

09:00 - 10:15

Panorama / Virtual Hall 3

**NG12 - CAR T***Chair:* Ruth Clout, GB*Chair:* Tereza Hasilová, CZ

NG12-01	<b>The principle of CAR T therapy: Why and how CAR T therapy works</b> <i>Speaker:</i> Robert Pytlík, CZ	09:00 - 09:20
NG12-02	<b>CAR T-cell: Clinical data in ALL, NHL and Myeloma</b> <i>Speaker:</i> Jiří Šrámek, CZ	09:20 - 09:40
NG12-03	<b>CAR-T cell: Toxicity and management</b>	09:40 - 10:00

Speaker: Kamila Polgárová, CZ

NG12-04      **QA**      10:00 - 10:15

*Multi-stakeholder Forum on Innovative Cellular Therapies*

09:00 - 10:15

South Hall 1A+B / Virtual Hall 4

**MSF1 - Multi-stakeholder Forum on Innovative Cellular Therapies 1 | AI - opportunities for cell and gene therapies.**

Chair: Jurgen Kuball, NL

Chair: Michael Hudecek, DE

MSF1-01      **EU vision/Health strategy from EU**      09:00 - 09:11

Speaker: Sandra Gallina, IT

MSF1-02      **AI in Advanced Therapies**      09:11 - 09:31

Speaker: Stephen Goldrick, GB

MSF1-03      **Impact of AI on healthcare professionals and their patients**      09:31 - 09:46

Speaker: Manel Juan, ES

MSF1-04      **Ethics on AI**      09:46 - 10:01

Speaker: Michael Morrison, GB

MSF1-05      **Q&A**      10:01 - 10:15

*Oral Session*

09:00 - 10:15

South Hall 2A+B / Virtual Hall 5

**OS10 - Oral session 10: GVHD I, clinical**

Chair: Zinaida Peric, HR

Chair: Mesire Aydin, NL

OS10-01      **LONGITUDINAL, INTEGRATED ANALYSIS OF GUT BACTERIOME, MYCOBIOME, VIROME AND METABOLOME DURING ALLOGENEIC STEM CELL TRANSPLANTATION REVEALS SUSCEPTIBILITY FOR ACUTE GRAFT-VERSUS-HOST DISEASE**      09:00 - 09:09

Oral Presenter: Erik Thiele Orberg, DE

OS10-02      **ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, INDUCES CLEAVAGE OF CELL SURFACE CD6 AND RAPID ONSET OF EFFICACY IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE GRAFT-VERSUS-HOST DISEASE**      09:09 - 09:18

Oral Presenter: Stephen Connelly, US

OS10-03      **RUXOLITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE: A COMPARISON OF RESPONSE BY ORGAN CLASS FROM THE RANDOMIZED, PHASE 3 REACH2 STUDY**      09:18 - 09:27

Oral Presenter: Mohamad Mohty, FR

OS10-04      **UPDATED INTERIM RESULTS FROM THE EQUATE STUDY: PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY DIAGNOSED ACUTE GRAFT-VERSUS-HOST DISEASE**      09:27 - 09:36

Oral Presenter: Corey Cutler, US

OS10-05      **PROSPECTIVE TRIAL OF IBRUTINIB FOR THE TREATMENT OF PEDIATRIC CHRONIC GRAFT-VERSUS-**      09:36 - 09:45

**HOST DISEASE***Oral Presenter:* Marco Zecca, IT

- |         |   |               |
|---------|---|---------------|
| OS10-06 | <b>POOLED ALLOGENIC FECAL MICROBIOTHERAPY MAAT013 FOR THE TREATMENT OF STEROID-REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE: RESULTS FROM THE PHASE IIA HERACLES STUDY AND EXPANDED ACCESS PROGRAM</b> | 09:45 - 09:54 |
|         | <i>Oral Presenter:</i> Florent Malard, FR   |               |
| OS10-07 | <b>MINNESOTA ACUTE GVHD RISK SCORE DEFINES SURVIVAL AT ONSET OF ACUTE GVHD AFTER PTCY PROPHYLAXIS.</b>  | 09:54 - 10:03 |
|         | <i>Oral Presenter:</i> Maria Teresa Lupo-Stanghellini, IT   |               |
| OS10-08 | <b>OVERLAP CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) IS ASSOCIATED WITH AN ADVERSE PROGNOSIS: SECONDARY ANALYSIS OF THE ABA2 TRIAL</b>   | 10:03 - 10:12 |
|         | <i>Oral Presenter:</i> Lev Gorfinkel, US  |               |

*Oral Session*

09:00 - 10:15

North Hall / Virtual Hall 6

**OS11 - Oral session 11: Aplastic anemia, autoimmune diseases***Chair:* Dominique Farge, FR*Chair:* Sujith Samarasinghe, GB

- |         |   |               |
|---------|---|---------------|
| OS11-01 | <b>DETERMINANTS OF CLONAL EVOLUTION IN APLASTIC ANEMIA</b>  | 09:00 - 09:09 |
|         | <i>Oral Presenter:</i> Carmelo Gurnari, US  |               |
| OS11-02 | <b>LOW DOSE CYCLOPHOSPHAMIDE CONDITIONING IS SAFE IN SYSTEMIC SCLEROSIS PATIENTS INELIGIBLE FOR STANDARD DOSE REGIMENS - AN INTERIM ANALYSIS OF THE PROSPECTIVE ASSURE TRIAL</b>                                | 09:09 - 09:18 |
|         | <i>Oral Presenter:</i> John Moore, AU   |               |
| OS11-03 | <b>LATE COMPLICATIONS AFTER AUTOLOGOUS HSCT FOR AUTOIMMUNE DISEASES: A RETROSPECTIVE STUDY FROM THE EBMT AUTOIMMUNE DISEASES, TRANSPLANT COMPLICATIONS AND PAEDIATRIC DISEASES WORKING PARTIES</b>              | 09:18 - 09:27 |
|         | <i>Oral Presenter:</i> Kirill Kirgizov, RU  |               |
| OS11-04 | <b>LONGITUDINAL CHANGES ON QUANTITATIVE CHEST HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN DIFFUSE SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION.</b> | 09:27 - 09:36 |
|         | <i>Oral Presenter:</i> Grégory Pugno, FR  |               |
| OS11-05 | <b>IN-DEPTH DIAGNOSTICS OF PEDIATRIC BONE MARROW FAILURE INCREASES DETECTION RATE OF UNDERLYING CAUSES: A MULTI-CENTER PROSPECTIVE COHORT STUDY</b>   | 09:36 - 09:45 |
|         | <i>Oral Presenter:</i> Khaled Atmar, NL   |               |
| OS11-06 | <b>LONG-TERM FOLLOW-UP OF HAPLOIDENTICAL TRANSPLANTATION IN SEVERE APLASTIC ANAEMIA: A MULTICENTRE PROSPECTIVE STUDY</b>  | 09:45 - 09:54 |
|         | <i>Oral Presenter:</i> Lanping Xu, CN   |               |

OS11-07 **IMPROVED SURVIVAL AFTER HAPLOIDENTICAL CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE COMPARED TO UNRELATED CORD BLOOD TRANSPLANTATION IN PATIENTS WITH FANCONI ANEMIA** 09:54 - 10:03

*Oral Presenter:* Carmem Bonfim, BR

OS11-08 **BULSUFAN DECREASES THE INCIDENCE OF MIXED CHIMAERISM IN HLA-MATCHED DONOR TRANSPLANTATION FOR SEVERE APLASTIC ANAEMIA** 10:03 - 10:12

*Oral Presenter:* Zhengli Xu, CN

*Educational*

09:00 - 10:00

Terrace 2A

**E11 - CMV - still a challenge?**

*Chair:* Petr Hubáček, CZ

*Chair:* Hermann Einsele, DE

E11-01 **Introduction** 09:00 - 09:05  
*Speaker:* Petr Hubáček, CZ

E11-02 **CMV - the transplantation troll - the molecular mechanism of effective manipulation with immunity** 09:05 - 09:20  
*Speaker:* Sebastian Voigt, DE

E11-03 **CMV infection and disease - Definitions and clinical impact** 09:20 - 09:35  
*Speaker:* Christine Robin, FR

E11-04 **Therapy and vaccination of CMV infection in HSCT - pharmacological and cellular approaches** 09:35 - 09:50  
*Speaker:* Tobias Feuchtinger, DE

E11-05 **Conclusions** 09:50 - 09:59  
*Speaker:* Hermann Einsele, DE

*Workshop*

09:00 - 10:00

Terrace 2B

**W9 - Novel insights into systemic hyperinflammation syndromes**

*Chair:* Jiří Šrámek, CZ

*Chair:* Lucrecia Yáñez, ES

W9-01 **Introduction** 09:00 - 09:05  
*Speaker:* Jiří Šrámek, CZ

W9-03 **Cytokine release syndrome after CAR-T-Cell therapy** 09:20 - 09:35  
*Speaker:* Míriam Sánchez-Escamilla, ES

W9-04 **Secondary haemophagocytic lymphohistiocytosis** 09:35 - 09:50  
*Speaker:* Paul La Rosee, DE

W9-05 **Conclusions** 09:50 - 10:00  
*Speaker:* Lucrecia Yáñez, ES

*Poster Sessions*

09:00 - 14:30

ePoster Area

**ePoster Viewing**

*On Demand Library*

09:00 - 14:30

On-demand Library

**On-demand Library***Breaks*

10:15 - 10:45

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition***Oral Session*

10:45 - 12:00

Congress Hall / Virtual Hall 1

**OS12 - Oral session 12: Acute leukemia***Chair:* Frédéric Baron, BE*Chair:* Yasmina Serroukh, NL

- |         |   |               |
|---------|---|---------------|
| OS12-01 | <b>PREDICTION OF NON-RELAPSE MORTALITY IN PATIENTS WITH AML AND ALL RECEIVING ALLOSCT IN FIRST CR WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS</b><br><i>Oral Presenter:</i> Sjoerd J. F. Hermans, NL            | 10:45 - 10:54 |
| OS12-02 | <b>ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH HYPERDIPLOID COMPLEX KARYOTYPE: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY (ALWP) OF THE EBMT.</b><br><i>Oral Presenter:</i> Xavier Poiré, BE     | 10:54 - 11:03 |
| OS12-03 | <b>IMPACT OF <i>IDH1</i> AND <i>IDH2</i> MUTATIONAL SUBGROUPS IN ACUTE MYELOID LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</b><br><i>Oral Presenter:</i> Desiree Kunadt, DE                                 | 11:03 - 11:12 |
| OS12-04 | <b>POST-REMISSION TREATMENT PATTERN AND SURVIVAL OUTCOMES IN CONNECT® MYELOID DISEASE REGISTRY PATIENTS WITH ACUTE MYELOID LEUKEMIA</b><br><i>Oral Presenter:</i> Gail Roboz, US  | 11:12 - 11:21 |
| OS12-05 | <b>EVALUATION IN TRENDS IN OUTCOME OVER 2 DECADES OF PATIENTS WITH SECONDARY AML UNDERGOING ALLO-HCT FROM SIBLING AND UNRELATED DONORS: AN ALWP EBMT ANALYSIS</b><br><i>Oral Presenter:</i> Arnon Nagler, IL                          | 11:21 - 11:30 |
| OS12-06 | <b>ALLOGENEIC TRANSPLANTATION FOR AML AGED ≥70 YEARS. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (EBMT).</b><br><i>Oral Presenter:</i> Enrico Maffini, IT             | 11:30 - 11:39 |
| OS12-07 | <b>CD34+ DOSE EFFECTS ON CLINICAL OUTCOMES AFTER FLUDARABINE-BUSULFAN CONDITIONING REGIMEN FOR ACUTE MYELOID LEUKEMIA USING PERIPHERAL BLOOD STEM CELLS - STUDY FROM THE ALWP OF EBMT</b><br><i>Oral Presenter:</i> Eolia Brissot, FR | 11:39 - 11:48 |
| OS12-08 | <b>SEGREGATION OF HIGH-RESOLUTION B HAPLOTYPES POINTS TOWARDS PROTECTIVE DONOR KIR GENOTYPES AFTER UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH AML OR MDS</b>   | 11:48 - 11:57 |

Oral Presenter: Johannes Schetelig, DE

Oral Session

10:45 - 12:00

Forum Hall / Virtual Hall 2

**OS13 - Oral session 13: CAR-T II**

Chair: Nico Gagelmann, DE

Chair: Francesca Del Bufalo, IT

- |         |   |               |
|---------|---|---------------|
| OS13-01 | <b>CD19 CAR-T THERAPY IN CHILDREN WITH RELAPSED AND REFRACTORY B-CELL ALL</b><br><i>Oral Presenter: Olga Molostova, RU</i>  | 10:45 - 10:54 |
| OS13-02 | <b>PROFILES OF CYTOKINES ARE ASSOCIATED WITH PROLONGED HEMATOLOGIC TOXICITIES AFTER BCMA TARGETED CAR-T CELL THERAPY</b><br><i>Oral Presenter: Linqin Wang, CN</i>  | 10:54 - 11:03 |
| OS13-03 | <b>IMPACT OF ANAKINRA DOSE ON OUTCOMES IN PATIENTS WITH REFRACTORY CRS AND/OR ICANS AFTER CAR T-CELL THERAPY</b><br><i>Oral Presenter: Nicolas Gazeau, US</i>   | 11:03 - 11:12 |
| OS13-04 | <b>TREATMENT OF ADULT ALL PATIENTS WITH THIRD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS - RESULTS OF THE HEIDELBERG TRIAL 1 (HD-CAR-1 TRIAL)</b><br><i>Oral Presenter: Maria-Luisa Schubert, DE</i>                        | 11:12 - 11:21 |
| OS13-05 | <b>R/R B-ALL RECEIVING HAPLOIDENTICAL HSCT AFTER CAR-T THERAPY ACHIVES COMPARABLE OUTCOMES TO B-ALL TRANSPLANTED IN CR1 AFTER CHEMOTHERAPY</b><br><i>Oral Presenter: Tingting Yang, CN</i>  | 11:21 - 11:30 |
| OS13-06 | <b>PRIMARY ANALYSIS OF ZUMA-7: A PHASE 3 RANDOMIZED TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS STANDARD-OF-CARE (SOC) THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA</b><br><i>Oral Presenter: Tom van Meerten, NL</i> | 11:30 - 11:39 |
| OS13-07 | <b>REAL-LIFE EXPERIENCE WITH COMMERCIAL CAR-T CELLS FOR LYMPHOMA PATIENTS: EARLY EXPANSION KINETIC PREDICTS DISEASE RESPONSE AND SURVIVAL</b><br><i>Oral Presenter: Martina Pennisi, IT</i>   | 11:39 - 11:48 |
| OS13-08 | <b>DEVELOPMENT, SAFETY AND EFFICACY OF LOCALLY PRODUCED NOVEL BCMA CART CELLS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA</b><br><i>Oral Presenter: Polina Stepensky, IL</i>   | 11:48 - 11:57 |

Nurses Group

10:45 - 12:00

Panorama / Virtual Hall 3

**NG13 - How do I manage... Palliative care and advanced care planning?**

Chair: Sarah Liptrott, CH

Chair: Michal Kouba, CZ

- |         |  |               |
|---------|--|---------------|
| NG13-01 | <b>Advanced care planning</b><br><i>Speaker: Ida Korfage, NL</i> | 10:45 - 11:05 |
| NG13-02 | <b>Symptom management</b>  | 11:05 - 11:25 |

	<i>Speaker:</i> Ellie Cooke, GB	
NG13-03	<b>Breathlessness management</b> <i>Speaker:</i> Ruth Ting, GB	11:25 - 11:45
NG13-04	<b>QA</b>	11:45 - 12:00

*Multi-stakeholder Forum on Innovative Cellular Therapies*  
10:45 - 12:00

South Hall 1A+B / Virtual Hall 4

**MSF2 - Multi-stakeholder Forum on Innovative Cellular Therapies 2 | Innovative Therapies: from bench to bedside.**

*Chair:* Christian Chabannon, FR

*Chair:* Julio Delgado, ES

MSF2-01	<b>Starting material: Blood, Tissues and Cells</b> <i>Speaker:</i> Stefaan Van Der Spiegel, BE	10:45 - 11:00
MSF2-02	<b>Authorisation of ATMPs in the EU: scientific and regulatory considerations</b> <i>Speaker:</i> Patrick Celis, NL	11:00 - 11:15
MSF2-03	<b>Health system evaluation of ATMPs</b> <i>Speaker:</i> Karen Facey, GB	11:15 - 11:30
MSF2-04	<b>Access to treatment &amp; patient advocacy</b> <i>Speaker:</i> Natacha Bolaños, ES	11:30 - 11:45
MSF2-05	<b>Q&amp;A</b>	11:45 - 12:00

*Oral Session*  
10:45 - 12:00

South Hall 2A+B / Virtual Hall 5

**OS14 - Oral session 14: GVHD II, clinical and preclinical**

*Chair:* David Michonneau, FR

*Chair:* Kim Orchard, GB

OS14-01	<b>IFN-GAMMA PRODUCING REGULATORY T CELLS COUNTERBALANCE T CELL-MEDIATED INJURY TO THE INTESTINAL STEM CELL COMPARTMENT IN MICE AND HUMANS</b> <i>Oral Presenter:</i> Sascha Göttert, DE	10:45 - 10:54
OS14-02	<b>BIOMARKER ANALYSIS IN PATIENTS WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-VS-HOST DISEASE TREATED WITH RUXOLITINIB OR BEST AVAILABLE THERAPY IN THE RANDOMIZED PHASE 3 REACH3 STUDY</b> <i>Oral Presenter:</i> Franco Locatelli, IT	10:54 - 11:03
OS14-03	<b>DECIPHERING THE EFFECTS OF GRAFT TREGS ON CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A MULTICENTER STUDY OF PATIENTS WITH ACUTE LEUKEMIA UNDERGOING ALLOGENEIC PBSCT</b> <i>Oral Presenter:</i> Mario Delia, IT	11:03 - 11:12
OS14-04	<b>LOW SOLUBLE PROGRAMMED CELL DEATH PROTEIN 1 LEVELS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION PREDICT MODERATE OR SEVERE CHRONIC GVHD AND INFERIOR OVERALL SURVIVAL</b>	11:12 - 11:21

*Oral Presenter:* Lambros Kordelas, DE

- |         |   |               |
|---------|---|---------------|
| OS14-05 | <b>COMPARISON BETWEEN ATG AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS IN NONMYELOABLATIVE MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATIONS</b> | 11:21 - 11:30 |
|         | <i>Oral Presenter:</i> Mesire Aydin, NL   |               |
| OS14-06 | <b>DECIPHERING ANTIGEN SPECIFICITY OF PROTECTIVE REGULATORY T CELL CLONES IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION</b>  | 11:30 - 11:39 |
|         | <i>Oral Presenter:</i> Yankai Xiao, DE  |               |
| OS14-07 | <b>EX VIVO GENERATE D THROUGH PHARMACOLOGICAL HYPOMETHYLATION HLA-G+ T-REGULATORY CELLS, DO NOT INDUCE ALLOREACTIVITY</b>   | 11:39 - 11:48 |
|         | <i>Oral Presenter:</i> Panayiota Christofi, GR  |               |
| OS14-08 | <b>DONOR PLASMACYTOID DENDRITIC CELLS REGULATE GVHD AND GVL ACTIVITIES OF DONOR T CELLS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b>                           | 11:48 - 11:57 |
|         | <i>Oral Presenter:</i> Pankoj K. Das, US  |               |

*Oral Session*  
10:45 - 12:00

North Hall / Virtual Hall 6

**OS15 - Oral session 15: New drugs, gene therapy, and experimental transplantation**

*Chair:* Despina Moshous, FR

*Chair:* Arjan Lankester, NL

- |         |  |               |
|---------|--|---------------|
| OS15-01 | <b>HEMATOPOIETIC STEM CELL TRANSPLANT FOR KRABBE DISEASE IS AUGMENTED BY ADDITION OF INTRAVENOUS AAV GENE REPLACEMENT THERAPY</b>  | 10:45 - 10:54 |
|         | <i>Oral Presenter:</i> Maria Escolar, US   |               |
| OS15-02 | <b>EFFICACY AND SAFETY OF PEGCETACOPLAN TREATMENT IN COMPLEMENT-INHIBITOR NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE PHASE 3 PRINCE STUDY</b> | 10:54 - 11:03 |
|         | <i>Oral Presenter:</i> Andrija Bogdanovic, RS  |               |
| OS15-03 | <b>GLYCOLYTIC ENZYME PFKFB3 DETERMINES BONE MARROW ENDOTHELIAL PROGENITOR CELL DAMAGE POST CHEMOTHERAPY AND IRRADIATION</b>  | 11:03 - 11:12 |
|         | <i>Oral Presenter:</i> Zhong-shi Lyu, CN   |               |
| OS15-04 | <b>A TRANSCRIPTOMIC-BASED RATIONAL APPROACH FOR CONSIDERING VISTA AS A NEW MOLECULAR TARGET IN ACUTE MYELOID LEUKEMIA</b>  | 11:12 - 11:21 |
|         | <i>Oral Presenter:</i> Simona Pagliuca, FR   |               |
| OS15-05 | <b>THE HISTONE DEMETHYLASE KDM6A REGULATES HEMATOPOIETIC STEM AND PROGENITOR CELLS EMERGENCE AND ITS LOSS CAUSES MYELOID-BIASED DIFFERENTIATION IN ZEBRAFISH</b>             | 11:21 - 11:30 |
|         | <i>Oral Presenter:</i> Huiqiao Chen, CN  |               |
| OS15-06 | <b>A COMBINATORIAL TRANSCRIPTIONAL MECHANISM AND PHARMACOLOGIC REVERSAL OF LEUKEMIA IMMUNE EVASION</b>   | 11:30 - 11:39 |



*Oral Presenter:* Maxim Pimkin, US

OS15-07      **A PHASE 2 STUDY OF ITACITINIB FOR THE PREVENTION OF CYTOKINE RELEASE SYNDROME (CRS) INDUCED BY IMMUNE EFFECTOR CELL (IEC) THERAPY: PRELIMINARY RESULTS**      11:39 - 11:48

*Oral Presenter:* Matthew Frigault, US

OS15-08      **INCREASED DIAGNOSTIC TELOMERE LENGTH ASSOCIATES WITH HIGHER RELAPSE RATES IN TRANSPLANTED ACUTE MYELOID LEUKEMIA PATIENTS**      11:48 - 11:57

*Oral Presenter:* Lara Bischof, DE

*Educational*

10:45 - 11:45

Terrace 2A

**E12 - Update on viral infections in the transplant setting**

*Chair:* Markéta Marková, CZ

*Chair:* Hans Hirsch, CH

E12-01      **Introduction**      10:45 - 10:50

*Speaker:* Markéta Marková, CZ

E12-02      **Herpes viruses (other than CMV)**      10:50 - 11:05

*Speaker:* Per Ljungman, SE

E12-03      **Adenoviruses**      11:05 - 11:20

*Speaker:* Thomas Lion, AT

E12-04      **Known and emerging RNA viruses**      11:20 - 11:35

*Speaker:* Jaap Jan Boelens, US

E12-05      **Conclusions**      11:35 - 11:38

*Speaker:* Hans Hirsch, CH

*Workshop*

10:45 - 11:45

Terrace 2B

**W10 - Modulation of microbiome pre-, peri- and post-transplant - is it time to become routine practice?**

*Chair:* Jakub Radocha, CZ

*Chair:* Florent Malard, FR

W10-01      **Introduction**      10:45 - 10:50

*Speaker:* Jakub Radocha, CZ

W10-02      **The gut microbiota and HSCT: potential roles and impacts on transplant outcomes**      10:50 - 11:05

*Speaker:* Daniele Zama, IT

W10-03      **Antibiotics and gut microbiome. Help and harm**      11:05 - 11:20

*Speaker:* Elisabeth Meedt, DE

W10-04      **Fecal microbiota transplantation for treatment of GVHD**      11:20 - 11:35

*Speaker:* Roni Shouval, US

W10-05      **Conclusions**      11:35 - 11:45

*Speaker:* Florent Malard, FR

*Breaks*

12:00 - 12:15

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition***Plenary Session*

12:15 - 13:30

Congress Hall / Virtual Hall 1

**P4 - New developments in CAR T cell therapy***Chair:* Christian Chabannon, FR*Chair:* Harry Dolstra, NL

P4-01	<b>CRISPR-engineered T cells in patients with refractory cancer</b> <i>Speaker:</i> Carl June, US	12:15 - 12:35
P4-02	<b>"Off the shelf "allogeneic" CAR-T-cells: development and challenges</b> <i>Speaker:</i> Michael Bishop, US	12:35 - 12:55
P4-03	<b>CAR-NK cells - current status and perspective</b> <i>Speaker:</i> Evelyn Ullrich, DE	12:55 - 13:15
P4-04	<b>QA</b>	13:15 - 13:30

*Oral Session*

12:15 - 13:30

Forum Hall / Virtual Hall 2

**OS16 - Oral session 16: Conditioning***Chair:* Eolia Brissot, FR*Chair:* Alessandro Rambaldi, IT

OS16-01	<b>TBI/FLUDARABINE VERSUS BUSULFAN/FLUDARABINE AS A MYELOABLATIVE CONDITIONING FOR ADULTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH ALLO-HCT. A STUDY FROM THE ALWP OF THE EBMT</b> <i>Oral Presenter:</i> Ryszard Swoboda, PL	12:15 - 12:24
OS16-02	<b>TOTAL BODY IRRADIATION/FLUDARABINE VERSUS BUSULFAN/FLUDARABINE AS CONDITIONING IN ALL PATIENTS &amp;GT;45 YEARS IN 1<sup>ST</sup> CR - A REGISTRY-BASED STUDY BY THE ALWP OF THE EBMT</b> <i>Oral Presenter:</i> Klaus Hirschbühl, DE	12:24 - 12:33
OS16-03	<b>COMPARISON OF FLUDARABINE PLUS REDUCED VERSUS MYELOABLATIVE DOSE BUSULFAN IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <i>Oral Presenter:</i> Kimimori Kamijo, JP	12:33 - 12:42
OS16-04	<b>FLUDARABINE VERSUS CYCLOPHOSPHAMIDE IN COMBINATION WITH MYELOABLATIVE TBI AS CONDITIONING FOR PATIENTS WITH AML TREATED WITH ALLO-HCT. A STUDY FROM THE ALWP OF THE EBMT</b> <i>Oral Presenter:</i> Sebastian Giebel, PL	12:42 - 12:51
OS16-05	<b>SURVIVAL ADVANTAGE OF TREOSULFAN PLUS FLUDARABINE (FT14) COMPARED TO BUSULFAN PLUS FLUDARABINE (FB4) IN ACTIVE ACUTE MYELOID LEUKEMIA POST ALLOGENEIC TRANSPLANTATION: STUDY OF THE EBMT-ALWP</b>	12:51 - 13:00

Oral Presenter: Eleni Gavriilaki, GR

OS16-06 **GVHD AND GRFS IN PATIENTS WITH AML UNDERGOING ALLOGENEIC TRANSPLANTATION WITH TREOSULFAN-VERSUS BUSULFAN-BASED CONDITIONING: A SUBGROUP ANALYSIS OF THE RANDOMIZED PHASE III MC-FLUDT.14/L TRIAL** 13:00 - 13:09

Oral Presenter: Friedrich Stölzel, DE

OS16-07 **TREOSULFAN-BASED COMPARED TO THIOTEPA-BUSULFAN-FLUDARABINE CONDITIONING FOR HAPLOIDENTICAL TRANSPLANT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA.A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT.** 13:09 - 13:18

Oral Presenter: Francesco Saraceni, IT

OS16-08 **GRAFT-VERSUS-HOST DISEASE (GVHD) AND GVHD-FREE/RELAPSE-FREE SURVIVAL (GRFS) IN PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AFTER TREOSULFAN- VERSUS BUSULFAN-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT)** 13:18 - 13:27

Oral Presenter: Matthias Stelljes, DE

Nurses Group

12:15 - 13:45

Panorama / Virtual Hall 3

**NG14 - Nurses Programme: Closing Session**

Chair: Michelle Kenyon, GB

Chair: Klara Kabatová-Maxová, CZ

NG14-01 **Supportive care of patients with severe aGVHD** 12:15 - 12:35  
Speaker: Seckin Erdal, TR

NG14-02 **The therapeutic world of the ECP nurse** 12:35 - 12:55  
Speaker: Alba Pons Cornado, NO

NG14-03 **Mesenchymal stem cells as a treatment of GVHD** 12:55 - 13:15  
Speaker: Daniel Lysak, CZ

NG14-04 **Best of the best** 13:15 - 13:20  
Speaker: Michelle Kenyon, GB

NG14-05 **Highlights of physician's sessions** 13:20 - 13:35  
Speaker: Petr Sedláček, CZ

NG14-06 **Presentation Paris 2023** 13:35 - 13:45  
Speaker: Thomas Jezequel, FR

Oral Session

12:15 - 13:30

South Hall 1A+B / Virtual Hall 4

**OS17 - Oral session 17: Stem cell donor, stem cell source, mobilisation and collection**

Chair: Bronwen Shaw, US

Chair: Johannes Schetelig, DE

OS17-01 **COMPARISON OF MOBILIZED PERIPHERAL BLOOD STEM CELLS VERSUS UNMANIPULATED BONE MARROW HAPLOIDENTICAL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH OR WITHOUT ATG** 12:15 - 12:24

- Oral Presenter:* Claire Lacan, FR
- OS17-02      **A REFINED MODEL OF HLA-DP PERMISSIVENESS IMPROVES STRATIFICATION OF ACUTE GVHD AND TRM RISKS AFTER UNRELATED HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY FROM THE CIBMTR**      12:24 - 12:33  
*Oral Presenter:* Esteban Arrieta-Bolaños, DE
- OS17-03      **PBSC ALLOGENEIC GRAFT CRYOPRESERVATION DURING COVID-19 PANDEMIC: ANALYSIS OF THE SFGM-TC CENTER EXPERIENCE**      12:33 - 12:42  
*Oral Presenter:* boris calmels, FR
- OS17-04      **HLA CLASS I MISMATCHES WITH HIGH PEPTIDE DIVERGENCE IN THE GRAFT-VERSUS-HOST DIRECTION ARE ASSOCIATED WITH INFERIOR SURVIVAL AFTER 9/10 HLA-MATCHED UD-HCT: A CIBMTR RETROSPECTIVE STUDY.**      12:42 - 12:51  
*Oral Presenter:* Esteban Arrieta-Bolaños, DE
- OS17-05      **MATCHING BEYOND THE HLA NAME: A NEW CLASSIFICATION OF HLA-ALLELE MISMATCHES BASED ON PEPTIDE BINDING PROFILE**      12:51 - 13:00  
*Oral Presenter:* Alice Bertaina, US
- OS17-06      **CORD BLOOD SIGNIFICANTLY OUTPERFORMS OTHER CELL SOURCES IN CLEARING RESIDUAL HOST HEMATOLOGIC AND LYMPHOID TISSUES**      13:00 - 13:09  
*Oral Presenter:* RUBIYA NADAF, GB
- OS17-07      **DOES GRAFT CRYOPRESERVATION AFFECT THE OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTS? A UK MULTICENTRE CASE CONTROL STUDY DURING COVID19 PANDEMIC**      13:09 - 13:18  
*Oral Presenter:* Ruta Maniusyte, GB
- OS17-08      **HAPLO OR UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS: A RANDOMIZED MULTICENTER PHASE III STUDY.**      13:18 - 13:27  
*Oral Presenter:* Raynier Devillier, FR

*Oral Session*  
 12:15 - 13:30

South Hall 2A+B / Virtual Hall 5

**OS18 - Oral session 18: Paediatrics**

*Chair:* Peter Bader, DE

*Chair:* Marianne Ifversen, DK

- OS18-01      **EXCELLENT OUTCOMES AFTER T-REPLETE UNRELATED DONOR CORD BLOOD TRANSPLANT TO CURE HIGH RISK AND REFRACTORY PAEDIATRIC AML AND MDS**      12:15 - 12:24  
*Oral Presenter:* Claire Horgan, GB
- OS18-03      **EXPOSURE-RESPONSE ANALYSIS OF ATLG GRAFALON® IN PAEDIATRIC ALL PATIENTS: TOWARDS INDIVIDUALIZED DOSING TO PREVENT ACUTE GVHD AFTER HSCT**      12:24 - 12:33  
*Oral Presenter:* Lisa V.E. Oostenbrink, NL

OS18-04	<b>OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN 813 CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP</b> <i>Oral Presenter:</i> Su Han Lum, GB	12:33 - 12:42
OS18-05	<b>IMPACT OF ACUTE GVHD ON SURVIVAL AND DISEASE RELAPSE IN PAEDIATRIC PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKAEMIA: AN EBMT REGISTRY-BASED ANALYSIS.</b> <i>Oral Presenter:</i> Giovanna Lucchini, GB	12:42 - 12:51
OS18-06	<b>ROLE OF ACUTE GVHD IN PAEDIATRIC PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA: AN IMPERFECT BALANCE.</b> <i>Oral Presenter:</i> Giovanna Lucchini, GB	12:51 - 13:00
OS18-07	<b>SECOND HEMATOPOIETIC STEM CELL TRANSPLANT IN CHILDREN WITH RELAPSED JMML: A THERAPEUTIC OPTION WITH LIMITED TOXICITY.</b> <i>Oral Presenter:</i> Maria Gabelli, GB	13:00 - 13:09
OS18-08	<b>ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH RUNX1 GERMLINE MUTATIONS: A JOINT EBMT PDWP AND EWOG-MDS ANALYSIS</b> <i>Oral Presenter:</i> Birgitte Strahm, DE	13:09 - 13:18

*Oral Session*  
12:15 - 13:30

North Hall / Virtual Hall 6

**OS19 - Oral session 19: Non-infectious late effects and complications**

*Chair:* Monica Cabrero, ES

*Chair:* Christian Niederwieser, DE

OS19-01	<b>HCT FRAILTY SCALE FOR ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION</b> <i>Oral Presenter:</i> Maria Queralt Salas, ES	12:15 - 12:24
OS19-02	<b>RANDOMISED TRIAL ON THE IMPACT OF VIRTUAL-BASED MULTIMODAL TRAINING PROGRAMME ON PHYSICAL FITNESS AND QUALITY OF LIFE IN PATIENTS LATE POST-HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT)</b> <i>Oral Presenter:</i> David Ma, AU	12:24 - 12:33
OS19-03	<b>EVALUATION OF SECONDARY MALIGNANT NEOPLASMS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A RETROSPECTIVE MULTICENTRIC GETH (GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO) STUDY</b> <i>Oral Presenter:</i> Maria Huguet, ES	12:33 - 12:42
OS19-04	<b>HLA-HAPLO-IDENTICAL DONOR HSCT ACHIEVED BETTER QOL WITHOUT COMPROMISE OF SURVIVAL COMPARED TO HLA-MATCHED-SIBLING DONOR HSCT</b> <i>Oral Presenter:</i> Xiaoyu Zhang, CN	12:42 - 12:51
OS19-06	<b>PREDICTORS AND SIGNIFICANCE OF RENAL</b>	13:00 - 13:09

**DYSFUNCTION IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE***Oral Presenter:* David Beshensky, US

- |         |   |               |
|---------|---|---------------|
| OS19-07 | <b>CARDIOTOXICITY IN PEDIATRIC PATIENTS WHO UNDERWENT STEM CELL TRANSPLANTATION: RETROSPECTIVE ANALYSIS ON 289 CHILDREN</b><br><i>Oral Presenter:</i> Francesca Compagno, IT  | 13:09 - 13:18 |
| OS19-08 | <b>SEXUAL FUNCTION OF ADULT LONG-TERM SURVIVORS AND THEIR PARTNERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (S-FAST): A STUDY BY THE EBMT TCWP AND EBMT NURSES GROUP</b><br><i>Oral Presenter:</i> Lars Klingen Gjørde, DK | 13:18 - 13:27 |

*Joint Session*  
12:15 - 13:17

Terrace 2A

**JS02 - Joint session EBMT-EHA: Academical clinical trials in Europe***Chair:* John Gribben, GB*Chair:* Nicolaus Kröger, DE

- |        |  |               |
|--------|--|---------------|
| JS02-1 | <b>Breaking down national barriers. Examples from the myeloma network</b><br><i>Speaker:</i> Pieter Sonneveld, NL          | 12:15 - 12:36 |
| JS02-2 | <b>How this can be translated into the transplant setting. Example from the UK</b><br><i>Speaker:</i> Charles Craddock, GB | 12:36 - 13:02 |
| JS02-3 | <b>Discussion</b>  | 13:02 - 13:17 |

*Workshop*  
12:15 - 13:16

Terrace 2B

**W11 - Survivorship beyond survival***Chair:* Petra Keslova, CZ*Chair:* Hélène Schoemans, BE

- |        |  |               |
|--------|--|---------------|
| W11-01 | <b>Introduction</b><br><i>Speaker:</i> Petra Keslova, CZ                         | 12:15 - 12:20 |
| W11-02 | <b>Return to work among HSCT survivors</b><br><i>Speaker:</i> André Tichelli, CH | 12:20 - 12:35 |
| W11-03 | <b>Cognitive function in HSCT survivors</b><br><i>Speaker:</i> Smita Bhatia, US  | 12:35 - 12:50 |
| W11-04 | <b>Patient peer support</b><br><i>Speaker:</i> Susan Stewart, US                 | 12:50 - 13:05 |
| W11-05 | <b>Conclusions</b><br><i>Speaker:</i> Hélène Schoemans, BE                       | 13:05 - 13:16 |

*Breaks*  
13:30 - 13:45

Congress Hall / Virtual Hall 1

**Break, ePoster Viewing, Visit Exhibition**

*General*

13:45 - 14:30

Congress Hall / Virtual Hall 1

**GS4 - Closing Session***Chair:* Nicolaus Kröger, DE*Chair:* Petr Sedláček, CZ*Chair:* Pavel Jindra, CZ

GS4-01	<b>Presentation of the Springer Nature Poster Awards</b> <i>Speaker:</i> Nicolaus Kröger, DE	13:45 - 13:50
GS4-02	<b>Best Young Abstracts</b> <i>Speaker:</i> Harry Dolstra, NL	13:50 - 13:55
GS4-03	<b>Congress Co-Presidents closing remarks</b> <i>Speaker:</i> Petr Sedláček, CZ <i>Speaker:</i> Pavel Jindra, CZ	13:55 - 14:05
GS04-04	<b>Local President for EBMT 2023 Paris: Welcome</b> <i>Speaker:</i> Mohamad Mohty, FR	14:05 - 14:15
GS4-05	<b>EBMT President closing remarks</b> <i>Speaker:</i> Nicolaus Kröger, DE <i>Speaker:</i> Anna Sureda, ES	14:15 - 14:25
GS4-06	<b>New EBMT President Induction: Passing of the hammer</b> <i>Speaker:</i> Nicolaus Kröger, DE <i>Speaker:</i> Anna Sureda, ES	14:25 - 14:30